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 The control of subcellular protein localization to alter function offers great 
potential for treatment of diseases caused by mislocalization. Further, inducing 
mislocalization may assist in the determination of a protein’s function. To this end, 
three localization-controllable constructs have been created. A central feature among 
them is their ability to respond only to an externally administered ligand, which is 
mediated through the incorporation of a steroid hormone ligand-binding domain.  
Controlled cytoplasm-to-nucleus translocation can be accomplished through 
the “protein switch,” which was optimized in this work to produce a significant shift 
in localization from the cytoplasm to the nucleus upon ligand induction. The 
glucocorticoid receptor ligand-binding domain confers ligand-responsiveness, and 
nuclear export and nuclear localization signals help shift the balance of localization. 
Controlled targeting of proteins to the cytoskeleton can be accomplished 
through the isolation of the estrogen receptor ligand-binding domain. When this 
domain binds the antagonist fulvestrant, it forms insoluble protein aggregates that 
associate with the cytoskeleton. A protein fused to the ligand-binding domain will 
get sequestered in the cytoskeleton, and any cellular activity it had is lost.  
Controlled targeting of a protein to the ubiquitin-proteasome pathway can be 
achieved by regulating the access of the tumor suppressor p53 to the nucleus, where 
it binds the protein responsible for its ubiquitination and proteasomal degradation. 
When p53 was fused to the protein switch, it remained cytoplasmic before ligand 
 iv 
addition, but after ligand it translocated to the nucleus and subsequently sent to the 
proteasome. This technology has the potential to target other intracellular proteins 
to the proteasome if a binding domain is incorporated.  
This dissertation focuses on the creation and characterization of these 
localization-controllable constructs so that they may be used in future applications 
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BACKGROUND AND SIGNIFICANCE 
Summary 
The classic paradigm for treatment of disease has focused on small molecules, 
peptides, and antibodies that hit “druggable targets” and that are easy to formulate 
and administer. However, intracellular disease targets may lack small molecules 
that modulate their function, and protein internalization may not efficiently occur to 
be an effective option. With heightened technology comes the ability to move beyond 
that paradigm to more complex means of disease treatment: targeted gene therapy 
involving delivery through viral or polymer vectors. If limited by lack of small 
molecules or a druggable target, why not introduce a gene that encodes a protein 
with novel activity, or that replaces the activity of a dysfunctional one? With this 
technology, one no longer has to find a “druggable target,” search a large library of 
small molecules, or deliver large amounts of a drug in order to reach a therapeutic 
concentration. A relatively small amount of a therapeutic can be administered, and 
it will seek out the programmed site. The advantage of polymer and viral delivery is 
the internalization of the payload—DNA for example. DNA can be engineered in the 
lab to contain the sequence that encodes a protein with therapeutic function, which 
can subsequently be introduced into diseased tissue. These tissues will then produce 
this therapeutic protein on their own. The potential of this technology is enormous, 
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but it is currently limited by concerns of toxicity and off-target effects. This has not 
prevented the pharmaceutical industry from creating hundreds of gene therapy 
drugs with a variety of targets, including cancer, diabetes, and heart disease. Adding 
a gene that complements what is lacking internally may rescue cells that are 
experiencing the negative effects, but may have little effect on tissues where that 
pathway is intact or irrelevant.  
 To effectively capitalize on the therapeutic potential of gene therapy, there 
needs to be an arsenal of tools and mechanisms for diagnosis, research, and 
treatment. The work presented here adds to that arsenal by providing several means 
of intracellular protein localization control. The subcellular transport and 
localization of proteins is necessary for cells to function properly—protein may be 
functional in one compartment, but inactive in another. It is also possible that a 
protein is dysfunctional if it has localized to the wrong compartment, and this 
dysfunction may lead to disease (1). Correcting this dysfunction is one potential 
treatment modality, but harnessing the altered function of a protein in a particular 
compartment is another. Three uses of protein localization control are described in 
this dissertation, and are illustrated in Figure 1.1.  
 The first approach is the control of cytoplasm-to-nucleus translocation. This 
concept has been pioneered in the Lim laboratory, and utilizes a combination of 
signal sequences in conjunction with a ligand-responsive domain, and it has been 
named the “protein switch” (2-4). In the unliganded state, the protein switch 
localizes mostly in the cytoplasm, but after ligand addition it translocates to the 
nucleus. The optimization of the various domains needed to make the protein switch 





























































































































































































































































































The second approach is sequestering a protein to the insoluble cytoskeletal 
fraction. This is accomplished by fusing a protein of interest to the estrogen receptor 
ligand-binding domain (ERLBD), then adding the drug fulvestrant. Fulvestrant is a 
member of the selective estrogen receptor downregulator family of drugs, and results 
in aggregation and accumulation of the receptor in the cytoplasm, followed by 
proteasomal degradation. However, isolating only the ligand binding domain results 
in a protein that aggregates at the cytoskeleton in response to fulvestrant, and its 
cytoplasm or nucleus localization can pre-determined. A protein fused to the ERLBD 
thus results in aggregation at the cytoskeleton, which blocks the activity of that 
protein. The design and activity of this cytoskeleton-directed protein will be 
discussed. 
 The third and final approach of protein localization control is the targeting of 
proteins to the degradation pathway. These proteins capable of controlled 
degradation have been termed “protargs,” or proteasomal-targeted protein. 
Intracellular proteins can be marked for degradation by conjugation with ubiquitin 
moieties. Ubiquitinated proteins are recognized by the 26S proteasome, which is the 
major proteolytic machine within the cell. Specific ubiquitin ligases, called E3 
ligases, are necessary to add ubiquitin moieties when a protein needs to be degraded. 
When an E3 ligase is localized in one subcellular compartment, it is possible to 
control its access to its target protein. An example explored in this dissertation is the 
interaction of p53 with MDM2—the E3 ligase responsible for the ubiquitination and 
degradation of p53. When MDM2 is in the nucleus, the entry of p53 to the nucleus 
can be controlled with the protein switch, and thus the ubiquitination and 
degradation of p53 can be controlled. By extension, if a protein is fused to this p53, 
its degradation can be controlled as well. We have also proposed another protarg 
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based on the response of the estrogen receptor (ER) to the antagonist fulvestrant. 
This interaction results in proteasomal degradation. While we have proposed this as 
a viable mechanism for proteasomal targeting, its utility is not yet proven. The 
initial work will be discussed, but it has not yet demonstrated protein localization 
control. 
Background 
Targeting the Nucleus: Cytoplasm-to-Nucleus  
Protein Switch 
 The nucleocytoplasmic translocation of proteins can be harnessed to allow 
external control of an exogenous protein to utilize intracellular transport 
mechanisms (2, 3). This designed protein has been termed “protein switch” or PS, 
and is comprised of a nuclear export signal (NES), a nuclear localization signal 
(NLS), and a ligand-binding domain (LBD). Enhanced green fluorescent protein 
(EGFP) has been fused to the PS to allow convenient microscopic tracking. After 
translation, the PS takes on a conformation such that the NES is dominant, and the 
NLS is at least partially masked, resulting in a predominant cytoplasmic 
localization. After ligand induction, the conformation of the PS changes, the NLS 
becomes unmasked, and the protein translocates into the nucleus (3). The process 
for nuclear import and export that makes this PS possible is briefly summarized 
here, and more thoroughly discussed in Chapter 2.  
Nucleocytoplasmic Transport 
Eukaryotic cells have developed effective and selective transport machinery 
to ensure proteins are in the correct subcellular compartment. While transcription of 
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DNA happens in the nucleus, mRNA is exported to the cytoplasm for translation. 
For those proteins needed in the nucleus, such as steroid hormones, histones, and 
transcription factors, shuttling back into the nucleus must occur (5-10), but this 
must be done selectively (5, 11). Selectivity is possible because of the nuclear pore 
complex (NPC): the approximately 125 MDa structure forms aqueous channels in 
the lipid bilayer of the nuclear envelope at regular intervals (12, 13). These channels 
form the only site where ions, small molecules, and macromolecules pass. The 
overall structure is such that an interaction with the karyopharin family of 
transport receptors is permitted, but nonshuttling proteins are deflected (14-18). The 
NPC produces a gated, iris-like movement to select for proteins to translocate, but 
only for macromolecules greater than 39 nm in diameter (40-60 MDa) (19, 20). 
Smaller molecules may passively diffuse through the pore complex.  
Proteins that contain a “classic” NLS are imported into the nucleus by an 
importin α/β heterodimer (21). Protein import begins in the cytoplasm, with importin 
α recognizing an NLS. Cargo-bound importin α binds importin β, and translocation 
through the nuclear pore occurs (5, 22). On the nucleoplasmic side, RanGTP is 
needed to release the cargo, where it can subsequently function. The import proteins 
are recycled back to the cytoplasm for more import events to occur (5, 20, 23, 24). 
Classic NLSs fall into two categories: those that contain a single stretch 
(monopartite) of basic amino acids, or those that contain a bipartite sequence with 
two short sequences of basic amino acids separated by a spacer (12, 25, 26). An 
example of a classic monopartite NLS is the NLS in SV40 large T antigen 
(PKKKRKV), which is similar to the one used in the protein switch.  
For nuclear export, cargo proteins bind to transporters like CRM1 or 
calreticulin (CRT) in the presence of RanGTP.  This cargo/exporter/RanGTP complex 
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translocates through the NPC to the cytoplasm, where it is released by hydrolysis of 
RanGTP (5, 20, 23, 24). The export signals recognize the NES in the protein, which 
has been classified as a leucine rich sequence (5, 27). These classical NESs are about 
10 amino acids in length with hydrophobic residues such as leucine (28-31). 
Ligand-Inducibility: Using Steroid Hormone Receptors 
 Steroid hormone receptors (SHR) are part of the nuclear receptor superfamily 
of intracellular proteins that regulate gene transcription in response to ligands, and 
represent “the largest known family of transcription factors in eukaryotes” (32). 
SHRs include the glucocorticoid receptor (GR), estrogen receptor (ER), progesterone 
receptor (PR), androgen receptor (AR), mineralocorticoid receptor (MR), and 
ecdysone receptor (EcR) (33). The genes they regulate are important for growth and 
development, homeostasis, reproduction, and apoptosis. The general mechanism of 
SHRs are to bind ligand, release chaperone proteins like heat shock proteins (HSPs), 
translocate to the nucleus and form homodimers, bind DNA at the hormone response 
element with the help of coactivators, and initiate transcription (34, 35). The ER 
binds to the response element sequence AGGTCA, whereas the other SHRs 
recognize AGAACA (35). Interestingly, as the receptors are binding DNA as dimers, 
one receptor binds the conserved response element, and the other binds a less 
conserved sequence exactly three nucleotides away (35). 
 The structure of steroid hormone receptors is conserved, with a variable N-
terminal transactivation region, a DNA binding domain (DBD), a hinge region, the 
ligand-binding domain (LBD), and a C-terminal domain that also has 
transactivation functions (32, 35-37).  There are two activation function (AF) regions, 
where AF-1 in the N-terminus has ligand-independent function, and AF-2 within the 
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LBD has strict ligand dependence (38). The ability of SHRs to respond to ligands 
comes from the functionality in the LBD, and is crucial to the ability of the protein 
switch to respond to ligand. 
 The LBD functions to bind ligand and induce transcription, but also to 
mediate dimerization, interact with heat-shock proteins, coactivators and 
corepressors, and mediate nuclear translocation (38-40). LBDs have three main 
functional regions: the ligand binding pocket, dimerization region, and cofactor 
binding groove (40, 41). The accepted model for ligand binding is the “mouse-trap” 
model, which is that ligand binding creates a conformational change in the LBD that 
shifts the AF-2 region to allow for cofactor binding (42).  These LBDs have 12 α-
helices, called H1-H12. These helices are arranged into a “three-layered, antiparallel 
helical sandwich” (38). Together, these three helical sheets form an interior ligand-
binding pocket (35, 43-47). The size of the binding pocket correlates with the 
specificity of the receptor. Larger binding pockets allow for varied ligand structures, 
whereas smaller binding pockets have higher affinity for fewer ligands. The pocket 
allows for hydrophobic interactions, hydrogen bonding, and steric specificity for 
ligands, even among closely related steroid structures (35, 43-47). In the unliganded 
state, helix 12 is positioned in a way that it cannot interact with coactivators, but a 
conformational change upon ligand binding shifts its position, stabilizing it against 
the binding pocket and exposes a region that is able to interact with coactivators (45, 
46). Antagonist binding blocks this coactivator interaction, either through blocking 
the necessary conformation of helix 12 to allow coactivator binding, or by causing 
helix 12 to mimic the coactivator (44, 48). 
 These LBDs perform a crucial role in subcellular targeting because of their 
ability to conformationally respond to agonists or antagonists, creating ligand-
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inducibility. This domain influences the subcellular localization in both the liganded 
and unliganded states. The subcellular localization of the GR, for example, is greatly 
influenced by the LBD itself. Without ligand, the GR is cytoplasmic, but becomes 
nuclear upon agonist binding. Replacing the LBD of the PR, a predominantly 
nuclear receptor, with GRLBD changes the localization to predominantly 
cytoplasmic (49-53). In the cytoplasm, the receptor interacts with the chaperone 
protein HSP90, which is partially responsible for maintaining the receptor in this 
compartment (52-59). The HSP90 inhibitor geldanamycin blocks the interaction with 
GR, and results in nuclear translocation of the receptor. This translocation is 
possible due to two NLS signals located in the LBD (37, 59-62). Upon ligand binding, 
HSP90 is released, and localization signals are exposed, and the receptor 
translocates to the nucleus through the NPC (53, 63-66). 
Protein Switch: Design and Applications 
The protein switch is designed to be a means to correct or exploit the function 
of mislocalized proteins. Mislocalized proteins include tumor suppressors (p53, 
BARD1, BRCA1, INI1/hSNF5), transcription factors (FOXO, NF-kB), cell signaling 
proteins (β-catenin, rhodopsin, vasopressin receptor, LDL receptor, CTFR, dopamine 
D3 receptor), and may be mislocalized from virtually any part of the cell (Chapter 2, 
Davis et al. 2007 (1) and references therein). The bi-directional protein switch 
developed in our lab is capable of cytoplasmic-to-nuclear translocation when bound 
to cognate ligand. This research focuses on the selection of appropriate signal 
sequences to balance the cytoplasmic and nuclear localization upon induction, and a 
ligand-binding domain that produces the right conformational change that exposes 
the nuclear localization signal in order to create the translocation response.  
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The first protein switch was conceived of, and designed by, Charu Kanwal. It 
contained a nuclear export signal (NES) and a ligand binding domain (LBD) that is 
responsive to an external ligand (4). EGFP was selected as a gene of interest to track 
the localization of a protein construct using fluorescence microscopy (4, 31, 67-70). In 
the absence of external ligand (“off” position), the protein construct was mostly 
present in the cytoplasm due to the dominant effect of the NES. Upon ligand 
addition (“on” position), the protein construct translocated to the nucleus. This 
process is thought to occur due to a change in conformation of the LBD that masks 
the NES and harnesses the inherent translocation properties of steroid hormone 
receptors. This response was found to be dose-dependent (4). One conclusion drawn 
from this work was that the relative strength of the NES had an impact on the 
initial localization of the construct; a strong NES may overpower the ability of the 
protein to translocate to the nucleus. To build on this data, the optimization of this 
protein switch was then to make the “off” state more cytoplasmic and the “on” state 
more nuclear. The utility of the protein switch constructs lies in the ability to keep 
the attached therapeutic protein in one cellular compartment when inactive, and 
upon addition of ligand, controlled movement to another compartment where it has 
activity (or blocks activity, as the case may be).  
The first protein switch used a truncated form of the LBD from the 
progesterone receptor that is responsive to mifepristone (RU486) (71), and non-
responsive to natural agonist progesterone or synthetic agonist R5020. The benefit 
of an LBD with this ligand response is that naturally occurring hormone in the body 
would not trigger the translocation of the switch, meaning that it can be only 
externally controlled. A drawback of this ligand choice is that mifepristone can 
antagonize wild-type endogenous progesterone and glucocorticoid receptors, and is 
 11 
also used as an abortifacient (4). The need for this ligand is sub-optimal if this 
system is to ever reach the clinic, so a new LBD that responds to a ligand with fewer 
side effects or controversies was warranted. 
As previously mentioned, further optimization included making the protein 
switch more cytoplasmic in the unliganded state, and more nuclear in the liganded 
state. We hypothesized that adding a nuclear localization signal (NLS) to the protein 
switch may increase the nuclear translocation effect. The optimization revolved 
around balancing the relative NES and NLS strengths on the localization of 
constructs. The work thoroughly discussed in Chapter 2 focuses on the alternative 
NES, NLS, and LBD combinations that were examined in the optimization of the 
protein switch.  
Targeting the Cytoskeleton: Induced Interaction by  
Estrogen Receptor Ligand-Binding Domain 
One of the challenges of the protein switch optimization was that an LBD 
needed to produce a conformational change that tipped the balance of signal 
sequences in order to cause translocation. One such LBD that we tested was from 
the ER. During these experiments we learned that the ER antagonist fulvestrant 
causes cytoplasmic accumulation of the full-length receptor, with a transient 
association with cytokeratins 8 and 18 (CK 8/18) before finally being degraded by the 
proteasome. However, isolating the LBD portion alone did not result in proteasomal 
degradation, but did result in aggregation of our construct. Through a series of 
experiments delineated in Chapter 4, we found that fulvestrant caused the LBD to 
aggregate at the cytoskeleton. 
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The cytoskeleton of a eukaryotic cell is a dynamic structure comprised of 
proteinaceous filaments that fall into three types: intermediate filaments, 
microtubules, and actin filaments (also called microfilaments) (72-74). The 
intermediate filaments impart mechanical strength and organize the three-
dimensional structure of the cell (73, 75), the microtubules direct intracellular 
transport, and actin filaments influence the shape and protuberances of the cell, and 
participate in cell interactions with the environment (76). These proteins are able to 
rapidly rearrange and adapt to cellular needs and environmental conditions. For 
example, microtubules are most commonly associated with mitotic spindle formation, 
but also arrange as cilia and flagella that create cell or extracellular movement. 
Further, they can also be arranged as the transport network for materials within the 
cell, such as DNA and protein. Actin creates the contractile ring for cell division, but 
can also serve as the structure that creates muscle contraction. Intermediate 
filaments function intracellularly to encage the nucleus, and extracellularly to create 
strong structures, like hair and nails (74).  
Intermediate filaments include cytokeratins (keratins; CK), vimentins, and 
lamins, and all types are not necessary in every cell type. Cytokeratins, expressed in 
all types of epithelial cells, are the most diverse group in the intermediate filament 
category, with about 20 types in human epithelial cells, and at least 10 more are 
specific for hair and nails (74). The CKs can be divided into acidic (type I; CK9-19) or 
basic (type II; CK1-8) (72, 73, 77). Cytokeratin filaments come together in equimolar 
amounts to form heterodimers of type I and type II CKs, and the resulting chains 
dimerize to form a tetrameric subunit (72-74, 77). Multiple types of CKs within a cell 
will copolymerize to form a single network. Their diversity is useful in cancer 
diagnosis because a specific subset of CKs found in the tumor may hint at the 
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epithelial tissue from which the tumor originated (74). Indeed, CKs have been useful 
as immunohistochemical markers for diagnosis of tumor pathology (78). 
Cytokeratins in Cancer 
Adenocarcinomas arise from glandular tissue, and collectively comprise the 
majority of epithelial malignancies throughout the body (73, 78). Most 
adenocarcinomas express CK8 (and its obligate partner CK18), CK19, and variably 
CK7 and CK20 (72, 78). Both ductal and lobular types of breast adenocarcinomas 
constitutively express CK7,8/18, and 19 (72, 79). The CK7 positive and CK20 
negative phenotype has been associated with ovarian, endometrial, lung, salivary 
gland, and thyroid adenocarcinomas, as well as most mesotheliomas (72, 78, 80-82). 
Gastrointestinal cancers like pancreatic, esophageal, gastric and biliary tract 
adenocarcinomas are all CK7 positive, with variable CK20 positivity (80). 
Cytokeratin 7/20 negative cancers include prostate and hepatocellular carcinomas 
(72, 83).  
 In addition to diagnostic value, CKs also have value as prognostic markers in 
epithelial malignancies. For example, reduced expression of CK8 and CK20 is 
associated with tumor aggressiveness and decreased survival in patients with 
colorectal cancer (72, 84). There is also a well-defined relationship between 
cytokeratin expression and breast cancer. The basal-like subtype is defined by CK5/6 
positivity, and ER, PR, and human epidermal growth factor receptor-2 (HER2) 
negativity, and is associated with poor prognosis and low disease-free and overall 
survival (72, 85, 86). Downregulation of CK18 is associated with advanced tumor 
grade, bone metastasis, and decreased survival in metastatic breast cancer (72, 87-
90), and 25 to 80% of all breast carcinomas have loss of CK18 expression (90-93).  
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 Interestingly, while loss of CK expression is correlated with poorer prognosis 
in some tumor types, CK expression can protect against cellular stressors such as 
death receptor activation and chemotherapy. For instance, mice with CK8/18 
knockout are more susceptible to apoptosis mediated by Fas (extrinsic apoptotic 
pathway). Over-expression of CKs by transfection can impart multidrug resistance 
to chemotherapeutic agents (72, 94-97).  
The Estrogen-Receptor Aggregates to the Cytoskeleton 
The estrogen receptor (ER) is a member of the steroid hormone nuclear 
receptor  (SHR) family (98), and as such it has an N-terminal activation domain, a 
central DNA binding domain, and a C-terminal ligand binding domain (LBD) (32), 
and functions as a transcription factor when bound to ligand (36, 44). The stability of 
the ER has been shown to be dependent upon the ligand to which it is bound (99). 
Estradiol destabilizes ER, tamoxifen stabilizes, and fulvestrant (ICI) results in 
cytoplasmic aggregation and subsequent proteasomal degradation. Fulvestrant, a 
clinically useful antagonist of ER, is a member of the selective estrogen receptor 
down-regulators (SERDs) that act to disrupt the typical nucleocytoplasmic shuttling 
of ERα and causes rapid degradation (100, 101). The bulky side chain of fulvestrant 
induces a conformational change of helix 12 within ERα’s LBD that increases 
hydrophobicity and results in receptor insolubility (102, 103). After insolubility 
comes proteasomal degradation, likely due to cytokeratins 8 and 18, which facilitate 
proteasomal degradation of ERα (104). However, proteasomal degradation requires a 
functional helix 12, and an active transcriptional activation complex (105-107). 
Cytokeratins 8 and 18 are the primary intermediate filaments of single-layer 
epithelial cells (78). We hypothesized that a GFP fusion protein with the ligand-
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binding domain of ER (ERLBD) will target the insoluble cytoskeletal fraction when 
bound to fulvestrant. Isolating the LBD from ER will still provide a LBD for ligand 
control, but will not result in transactivation or proteasomal degradation because it 
lacks the other domains necessary for those processes. A construct capable of 
forming insoluble aggregates could be useful in sequestering active proteins, 
rendering them inactive.  
 
Targeting the Ubiquitin-Proteasome Pathway: 
p53 and ER Protargs 
 In the previous section, it was mentioned that we learned of the response of 
full-length ER to fulvestrant binding: receptor degradation by the proteasome. While 
we did examine what would happen if only the LBD was isolated, the potential to 
target the proteasome did not escape our attention. This led us to the hypothesis 
that the ubiquitin-proteasome pathway could be targeted if a fusion protein was 
constructed that contained a region that would ultimately get ubiquitinated and 
sent to the proteasome for degradation. We termed these constructs “protargs.” 
Several such protargs were proposed, and two are discussed in this dissertation. The 
first is based on the p53/MDM2 interaction, and the other was utilizing full-length 
ER.  
 Sending proteins to the ubiquitin-proteasome pathway is another means of 
controlling a protein’s function by localization. Intracellular proteins that are 
associated with disease, such as Bcr-Abl in chronic myeloid leukemia (CML) (108-
110), inhibitors of apoptosis such as survivin and XIAP (111, 112) and MDM2 (113, 
114) present themselves as interesting targets for therapy. Many of these disease-
associated proteins have small molecule inhibitors that are effective (tyrosine kinase 
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inhibitors against Bcr-Abl, for example (115)) but others do not have druggable 
domains. Survivin is a member of the inhibitor of apoptosis (IAP) family, whose 
over-expression has been associated with a wide array of cancers, and thus far small 
molecules have not successfully been developed against survivin, so novel gene 
therapy approaches may be particularly instrumental in blocking its activity (116-
118). We hypothesize that creating a protein capable of exploiting the ubiquitin-
proteasome system will direct these proteins to the proteasome, and may be an 
effective therapeutic modality. The first protarg described is based on the tumor 
suppressor p53 and its induced proteasomal degradation by MDM2. This work has 
led to a manuscript submitted for publication, but the ER protarg has yet to be 
proven as an effective proteasome targeted protein. The foundation of this concept is 
introduced here. 
The ubiquitin-proteasome system is the major proteolytic system in 
eukaryotes, “with critical function in cell cycle control, apoptosis, inflammation, 
transcription, signal transduction, protein quality control, and many other biological 
processes” (119), and is integral to the balance of cellular anabolic and catabolic 
pathways (120). It is estimated that 80 to 90% of cellular proteins are degraded by 
the proteasome in both the cytoplasmic and nuclear compartments (71, 121-124). 
The involvement of the proteasome in the degradation of oncogenes and tumor 
suppressors has drawn attention to the proteasome as a potential tool in cancer 
therapy (125, 126). The process begins with an enzyme cascade involving E1, E2, 
and E3 enzymes that together coordinate the conjugation of ubiquitin to a target 
protein. The processes of proteasome recognition and degradation of proteins will be 
discussed here. 
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The 26S Proteasome 
The proteasome is a large protease, with a size of over 2.5 mDa. It functions 
as a protease that degrades proteins conjugated with ubiquitin moieties (119, 123, 
127). The proteasome is responsible for recognition of proteins marked for 
degradation, protein unfolding, and ubiquitin hydrolysis—all distally from the 
actual site of proteolysis. These mechanisms are mediated by the different subunits 
of the proteasome. In order to protect the cell from unregulated proteolytic activity, 
the proteasome has a barrel shape, which the proteolytic activity occurring 
internally, restricting access to only those proteins recognized and unfolded by the 
“lid” structure (128, 129).   
 The proteasome can be split up into two structurally and functionally distinct 
units: the 19S regulatory lid, and the 20S core particle (120). The 20S proteasome 
contains 28 subunits, with two copies each of seven distinct α and β subunits. The 
barrel shape comes from two rings of β-type subunits capped on top and bottom with 
a ring of α-type subunits, such that the arrangement is [(α1- α7)(β1- β7) (β1- β7) (α1- 
α7)], with pseudo seven-fold symmetry (120, 130).  This subunit arrangement yields 
three inner compartments, two antechambers, and a proteolytic chamber. The 
proteolytic chamber is formed by the β-type subunits (120). The 19S regulatory unit 
is V shaped, and caps the 20S core on both ends (131, 132). The 19S particle, often 
referred to as the regulatory particle, is composed of 19 subunits, six ATPases that 
form the base, and 13 regulatory subunits (133). The base is proximal to the core, 
and is comprised of six ATPases (Rpt1-6) of the AAA family (134, 135).  These 
ATPases form a pseudo-symmetrical ring structure that forms the interface with the 
α-type subunits of the 20S core (119, 129, 136-138). The ATPases function to catalyze 
the assembly of the 19S and 20S complex into the 26S proteasome, gating the entry 
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of proteins into the catalytic core, and to bind, unfold, and translocate proteins into 
the core (128, 131, 135, 139-142). The 13 regulatory subunits are termed Rpn1-3, 
Rpn5-13, and Rpn15. The lid consists of Rpn3/5/6/7/8/9 (119, 143). The Rpns are 
positioned in such a way that Rpn8 and 11 are at the tip, which are the subunits 
involved in deubiquitination (143). 
Substrate Recognition and Deubiquitination 
Proteins tagged with at least four ubiquitin moieties are recruited to the 
proteasome for degradation (144, 145). Rpn10 and 13 are the subunits of the 19S 
proteasome responsible for recruiting ubiquitinated substrates (143, 146). A distance 
of 90 Å separates these two subunits, which is the length of 4 ubiquitin moieties (144, 
145). A commitment step follows initial docking of the protein (147). Lasker et al. 
have recently put forth a hypothesis that other subunits in the regulatory particle, 
namely Rpt1/2 and Rpt4/5, rotate to swing Rpn10 and Rpn13 closer to Rpn11 to 
allow access to the ubiquitinated protein (143).  This motion may also open the gate 
to the core. Rpn11 recognizes ubiquitin chains at the proximal ubiquitin to the 
protein to which it is attached, resulting in whole ubiquitin chain cleavage, a process 
that is ATP-dependent (148). As a side note, there are other deubiquitinating 
enzymes can remove ubiquitins before they reach the proteasome (Ubp6 and Uch37), 
but they antagonize protein degradation rather than facilitate it (149). 
The proteolytic activity of the proteasome originates from the β-type subunits, 
which are part of the N-terminal nucleophile hydrolases superfamily (150, 151). The 
amino acids necessary for proteolytic activity are N-terminal thr-1, glu-17, lys-33, 
and asp-166. The N-terminal thr-1 on each β-type subunit is a nucleophile that 
attacks the carbonyl carbon of a peptide bond with its side-chain amino group and a 
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water molecule (152-156). The main proton acceptor is the main-chain amino group 
(157). The proteolytic activity of the proteasome is often referred to as having 
caspase-like, trypsin-like, and chymotrypsin-like activity (158). This is due to the 
preferences that different β-type subunits have for amino acid residues. β1 prefers 
acidic residues, β2 cleaves on the carboxyl side of lysine or arginine, and the β5 
cleaves after hydrophobic residues, but these enzymes have relatively low specificity 
(157). As the protein is degraded, peptides are trapped within the chamber until 
they are about seven to nine residues in length (159). This is likely related to the 
physical distance between active sites within the proteasome (119).  
Ubiquitin and its Ligases  
Ubiquitin is a protein with 76 amino acids. As previously mentioned, 
ubiquitin is conjugated to proteins in a coordinated effort by ubiquitin enzymes. This 
may occur singly, called monoubiquitination, which may not result in protein 
degradation. Monoubiquitination has functions like histone processing, 
transcriptional activation, endocytosis, DNA repair, and endosomal sorting (160-
164). Polyubiquitination is the global signal for proteasomal degradation. 
The first step in protein ubiquitination is the creation of a thioester linkage 
between ubiquitin and a ubiquitin-activating enzyme (E1) in an ATP-dependent 
manner. The next step is trans-thiol esterification of the ubiquitin to a ubiquitin-
conjugating enzyme (E2; ubiquitin carrier protein (UBC)). A ubiquitin-protein ligase 
(E3) catalyzes the transfer of ubiquitin to the ε-amino group of a lysine residue 
within the target protein (165). Lysine residue 48 becomes a possible site for 
ubiquitination, which is necessary for chain formation (122, 163, 166). Chain 
elongation may involve other factors aside from E2 and E3. The specificity of E3 
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ligases is such that they recognize few proteins, which means there are many E3 
ligases (~600 in mammals) within the cell (167, 168). Specific combinations of E2 
and E3 enzymes must come together, but there are fewer E2s in the cell (~40 in 
mammals) (163, 167). E1, E2, and E3 enzymes do have some functions unrelated to 
ubiquitination, such as SUMOylation and NEDDylation, which are other post-
translational modifications for intracellular signaling (169). 
E3 ligases belong to one of three families: the HECT (homologous to E6AP 
carboxy terminus), the RING (really interesting new gene) finger, and U-box domain 
types (163, 167, 170). These different E3 families have separate mechanisms for 
transferring ubiquitin to their target protein.  
HECT domain E3s have roles that regulate cellular growth, protein 
trafficking, and the immune response (167, 170). The HECT domain is comprised of 
about 350 amino acids in the C-terminal end of the protein. The N-terminal domains 
are varied to allow for diverse substrate targeting. Within the C-terminal HECT 
domain, there are two lobes, where one interacts with the E2, and the other contains 
the active site that forms a cysteine thioester intermediate with ubiquitin (171). It is 
proposed that these two lobes are connected by a hinge that allows them to swing 
together for ubiquitin transfer with E2 enzymes (167, 171-173).  
While HECT E3s form a thioester intermediate with ubiquitin, the RING 
finger E3s provide direct transfer. RING finger domains have a Zn2+-coordinating 
domain with cysteine and histidine residues that mediate E2-dependent 
ubiquitination (174). Two Zn2+ ions and amino acid residues form a scaffold that 
brings the E2 and target protein together (175). An interesting property of the RING 
finger members is that they can act as monomers, acting independently to 
ubiquitinate proteins, or they may act with a dimer partner, forming homo- or 
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heterodimers. Examples of E3s requiring homodimerization are inhibitors of 
apoptosis, RNF4, SIAH, and TRAF2. Examples of E3s with heterodimer formation 
are MDM2 with MDMX, and BRCA1 and BARD1. The requirement for some E3s to 
form heterodimers is that one RING domain alone lacks the ability to stabilize the 
E2-binding RING domain (167). 
 U-box domain E3s are similar to RING domain ligases, but do not have Zn2+ 
coordinating the ubiquitin transfer, but do so with hydrogen bonds and salt bridges. 
An example of a U-box ligase is CHIP, a ligase that acts as a homodimer and 
requires protein chaperones, like HSP90, HSP70, and HSC70 (176-178). CHIP 
participates in sending proteins to the degradation pathway, but is also involved in 
chaperone-assisted protein folding (167, 178, 179). 
The Proteasome Pathway in Cancer Therapy  
 Clearly the proteasome and the proteins it degrades have major consequences 
in a broad range of cellular functions—both positive and negative. The impact that 
the proteasome has on proteins involved in cancer has drawn attention to the 
proteasome and the ancillary proteins in the pathway as druggable targets.  The 
typical approaches to target this pathway have focused on inhibiting the proteasome 
directly by blocking the catalytic activity of the β-type subunits, or by inhibiting the 
E3 ligases that affect a protein of interest. The most famous example of a 
proteasomal inhibitor is bortezomib (Velcade®), the first Food and Drug 
Administration (FDA)-approved drug in its class, and indicated in the treatment of 
patients with multiple myeloma (180). The FDA has recently approved a new 
proteasome inhibitor, carfilzomib (Kyprolis®), indicated for patients with multiple 
myeloma who have progressed after prior therapies, including bortezomib (181). 
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MDM2, the E3 ligase for p53 has been targeted, with at least two drugs in clinical 
trials (RO5045337, JNJ-26854165) (182). Rather than inhibiting the proteasome, we 
sought to utilize it—we wanted to send proteins deliberately to the proteasome for 
degradation. The first protarg discussed here is based on p53 and MDM2. The 
MDM2/p53 interaction that causes proteasomal targeting is discussed later in this 
introduction, and in Chapter 5.  
p53 Tumor Suppressor 
p53 was the first tumor suppressor to be identified, and now it is the most 
widely recognized and well-characterized tumor suppressor (183). First described in 
the literature in 1979, the name p53 came from its size: 53 kDa. It was initially 
thought to function as an oncogene because of its high expression in transformed cell 
types, and relatively low expression in nontransformed types (184-187). Further, it 
was thought that mutations in p53 enhanced its transformation efficiency (188). 
Ultimately, it was discovered that the original cDNA used in experiments was a 
mutated inactive form, and subsequent studies demonstrated conclusively that p53 
is indeed a tumor suppressor, not an oncogene (189).   
We now know the main functions of p53: to act as a transcription factor, cell 
cycle regulator, and initiator of apoptosis. More specifically, it binds to regulatory 
regions in the DNA of specific genes involved in regulating the cell cycle and 
induction of apoptosis in response to stress. p53 is maintained at low levels, but in 
response to stress it accumulates as a function of increased p53 translation and 
decreased p53 degradation (190). The accumulation occurs in the nucleus, which 
promotes the transcription of genes associated with apoptosis and cell cycle arrest. 
This can occur due to DNA damage, hypoxia or hyperoxia, nucleotide depletion, 
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aberrant growth signals, chemotherapeutic agents, ultraviolet light, or oncogene 
activation (189). 
Inactivating mutations in p53, or loss of p53 altogether, was found in nearly 
half of human cancer types, and is thought to be the most commonly altered gene in 
human tumors (189, 191, 192). In cancers where the gene is not inactivated, post-
translational modifications and other protein interactions may inactivate the 
function of p53 (193-195). As p53 is a nodal protein, interconnected to many proteins 
that perform important roles in cell cycle and cell death, it is unsurprising that loss 
of p53 function is selected in most cancer types (196). 
p53 Structure and Tetramerization 
 The p53 protein specifically binds to target sequences as a tetramer (197). 
Wild-type p53 (α-isoform) consists of 393 amino acids (aa), with five functional 
domains. These domains are: two N-terminal transactivation domains (TD1: aa 1–42, 
TD2: aa 43–63), a proline-rich domain (PRD: aa 64–92), the central DNA-binding 
domain (DBD: aa 102–292), the C-terminal tetramerization domain (aa 326–356) 
and basic domain (aa 364–393) (189). It is important to note that at least 10 
different isoforms of p53 have been described in the literature, and are beyond the 
scope of this dissertation (198, 199).  
The transcriptional activation domain is necessary to recruit transcriptional 
machinery, such as the TATA box binding protein (TBP) and TBP associated factors 
(TAF) of the initiation complex (200). The N-terminus contains the location of 
MDM2 binding and the proline-rich domain (amino acids 63-97) that is necessary for 
p53-mediated apoptosis and tumor growth suppression (201, 202). The DNA binding 
domain contains the region that binds to the consensus target sequence, and also 
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contains the most mutations (189). The tetramerization domain is necessary for 
transactivation of p53 and tumor suppression, as the active form of p53 is tetrameric 
(203). p53 forms an antiparallel dimer of dimers, that is two monomers form a dimer, 
with which it forms another antiparallel dimer (204). The C-terminus contains 
regulatory regions that regulate DNA binding, transcription activation, and post-
translational modification (189).  
As previously mentioned, mutations of p53 occur in about half of human 
tumors, and the majority of these mutations are located in the DBD, concentrated in 
only a few nucleotides, which influences the binding of p53 to its target sequences 
(189, 205). Some of these nucleotide changes result in the exchange of amino acids 
that make contact with the DNA, which eliminates or weakens the binding of p53 to 
DNA, or even alters the sequence specificity of the mutant p53. Mutant p53 may 
actually become oncogenic (206).  
Regulation of p53 
 The amount, localization, and activity of p53 can be posttranslationally 
regulated with modifications like phosphorylation, acetylation, ubiquitination and 
attachment of ubiquitin-like moieties such as SUMO and Nedd8 (207). The primary 
phosphorylation sites are at the N-terminal Ser and Thr residues. As these reside in 
the MDM2 binding domain, phosphorylation affects p53 stability (i.e. proteasomal 
degradation), and p53-associated apoptosis or senescence. Acetylation on the C-
terminus may block ubiquitination on critical lysine residues; these modifications 
stabilize p53 and promote apoptosis and senescence (208). 
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MDM2-p53 Interaction  
 MDM2 is the predominant ubiquitin ligase regulating p53 (209). MDM2, or 
murine double minute clone 2, is classified as an oncogene, and it is the major down-
regulator of p53 (190). It is a member of the RING family of E3 ligases (210) that 
was originally identified as a protein involved in abnormal cellular proliferation and 
tumorigenesis (211), and was found to be over-expressed in osteosarcomas and soft 
tissue tumors (195). The feedback loop of p53 with MDM2 is such that p53 binds to 
the regulatory region of the MDM2 gene, which stimulates transcription of the gene 
and ultimately increased MDM2 protein levels. As MDM2 levels rise, p53 
modification by ubiquitination increases, and p53 is degraded. As p53 levels 
decrease, less MDM2 is made (212, 213). Mouse genetic studies have demonstrated 
that MDM2 can regulate p53 activity in embryonic cells, preventing p53 from 
inducing apoptosis inappropriately (214). 
 The signal for proteasomal degradation is attachment of ubiquitin to the C-
terminal lysine residues of p53 by MDM2, which is a specific E3 ligase for p53 (207). 
The interaction of MDM2 with p53 occurs in the N-terminal region, with MDM2 
transferring a ubiquitin to p53 and thereby beginning the path to degradation (210). 
This monoubiquitinated p53 is shuttled out of the nucleus via the classical export 
pathway mediated by CRM1. p53 also contains an NES that is masked by tetramer 
formation, and the loss of tetramerization by ubiquitination also results in increased 
export of the protein (215). The MDM2/p53 interaction also blocks the 
transactivation function of p53 by binding a region that is necessary for increasing 
RNA polymerase II-mediated transcription, so genes for cell cycle arrest and 
apoptosis are not upregulated (216). As levels of MDM2 rise, transactivation of p53 
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is blocked, and p53 is marked for degradation and levels fall, leading to a 
commensurate drop in MDM2 levels (190). 
The role that MDM2 plays in p53s activity naturally draws focus to how it 
may be involved in the development of tumors. Tumor types with over-expressed 
MDM2 may proliferate even with wild-type p53, but this is only noted in 7 to 20% of 
tumors (most notably soft tissue tumors and sarcomas) (190, 217). 
Crystal structure analysis of MDM2/p53 reveals that MDM2 binds p53’s 
transactivation domain, with p53 having amino acids phe19, trp23, and leu26 
sliding deeply into a cleft in the N-terminus of MDM2, required for binding to 
transcriptional machinery (218). 
 Transfer of the ubiquitin moiety from an E2 ligase depends on the domain of 
MDM2 (219). While MDM2 is necessary and sufficient for ubiquitination of p53, its 
homologue MDMX is necessary for proper p53 regulation. MDMX also contains a 
RING domain, but does not demonstrate ubiquitin ligase activity towards p53 (220). 
MDMX regulates p53 by forming heteromers with MDM2 and enhances MDM2-
mediated ubiquitination of p53. The importance of MDMX is highlighted by 
knockout studies that demonstrate embryonic lethality (207). Like MDM2, MDMX is 
frequently over-expressed in tumors with wild-type p53 (206). 
The ubiquitination of p53 by MDM2 begins with the binding of MDM2 to the 
N-terminal BOX-I region of p53. This single interaction is not enough for MDM2 to 
ubiquitinate p53; small molecule mimetics of this interaction do not prevent the E3 
ligase activity of MDM2 (221-225). A second region within p53, called BOX-V, was 
determined to be capable of providing a ubiquitination signal and docking site for 
MDM2 (222, 226). BOX-V-like peptides that bind MDM2 are potent inhibitors of the 
ubiquitination action of MDM2. This led Wallace et al. to propose a model where 
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binding of MDM2 to the N-terminal BOX-I region of p53 allosterically promotes 
binding of the acidic domain of MDM2 to the BOX-V region (222, 227). In other 
words, the allosteric activation of MDM2 by the N-terminal BOX-I region allows a 
conformation in MDM2 to bind the BOX-V region within p53s DBD to allow E2 
transfer of ubiquitin to the C-terminus of p53. 
p53-Directed Therapies 
Several different approaches to restore or promote p53 action are described in 
the literature, and range from small molecule inhibitors of p53 regulators, to 
replacement of the TP53 gene. p53 therapies may seek to restore wild-type p53 
activity by introducing wild-type p53 to replace the lack of tumor suppression by 
mutant p53 (228-230). Cell-based experiments have shown that the ectopic 
expression of wild-type p53 induces apoptosis or senescence in cells with mutant p53 
(231-236). A drawback of this approach is that in cells with mutant p53, 
oligomerization between endogenous and exogenous p53 may occur, and the effect of 
the wild-type protein is dampened or abrogated entirely (237). However, p53-
negative tumors may respond highly to this approach (238). 
The most commonly used methods to introduce exogenous wild-type p53 are 
delivery by retroviral and adenoviral vectors (239). While retroviral vectors integrate 
their DNA into the genome, adenoviral vectors do not (240). Integration of viral DNA 
may itself result in tumorigenesis. Adenoviral vectors are able to infect non-
proliferating cells, but normal cells appear to be largely unaffected by the over-
expression of p53 (241).  Advexin®, a replication-deficient adenovirus carrying wild-
type p53, has been tested in clinical trials, but the FDA has not approved it for use 
in the United States. In China, a virally delivered form of p53, called Gendicine®, is 
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already being used therapeutically for head and neck squamous cell carcinoma with 
some success (242). The complete remission (CR) and partial response (PRR) rates in 
phase I/II studies were 64% and 29% respectively in combined therapy of Gendicine 
and radiotherapy. Radiotherapy alone produced a CR of 19% and PR of 60% (243). 
These results are not without controversy as the clinical trials in China are 
considered to be less rigorous than in the United States, and some experts consider 
the trial methodology to be flawed (244). 
Small molecule therapeutics have been developed to compensate for specific 
p53 mutations that prevent necessary protein interactions or result in 
destabilization of the protein. Three compounds with proven activity are PRIMA-1 
(p53 reactivation and induction of massive apoptosis), CP31398, and PhiKan083 
(206). PRIMA-1 restores DNA binding of p53 with several different mutations in the 
DNA binding domain, and results in the activation of the mitochondrial apoptosis 
pathway via upregulation of Puma and Bax (245, 246). CP31398 compensates for the 
destabilization of the DNA binding domain due to mutations in p53, possibly by 
alkylating cysteine residues. The stabilized protein was able to upregulate the cell 
cycle inhibitor p21 and induced apoptosis (206). PhiKan083 also functions by 
stabilizing the Y220C mutation commonly seen in p53 (206). Many other small 
molecules are in development that similarly restore activity of mutant p53, but they 
will not be discussed here. 
MDM2-Directed Therapies 
Targeting MDM2 is a means of reactivating p53 in tumor cells with wild-type 
p53, which means interruption of the cell cycle and/or apoptosis (182). MDM2 is 
over-expressed in certain tumor types, so it is an attractive target for cancer therapy. 
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MDM2 over-expression negatively correlates with prognosis in sarcoma, glioma, and 
acute lymphocytic leukemia (114, 182), and inhibition of MDM2 has shown growth 
inhibition of lymphoma, sarcoma, and hepatocellular carcinoma in animal studies 
(182, 247). Over-expression of MDM2 is the result of single nucleotide 
polymorphisms in the promoter region (248), and the result is loss of p53 activity. A 
diverse group of compounds has been identified by high-throughput screening, as 
well as by computational database screening, that inhibit the p53-MDM2 interaction. 
These small molecules target this interaction by inhibiting MDM2, blocking MDM2 
binding on p53, or inhibiting the E3 ligase activity of MDM2 (182). The most 
promising of these compounds directed against MDM2 are the small molecule 
inhibitors called nutlins (206). Nutlins are imidazoline compounds that displace p53 
by mimicking the BOX-I region, binding the p53 pocket of MDM2 with nanomolar 
potency (90 to 260 nM) (249, 250). Currently, there are three nutlins, nutlin-1, -2 
and -3, which share a common structure but differ in their substituting moieties. 
These nutlins inhibit MDM2 because they mimic the key amino acids in p53 that 
MDM2 recognizes. The result is that p53 is stabilized, target gene expression is 
induced, and cell cycle arrest or apoptosis follows. The pro-apoptotic function of 
nutlin-3 (RO5045337) has been examined in several tumor cell lines and primary 
lines (250-252). These experiments demonstrated a requirement for wild-type p53 
for nutlins to have a cytotoxic effect. This drug is already in early-phase clinical 
trials, and is one to watch as an agent with potentially interesting outcomes.  
p53 Protarg: Design and Applications 
We propose a novel proteasome targeting, or “protarg” system. This will be a 
protein fusion of a control domain, a ubiquitin-interacting domain (UID), and a 
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functional domain—one that interacts with the intracellular environment, or one 
that can dimerize with an endogenous protein. The degradation of protargs will be 
induced when ubiquitin ligases interact via the UID and subsequently translocate to 
the proteasome for proteolysis. The protarg tested will be based on the p53-MDM2 
interaction, where the access of MDM2 to p53 will be under control of externally 
applied ligand. The protein switch (PS) previously described and elucidated in 
Chapter 2, will be applied as the control domain. Fused to the PS will be a p53 
domain capable of interacting with—and being ubiquitinated by—MDM2. The 
functional domain is not explored in this work, but will be discussed in the final 
chapter. We hypothesized that the PS would dictate the localization of the p53 
domain such that without ligand, it would be cytoplasmic, and therefore untouched 
by MDM2. With PS induction by dexamethasone, the construct would translocate to 
the nucleus and interact with MDM2, and ultimately result in nuclear export and 
proteasomal degradation.  
ER Protarg 
The human estrogen receptor is a member of the nuclear hormone family of 
transcription factors that, when activated by agonist, binds to an estrogen 
responsive element (ERE) located within the regulatory sequences of target genes 
(253). The receptor has three main functions: hormone-independent transactivation 
through the N-terminal AF1 domain, DNA binding through the DNA binding 
domain, and ligand binding and transactivation through the ligand-binding domain 
(LBD) (32, 36, 253, 254). The endogenous hormone that activates estrogen receptor 
is estradiol, which acts to induce a conformational change of helix 12 (within the 
LBD) that allows for coactivator binding and subsequent interaction with EREs. 
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Further, estradiol binding induces ER proteasomal degradation. Much research has 
been done to determine the effect of ligands on the conformation of helix 12, and 
receptor degradation. The pure antagonist fulvestrant has been found to block all 
ER transactivation, and potently induces the proteasomal degradation of the 
receptor (99, 100, 104, 255, 256). Fulvestrant binding induces a unique 
conformational change in helix 12 that allows for the interactions with cytokeratins 
8 and 18 (CK8/18), and simultaneously recruits ubiquitin ligases to begin the 
degradation targeting process (104, 107). These CK8/18 intermediate filaments are 
closely associated with proteasomes, and this is thought to facilitate the quick 
degradation of the ER. We propose to exploit this efficient degradation process to 
create a ligand-controllable protarg responsive to the ligand fulvestrant. This system 
will provide the most control, resulting in on/off proteasomal degradation: on in the 
presence of fulvestrant, off in its absence. The estrogen receptor used in these 
studies needs to be capable of degradation upon fulvestrant binding, but it should 
not transactivate gene expression if bound to endogenous hormone estradiol. Work 
by Valley et al. showed that the mutation of a serine 167 to alanine abolished a 
phosphorylation event necessary for complete transactivation of the receptor, but 
maintained the ligand-induced degradation (105-107). Other groups have attempted 
to determine critical amino acid residues necessary for fulvestrant-induced 
degradation, but all have been done in a full-length ER context, with results varying 
between cell lines (107, 257, 258). Thus, to retain fulvestrant-induced degradation 
without introducing a receptor capable of promoting cellular proliferation, a full-
length receptor with the S167A mutation will be used. The first use of this 
particular protarg was the intracellular inhibitor of apoptosis (IAP) survivin. 
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Survivin as a Cancer Target 
Survivin is a member of the inhibitor of apoptosis (IAP) family of proteins, 
undetectable in differentiated tissue, but over-expressed in embryonic and cancerous 
cells (259). Survivin is one of a few nodal proteins involved in multiple signaling 
pathways implicated in tumor progression (112). Initially characterized by Altieri 
and colleagues in 1997 (259), an immense body of research has been conducted on 
survivin in the last 12 years, including clinical trials of inhibitors of this important 
cancer pathway. Altieri best summarized survivin’s importance as “…one of the 
most tumor-specific molecules, which antagonizes apoptosis, promotes tumor-
associated angiogenesis, and acts as a resistance factor to various anticancer 
therapies” (112). Many potential roles for survivin in the inhibition of apoptosis and 
its role in normal cell division have been described in the literature and will be 
briefly summarized here.  
Survivin’s function at cell division is to target members of the chromosome 
passenger complex (CPC) to kinetochores. This complex, comprised of inner 
centromere protein (INCENP), aurora-B kinase, and borealin, has important 
functions for normal mitotic processes, including chromosome condensation, 
chromosome congression, sister chromatid separation, and cytokinesis (260, 261). 
Functional CPC is responsible for the attachment of chromosome kinetochores to 
mitotic spindles (262). Defects in this pathway lead to mitotic defects, such as 
aneuploidy. Aside from CPC survivin, a distinct pool of microtubule-associated 
survivin exists, which functions to enhance spindle formation through increased 
microtubule stability (263). Microtubule-associated survivin is phosphorylated by 
cyclin-dependent p34cdc2-cyclin B1 at G2/M, which has been determined to be 
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essential to maintain microtubule stability and inhibit apoptosis of mitotic cells 
(264). 
Survivin’s anti-apoptosis has been attributed largely to its ability to interact 
with cytosolic proteins, specifically those involved in mitochondrial-associated cell 
death. Research has demonstrated the interaction of survivin with caspases, the 
family of cysteine proteases responsible for cytochrome c-induced apoptosis, prevents 
the formation of the apoptosome and downstream apoptotic pathways (265-267). One 
such interaction is the ability of survivin bound to hepatitis B X-interacting protein 
(HBXIP), to directly inhibit pro-caspase-9 (268). Activated caspase-9 is required to 
activate effector caspases-3 and caspase-7, which execute mitochondrial-induced 
apoptosis (269). Thus, the disruption of this pathway prevents apoptosis and cell 
death. A separate pool of survivin in the mitochondria has been identified in tumor 
cells that, upon apoptotic stimuli, is expelled to the cytoplasm (270). XIAP (X-linked 
IAP) binds this pool of survivin, and antagonizes the effect of caspase-3 and 9 that, 
again, prevents cytochrome c-mediated apoptosis (270, 271). The second 
mitochondria-derived activator of caspase (SMAC, also called DIABLO) is also 
released by the mitochondria in response to apoptotic stimuli. This protein is 
capable of inhibiting XIAP, thereby preserving caspase activity and cell death (272). 
Survivin is capable of modulating the activity of SMAC/DIABLO. First, 
mitochondrial survivin delays the release of SMAC from the mitochondria after 
apoptotic stimuli (273). Second, cytosolic survivin can bind and sequester SMAC 
away from XIAP, thus allowing XIAP/survivin to antagonize caspases 3 and 9 (274).  
The transformation of survivin from an undetectable protein in differentiated 
tissue to a major player in cancer cells can be explained by the regulators of 
survivin’s expression, which is under the control of the BIRC5 promoter (259). The 
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tumor suppressor p53 is stabilized by DNA damage, which then represses BIRC5 
transcription (275). However, the loss of p53 function common in cancer may 
contribute to the over-expression and improved cell survival seen with survivin over-
expression (112, 276).  Oncogenic factors that bind to the BIRC5 promoter and 
induce the expression of survivin have been identified, such as transcription factor 4 
(TCF4) and signal transduction and activator of transcription 3 (STAT3) (277-279). 
It is this dysregulation and over-expression of survivin in tumor tissues that 
presents a unique target for cancer therapy, and is exceptionally well suited as a 
first target for our proposed targeted protein degradation system. 
Proteasomal Degradation of Survivin 
This ubiquitin-proteasome pathway degrades survivin, with ubiquitination 
occurring on multiple lysine residues (280). The exact survivin degradation pathway 
has not been fully elucidated, but its mechanism appears to be unique from other 
inhibitors of apoptosis, and may be dependent upon a XIAP-XAF1 complex, where 
XAF1 (XIAP-associated factor 1) activates the E3 domain of XIAP, which then 
ubiquitinates survivin and sends it to the degradation pathway (281, 282). 
Survivin’s half-life is cell line-, and cell cycle- dependent, and is typically short in 
embryonic cells (around 30 minutes). However, posttranslational processes involved 
in tumor cells increase survivin’s half-life, as evidenced by a reported half-life of 10 
hours in MCF-7 human breast cancer cells (283). The increased half-life of survivin 
in a tumor cell line highlights the potential to directly reduce its half-life by inducing 
its degradation.  
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The Controlled Degradation of Survivin 
The presence of survivin in tumor tissues provides a heightened survival 
threshold, increases cellular proliferation, and decreases responsiveness to cytotoxic 
agents (111). Specifically inducing the degradation of over-expressed survivin should 
reduce the survival threshold, decrease proliferation, and increase responsiveness to 
cytotoxic agents.  
The controlled proteasomal degradation of p53 was previously described, but 
we propose that protargs can be created with diverse ubiquitin-interacting domains 
(UID). Here, we propose a protarg with full-length estrogen receptor (ER), whose 
degradation can be controlled by the addition of fulvestrant. With a survivin binding 
domain fused to ER, we hypothesized that endogenous survivin will also be degraded 
due to its binding to the protarg via the survivin-binding domain (SBD).    
To degrade endogenous survivin, these protargs will promote survivin 
degradation in trans. In other words, the interaction of the protarg with E3 
ubiquitin ligases will also induce the ubiquitination of the survivin molecule to 
which it has bound. Evidence of in trans ubiquitination and degradation of proteins 
can be found in the MDM2/p53 interaction previously described (113, 284). 
Investigators have found that removal of the MDM2 binding domain from p53 still 
allowed the ubiquitination and degradation of that mutant by MDM2—through 
oligomerization with other wild-type p53 molecules still capable of the MDM2 
interaction (285).  
Native survivin (GenBank accession AK311917) exists as a homodimer (286, 
287), and our protargs will utilize this dimeric arrangement by including full-length 
survivin, allowing for protarg/survivin binding. As survivin is an inhibitor of 
apoptosis, the introduction of a wild-type survivin protarg fusion may confer an 
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oncogenic phenotype. Work by the Altieri group has shown that mutating survivin 
threonine 34 to alanine (located in the baculovirus IAP repeat domain) results in a 
dominant negative IAP phenotype (117, 264, 288). There is a phosphorylation event 
on threonine 34 cyclin-dependent p34cdc2-cyclin B1 at G2/M, and this has been 
determined to be crucial for survivin’s anti-apoptosis (264). Removal of this 
threonine prevents survivin’s inhibition of apoptosis. By using this mutation, the 
introduction of our protarg into a cell should not produce deleterious effects. 
Plasmids will be constructed by previously described methods such that the protarg 
follows the UID – survivin binding domain – EGFP arrangement.  
 
Current Survivin-Targeted Therapies 
The high specificity for survivin in cancer has garnered attention from the 
drug discovery community, and a small portfolio of clinically tested therapies has 
been produced (289). The nodal nature of survivin provides a unique target in cancer 
cells that has the ability to bypass the vast molecular heterogeneity, particularly in 
breast cancer (112). The traditional paradigm of druggable proteins is that suitable 
targets are those expressed on cell surfaces, contain catalytic activity, or have 
structural regions appropriate for small molecule binding (290). However, 
crystallographic data and studies of protein localization have not demonstrated 
these characteristics (286, 287). Thus nontraditional approaches to therapy have 
been pursued, such as antisense molecules, vaccines, and transcriptional repressors 
(112, 289, 291). In breast cancer patients, two phase I studies are currently in 
progress testing vaccine-based therapies in metastatic breast cancer (289). However, 
in a separate Japanese study of a survivin variant peptide vaccine, no beneficial 
clinical response was observed (292). 
 37 
Aside from breast cancer, studies on survivin targeted therapy have been 
conducted and are in phase I or II. The survivin antisense molecule LY2181308 has 
completed phase I trials, and is currently undergoing phase II studies in refractory 
acute myeloid leukemia and hormone refractory prostate cancer (293). While no data 
has been published on the phase I studies, results from xenograft models 
demonstrated inhibition of tumor cell proliferation, increased sensitivity to cytotoxic 
agents or radiation, spontaneous apoptosis, and reduced tumor growth (294). Two 
transcriptional repressors have also been studied: EM-1421 and YM155. EM-1421 
has completed phase I studies, and is undergoing phase II studies in a wide range of 
tumors including refractory leukemias and solid tumors (295). YM155 has completed 
phase I and phase II studies in refractory solid tumors, and had manageable side 
effects, potentially unrelated to treatment, but has produced only modest results 
(296-298). 
Nonclinical work has also been done with ribozyme RNA interference (116), 
gene therapy with dominant-negative survivin mutants C84A and T34A (266, 299), 
and a survivin/HSP90 antagonist (300).  The survivin promoter has been proposed 
for tumor-specific transcription of cytotoxic genes (301-303), and may prove useful 
for future studies of survivin protarg expression in tumor cells. 
The small portfolio of survivin therapies, while limited, has shown 
tolerability, but the efficacy is yet to be demonstrated as phase II and, potentially, 
phase III studies are published. While clinical data are lacking, xenograft models 
have consistently shown that disrupting the survivin network prohibits tumor cell 
survival and leads to tumor shrinkage (304).  
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Survivin and Breast Cancer 
In women, breast cancer is the leading cancer diagnosis, accounting for 29% 
of new diagnoses (305). It is the second leading cause of cancer deaths in women, 
second only to lung cancer. Currently, a woman has a one in eight chance (12%) that 
she will develop an invasive breast cancer at any point in her life (306). The most 
recent statistics show an overall 5-year survival rate of 89% (307), but advanced 
tumors result in shorter recurrence-free and overall survival times (308). While the 
overall survival statistics are promising, the heterogeneity of the disease leads to 
difficulty in personalized treatment, and aggressive advanced tumors are lacking in 
safe and effective treatments.  
Molecular markers often serve as targets for clinical management of the 
disease. For example, an estrogen receptor positive tumor can be effectively treated 
with estrogen antagonists, such as tamoxifen, reducing the risk of cancer death by 
30% each year (309). Tumors over-expressing HER2/neu direct therapy toward 
trastuzumab-containing regimens, which reduces the rate of disease recurrence by 
half (310, 311). Advanced tumors lacking druggable molecular markers become more 
resistant to conventional antineoplastic treatment, such as doxorubicin, 
cyclophosphamide, and paclitaxel, leaving patients with few successful treatment 
options.  
In the past few years, the prognostic importance of the inhibitor of apoptosis 
survivin has been implicated in breast cancer (312-315). In studies of breast cancer 
patients with grade I-III tumors, survivin over-expression was determined to be a 
poor prognostic factor. Survivin expression occurred in 60-90% of these patients. 
High survivin expression levels (set at > 1.4 ng/mg total protein) was associated with 
nodal positivity, worse disease-free survival, and worse overall survival rates (312). 
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Survivin was also associated with estrogen and progesterone receptor negative 
status. Recently, an acetylated form of survivin (acetyl129) was evaluated in breast 
cancers, and it was found that the acetylated form was associated with a favorable 
outcome in luminal-type tumors, whereas unacetylated survivin was associated with 
a poor outcome in the basal phenotype (316). This evidence, along with studies 
linking survivin with clinically aggressive disease including tamoxifen-treated 
recurrent diseases (317), antineoplastic resistance (277), and metastasis (318), 
brings survivin to the forefront in searching for a new target among the complex 
molecular subtypes of breast cancer. 
 
Statement of Objectives 
 The controlled localization of proteins may be potentially harnessed for 
therapeutic use. Three such localization-controlled constructs are discussed: 
cytoplasm-to-nucleus protein switch, ER LBD induced aggregation at the 
cytoskeleton, and proteasome-targeted p53 and ER constructs. The following 
hypotheses directed the scientific pursuit of localization controllable proteins: 
Hypothesis 1: Altering the nuclear export signal, nuclear localization signal, or 
ligand binding domain will alter the amount of protein translocating from the 
cytoplasm to the nucleus in response to ligand.  
Aim: To optimize the amount of protein translocation of a protein switch by altering 
the nuclear export and localization signals and combining them with various ligand-
binding domains. 
Hypothesis 2: A fusion protein containing the estrogen receptor ligand-binding 
domain can be sequestered in the insoluble cytoskeletal fraction by adding the 
antiestrogen drug fulvestrant.  
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Aim: To fuse a protein of interest to the estrogen receptor ligand-binding domain so 
that when the drug fulvestrant is added, the protein is sequestered in the insoluble 
cytoskeletal fraction where its activity is abolished. The degree of localization control 
is examined by adding signal sequences to direct subcompartment specificity. Also, 
we aimed to test the ability of sequestering a functioning peptide to the cytoskeleton 
in order to abolish its activity.  
Hypothesis 3: Controlling a protein’s interaction with an E3 ubiquitin ligase can 
regulate its targeting to the ubiquitin-proteasome pathway.  
Aim: To create proteasomal-targeted proteins capable of controlled proteasomal 
degradation with p53 or full-length ER. 
 These hypotheses and aims are discussed in the chapters that follow. Chapter 
2 reviews controlling protein compartmentalization to overcome disease, as 
published in Pharmaceutical Research (1). Chapter 3 describes Hypothesis 1. 
Chapter 4 describes the use of ERLBD to sequester proteins in the insoluble fraction, 
as published in Pharmaceutical Research (319). In Chapter 5, the p53 protarg and 
its ability to target the ubiquitin-proteasome pathway is presented as it was 
submitted to Molecular Pharmaceutics. Finally, Chapter 6 describes the use of full-
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CONTROLLING PROTEIN COMPARTMENTALIZATION  
TO OVERCOME DISEASE1 
Abstract 
Over the past decade, considerable progress has been made to improve our 
understanding of the intracellular transport of proteins. Mechanisms of nuclear 
import and export involving classical receptors have been studied. Signal sequences 
required for directing a protein molecule to a specific cellular compartment have 
been defined. Knowledge of subcellular trafficking of proteins has also increased our 
understanding of diseases caused due to mislocalization of proteins. A specific 
protein on deviating from its native cellular compartment may result in disease due 
to loss of its normal functioning and aberrant activity in the “wrong’’ compartment. 
Mislocalization of proteins results in diseases that range from metabolic disorders to 
cancer. In this review we discuss some of the diseases caused due to mislocalization. 
We further focus on application of nucleocytoplasmic transport to drug delivery. 
Various rationales to treat diseases by exploiting intracellular transport machinery 
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have been proposed. Although the pathways for intracellular movement of proteins 
have been defined, these have not been adequately utilized for management of 
diseases involving mislocalized proteins. This review stresses the need for 
designingdrug delivery systems utilizing these mechanisms as this area is least 
exploited but offers great potential. 
Introduction 
The discovery of the “Signal Hypothesis” led Gunter Blobel to win the 1999 
Nobel Prize for Physiology or Medicine (1-4). Blobel discovered that protein “zip 
codes” exist for directing proteins to subcellular compartments such as the nucleus, 
cytoplasm, mitochondria, endoplasmic reticulum, lysosomes and endosomes, 
peroxisomes, golgi, and nucleolus (Table 2.1). Proteins need to be directed to their 
proper cellular compartments in order to perform their necessary functions. For 
example, most transcription factors need to be in the nucleus to promote gene 
expression. Some proteins, such as the glucocorticoid receptor, may start in one 
compartment (cytoplasm), and move to another compartment (nucleus) in response 
to a stimulus (ligand). 
Spotlight on Nucleocytoplasmic Shuttling:  
from Basics to Therapeutic Potential 
Regulation via Subcellular Compartmentation  
and the Nuclear Pore Complex 
On the cellular level, macromolecular traffic between the interphase 
eukaryotic nucleus and cytoplasm of cells represents a highly sophisticated level of 
cellular regulation that requires effective and selective transport machinery. Protein 
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activity can be regulated by selective import and export (5, 21), a “compartmentation 
allows regulation of key cellular events” (5). Likewise, regulation of nuclear import 
provides a mechanism for control. Continuing with our example, transcription 
factors can be kept in the cytoplasm until a signal triggers their import into the 
nucleus where they can interact with DNA/genes (22). Import and export of proteins 
occurs through the nuclear pore complex (NPC) (Figure 2.1) (6). 
The approximately 125 MDa NPC perforates both lipid bilayers of the 
nuclear envelope (23), forming the exclusive site by which ions, small molecules, and 
macromolecules must pass. High resolution electron microscopic studies of 
Saccharomyces cerevisiae, Xenopus laevis, and rat liver cells have revealed an 
overall tripartite structure: cytoplasmic filaments, a central transporter, and a 
nuclear basket, all conferring 8-fold rotational symmetry in the plane normal to the 
membrane (24) [reviewed in (25-27)]. Eight long cytoplasmic filaments, connected 
proximally by a coaxial ring, radiate away from plane of the membrane, accounting 
for one-fourth of the total NPC mass. These projections contain so-called FG repeats, 
having amino acid repeats in the form of FXFG, GLFG, or FG (where F is 
phenylalanine, G is glycine, L is leucine, and X is any), which interact with 
karyopharins (family of transport receptors), and deflect non- shuttling proteins (28-
31). The cylindrical intramembrane transporter is surrounded by eight spokes which 
anchor it to the membrane, collectively accounting for nearly half of the entire mass. 
Central pores allow the passive diffusion of molecules less than 9 nm in diameter 
(~40 kDa) via an aqueous channel (32), while a gated, iris-like movement allows the 
selective active transport of macromolecules of up to 39 nm in diameter (40-60 kDa) 
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Figure 2.1. The nuclear pore complex. Half of the complex is cut away, except with 
the central transporter which is shown complete. NPCs exhibit octagonal 
symmetry about the plane perpendicular to the nuclear envelope. Eight filaments 
stretch into the cytoplasm, directly interacting with the karyopharin family of 
transporters. Connecting the filaments is a coaxial ring. Within the double 
membrane, a central transporter with eight repeating proteins is surrounded by a 
spoke complex. Nucleoplasmic filaments project into the nucleoplasm and connect 
distally by a ring structure, forming a basket. The NPC is the sole location for 
translocation across the nucleus’ double membrane. 
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(33, 34). On the nucleoplasmic side, eight long filaments project away from the 
membrane and connect distally by a ring, forming a basket. The specific proteins 
that make up the NPC are called nucleoporins (nups). Due to the highly symmetric 
nature of the structure, only about 100 nups constitute the complex, but many are 
present in repeats of 8-16 (26, 27). Nups and NPCs, however, are not as simple as a 
three-part structure only involved in nucleocytoplasmic shuttling. Several nups have 
been shown to shuttle within the cyto- and nucleoplasmic portions of the complex 
(35-38). Further, nups have been implicated in spindle and kinetochore assembly 
(39-41), and chromatin organization and transcriptional activation (42). 
Nuclear Import and Nuclear Localization Signals 
Nuclear import and export utilize non-universal pathways that include many 
specific proteins. Discussed in this paper are only generalized cycles established for 
the classical import and export signals. For more detailed reviews, see Görlich et al. 
(5), Weis (43), Pemberton et al. (44), and Macara (45). (Fig. 2.2) diagrams the 
generalized import pathway for classical nuclear localization signal-carrying 
proteins. Initiation of import begins in the cytoplasm, with the recognition of 
importin α to a nuclear localization signal (NLS). Importin α itself cannot interact 
with the NPC for translocation, so an adapter protein—importin β—is needed. This 
three-protein complex translocates across the nuclear envelope into the nucleoplasm. 
RanGTP binds to the amino- terminus of importin β, resulting in release of the 
cargo- importin α duplex. Subsequently, the cargo is available to function in the 
nucleoplasm, while importin α and β are recycled to the cytoplasm through separate 
RanGTP-dependent events. Back in the cytoplasm, RanGTP is hydrolyzed by  
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RanGAP to RanGDP, releasing bound karyopharins, where another round of import 
may take place.  
Nuclear localization signals (NLSs) were discovered decades ago as the 
means for active transport of larger macromolecules into the nucleus (46). Proteins 
containing classical nuclear localization sequences (NLSs) are imported into the 
nucleus by the importin α/β heterodimer (47). Importin α contains the NLS binding 
site, whereas importin β mediates the translocation through the nuclear pore (5, 48). 
Ran, a small GTPase which converts from RanGDP to RanGTP in the nucleus, plays 
a critical role in both import and export. Its nucleotide state is determined by 
regulators which have opposite localization, and thus a gradient across the 
membrane can be formed (49). Importins respond to the RanGTP/GDP gradient, 
approximately 200-fold (50), which is a driving force for the transport of cargo 
proteins from the cytoplasm to the nucleus (5). Classical NLSs are either a single 
stretch (monopartite) of basic amino acids like the one from SV40 large T antigen 
(PKKKRKV; critical residues underlined) (46, 51), or bipartite (two short sequences 
with spacer) basic amino acid stretches like the one from nucleoplasmin 
(KRPAATKKAGQAKKKKLDK) (6). With NLSs, flanking sequences often are 
important for localization as well (51). Additional tripartite signals have been 
identified in some steroid hormone receptors, encompassing a SV-40 monopartite 
signal within them (52). The human PR, like other steroid receptors, contains a 
constitutively active classical NLS (at position 637-645, RKFKKKFNK) and also 
contains a non-classical NLSs that is ligand inducible (NLSi) (53-55).  This non-
classical NLS has no apparent common motif compared to classical NLSs, although 
part of it encodes the 2nd zinc finger of the DNA binding domain (DBD) of PR.  PR’s 
NLSi aa sequence is RAMEGQHNYLCAGRNDCIVDKIRRKNCPACRLRKCCQAG-
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MVLGG (from position 593-636).  Underlined sequences containing basic amino 
acids R and K likely interact with importin machinery (56).  It has not been fully 
elucidated what import receptor(s) interact with NLSi, but presumably they must 
still enter the nucleus via the NPC (55). 
Nuclear Export and Nuclear Export Signals 
Importins and exportins both interact with RanGTP by an amino-terminal 
domain, but have opposite effects on protein trafficking.  During import, proteins are 
released upon RanGTP binding in the nucleus.  Conversely, in export, cargo proteins 
only bind to transporters in the presence of RanGTP (Figure 2.3).  Upon binding, the 
cargo/exporter/RanGTP complex translocates through to the cytoplasm where 
RanGAP catalyzes the hydrolysis of a phosphate bond.  RanGDP no longer binds to 
the exporter, and the whole complex dissociates.  RanGDP is imported to the nucleus 
by NTF2, preserving the Ran-nucleotide gradient.  RCC1 in the nucleus exchanges 
GDP for GTP, and now the cycle is ready for another turn (5, 34, 57, 58). CRM1 
(exportin 1) is the classical export receptor for cargos proteins containing leucine 
rich cargos NESs (5, 59).  The formation of a CRM1-cargo complex requires RanGTP.  
Export by CRM1 is saturable (5, 60, 61).  Another exporter is calreticulin (CRT) (62) 
which may function as an alternative exporter for proteins (such as steroid 
receptors) with leucine rich NESs (63-66).  CRT interacts with cargo in a RanGTP 
dependent manner.  However, Walther et al. have suggested that CRT can only 
export steroid receptors “under stress conditions” (67).  Classical NESs are ~10 
amino acid sequences with hydrophobic residues, including leucine.  We have noted 
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a common consensus NES is LX(1-3) LX(2-3) LXJ where L= Leu  X= spacer  J= Leu, 
Val or Ile (7), in agreement with others (8-10). 
Import, Export, and Other Signals:  
Application to Drug Delivery 
Using signal sequences for precise drug delivery is attractive due to the 
potential for drugs to be targeted to specific cellular compartments.  Peptide NESs 
have been attached to oligonucleotides for delivery to their site of action, the 
cytoplasm (68), while NLSs can be used to enhance non-viral gene transfer (69).  
Similarly, the M9 shuttling (import/export) signal sequence attached to cationic 
peptides have been used as a delivery system for plasmid DNA (70).  An excellent 
review summarizes the nuclear import, export, and shuttling signals, and their 
application to drug delivery (71).  In all of the examples mentioned here, signals 
have been used unidirectionally to target a drug--be it an oligonucleotide, polymer or 
plasmid--to a final compartment. 
Known signal sequences are in part defined by their ability to confer 
localization to a particular compartment, even when taken out of context of the 
whole protein.  Hodel et al. show that various NLSs linked to GFP can be used as a 
model system to test nuclear import (6), while we have shown the same for NESs to 
test nuclear export (7).  
When proteins mislocalize to the wrong compartment, disease can occur 
(Table 2.2).  Many types of cancers arise from mislocalized proteins (72).  For 
example, tumor suppressors that mislocalize to the cytoplasm in cancer cells include 
p53 (72, 73) and INI1/hSNF5 (74, 75).  For p53, the tumor suppressor activity of this 
protein is suppressed due to its inability to localize in the nucleus.  It has been  
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reported that mutations of p53 exist in half of all human cancers, leading to 
inactivation (72, 76).  On the other end of the spectrum, the nuclear localization of 
oncoprotein Ras may be important in oncogenic activation as well (77). Similarly, the 
mislocalization of cell cycle inhibitors can be detrimental.  Relocalization of a cell 
cycle inhibitor to the “wrong” compartment can lead to tumor progression.  This 
occurs with the cell cycle inhibitor p21WAF-1 which normally localizes in the nucleus 
where it exerts its inhibitory action.  Mislocalization of this protein to the cytoplasm 
leads to tumor progression (90). 
G-protein coupled receptors (GPCRs) can also mislocalize and cause disease 
(92).  Specific examples include mislocalized rhodopsin which can lead to retinitis 
pigmentosa, and mistargeted vasopressin V2 receptor leading to nephrogenic 
diabetes insipidus.  Finally, defects in trafficking or localization of the LDL receptor 
can cause familial hypercholesterolemia (94), and mislocalized CTFR leads to cystic 
fibrosis (95). See Table 2.2 for other examples of diseases caused by mislocalization. 
Specific Diseases Induced by Mislocalized Proteins 
Breast Cancer: BARD1 and BRCA1 
The breast cancer-associated protein BARD1 (thought to be a tumor 
suppressor) in itself contains proapoptotic activity when in the cytoplasm.  BARD1 
contains a nuclear export signal that allows compartmentalization into the 
cytoplasm.  However, the breast and ovarian cancer susceptibility protein 1 (BRCA1), 
a known tumor suppressor, can modulate BARD1 apoptotic activity by binding to 
BARD1 and blocking its export signal.  This results in a marked reduction of BARD1 
apoptotic activity.  Interestingly, it was found that “BRCA1 and BARD1 regulate the 
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subcellular localization of one another through the reciprocal masking of their 
respective nuclear export signals” (83).  However,  
when BARD1 and BRCA1 dimerize, their resulting nuclear compartmentalization 
leads to events that promote cancer (DNA repair activity and prolonged cell 
survival) (82-84) instead of apoptosis.  In this situation, the delicate balance between 
nuclear import and export dramatically alters the function of proteins, and this is 
controlled by the cell. 
Schizophrenia and the Dopamine D3 Receptor 
In some forms of schizophrenia, a mutant dopamine D3 receptor has been 
implicated.  This mutant dopamine receptor (D3nf) physically can interact with the 
normal version of the D3 receptor and causes mislocalization of D3 from the plasma 
membrane to an intracellular compartment, “a finding that may have significance in 
the etiology of schizophrenia” (96).  In these studies, it was suggested that D3nf may 
act as a dominant-negative regulator of D3 receptor activity, forcing wtD3 to 
mislocalize thereby resulting in disease. 
Leukemia and BCR-ABL 
BCR-ABL protein can be converted from an oncogene to an apoptotic factor if 
it can be sent to the nucleus (89).  BCR-ABL is an oncogene implicated in chronic 
myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic 
leukemia.  BCR-ABL proteins have abnormal tyrosine kinase activity that leads to 
oncogenesis (100). BCR-ABL proteins are oncogenic in the cytoplasmic compartment 
only, and must multimerize in order to be active.  BCR-ABL, when directed to the 
nucleus, indeed becomes apoptotic (89), so this is a possible new way to treat CML.  
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These same authors found that inhibiting export of BCR-ABL in cell culture using 
leptomycin B (LMB), a general export inhibitor (causing nuclear accumulation of 
BCR-ABL), resulted in cancer cell apoptosis.  However, LMB cannot be used 
clinically due to neuronal toxicity in phase I clinical trials (89).   
Colorectal Cancer and “β-Catenin” 
In most colorectal cancers the adenomatous polypsis coli (APC) protein, a 
tumor suppressor, is mutated (72, 101).  In normal cells this protein shuttles 
between the nucleus and the cytoplasm; however, in colorectal cancer APC is mostly 
nuclear due to truncations resulting in loss of functional NES.  The nuclear export of 
APC is very critical for its normal functioning in destabilizing and reducing the 
transcriptional activity of a signal transduction protein β-catenin.  Any level of 
nuclear import of APC reduces the transcriptional activity of β-catenin.  The 
mutations in APC lead to loss of its nuclear export function and inactivation.  This is 
indicated as an early event in tumorigenesis.  Loss of APC causes an increase in 
nuclear β-catenin and its transcription activity, which leads to tumor progression 
(88).  
Targeting Protein Compartmentalization For Therapy 
Targeting nucleocytoplasmic shuttling represents an under-explored area for 
drug delivery, drug targeting, and therapeutics (102, 103).  As the mechanisms of 
mislocalization are being elucidated, there exist more opportunities for drug therapy 
besides the standard direct inhibition (or activation) of the protein target.  There are 
several ways in which overcoming aberrant localization of protein can be achieved 
and are outlined as follows. 
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Blocking General Nuclear Import or Export Machinery 
If a disease is caused by mislocalization of a protein to the nucleus (or 
cytoplasm), inhibitors of general import (or export) could be utilized for treatment.  
To date, there are no small molecule inhibitors of nuclear import; however, there are 
several small molecule inhibitors of nuclear export.  These are inhibitors of CRM1, 
the general export receptor.  Leptomycin A and B (104), Ratjodone A (105, 106), and 
PFK050-637 (107) are all small molecule inhibitors of CRM1 that bind to a critical 
cysteine residue in CRM1 to abrogate nuclear export.  Another possible way to 
inhibit import or export would be to supply peptides encoding a NLS or NES, and 
competitively inhibit import/export of other cargo containing the NLS/NES signals.  
Hawiger and coworkers have designed cyclic peptides containing a cell-penetrating 
motif and a cyclized form of a NLS from NF-kB.  This peptide inhibits import of NF-
kB (108).  The main disadvantages with blocking general nuclear import or export 
would be toxicity due to general halting of transport of all proteins going into/out of 
the nucleus, like Leptomycin B (89, 109). 
Enhancing Import or Export of Proteins 
Proteins given therapeutically may be modified so that import (or export) is 
enhanced.  NLSs and NESs have routinely been added onto proteins to enhance or 
modify their cellular destination; for an excellent review see Jans et al. (71).  The 
main disadvantage with adding proteins with NLSs/NESs is that the patient still 
expresses the mislocalized protein, and in some cases, the mislocalized protein 
exhibits a dominant effect over the non-mislocalized protein (96). 
Another way to enhance import/export is to increase the interactions of 
proteins with the components of the NPC.  Molecular proteomics methods are being 
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used to determine interactions of proteins with nucleoporins (110).  This information 
could be used to enhance or block import (or export). 
Alteration of Posttranslational Modifications 
It is known that protein modifications including phosphorylation, 
methylation, and ubiquitinylation can lead to altered compartmentalization of 
proteins in cells (72).  Galectin-3 (Gal-3), a novel regulator of apoptosis, translocates 
from the nucleus to the cytoplasm under apoptotic stimuli.  Phosphorylation 
enhances export of Gal-3 to the cytoplasm.  Interestingly, an increase in the 
cytoplasmic levels of Gal-3 (and loss from the nuclei) correlates with tumor 
progression (78).    
Blocking Import/Export Partner 
Many proteins imported/exported via piggyback mechanisms with other 
proteins (and not via direct interactions with the actual import/export receptors).   A 
well-known example of this is heat shock protein 90 (Hsp90).  Hsp90, a molecular 
chaperone, is known to retain steroid hormone receptors (and other proteins) in the 
cytoplasm and may be involved in nuclear import of other proteins (111).  In another 
case mitogen activated protein kinase (MAPK) may be involved in regulating 
nuclear association of the human progesterone receptor (112).  The import/export 
partner itself (Hsp90 or MAPK) likely still interacts with the general import/export 
machinery. 
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Controlled Localization Using a Protein Switch 
Ligand inducible nuclear import signals and export signals (a bi-directional 
on/off switch) can be used for the controlled targeting of therapeutic proteins to 
subcellular compartments.  Our work has shown that a model protein (EGFP in this 
case) can be directed from the cytoplasm to the nucleus using ligand, in a dose-
dependent manner (113).  The protein is genetically engineered to constitute a 
nuclear export signal, a nuclear import signal, and a ligand-binding domain (LBD) 
from a steroid hormone receptor.  When the plasmid encoding this protein is 
transfected into mammalian cells, the protein is expressed mostly in the cytoplasm.  
When ligand is added, the protein translocates to the nucleus.  The rate and extend 
of nuclear import depends on the dose of ligand and the incubation time.  When 
ligand is removed from the system, the protein exports back to the cytoplasm.  The 
protein can be re-imported again by addition of ligand (113).  Since our initial 
studies, we have optimized the protein switch so that its localization is more 
cytoplasmic in the absence of ligand, and more of the protein translocates to the 
nucleus in the presence of ligand (unpublished data).  Optimization involves striking 
the desired balance between nuclear import and export signals of different strengths, 
and utilizing different steroid hormone receptor LBDs.  Such a protein switch could 
be used in gene therapy, for controlled localization (and function) of a protein such 
as a transcription factor, or any other type of protein that is active only in the 
nucleus of the cell.  Our first application of the protein switch will be for breast 
cancer; the nuclear corepressor NCoR will be engineered into the protein switch.  
NCor is known to repress both progesterone receptor and estrogen receptor 
mediated transcriptional activity.   
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Future Directions for Controlling Intracellular  
Localization of Proteins 
As we have outlined in this paper, malfunctioning of nucleo-cytoplasmic 
transport leading to mislocalization of proteins causes disease.  Thus, manipulation 
of transport pathways could be used to treat disease.  Exploiting the intracellular 
transport pathways provides an exciting area for treatment of such diseases.  
Specific signal sequences can be utilized in drug delivery systems to improve the 
efficacy of a drug by increasing the amount of drug reaching its active therapeutic 
compartment, or to increase compartment accumulation.  Based on the knowledge of 
intracellular transport, new modalities can be designed targeting specific 
components of the cellular transport machinery.  However, for regulating 
localization of proteins to treat diseases, further investigation of transport pathways 
that have not yet been clearly understood is warranted.  
The classical pathways of nucleo-cytoplasmic trafficking have been well 
defined. Consensus sequences have been proposed for nuclear import and export 
signals, and their strengths have been characterized.  Nevertheless, it has been 
studied that certain proteins despite having an import (or export) signal are 
localized to a different compartment.  In some cases this occurs because various 
proteins mutually regulate their localization by masking and de-masking the 
localization signal(s).  For example, breast-cancer associated protein BRCA1 is 
involved in masking the export signal of BARD1 via the dimerization domain and 
keeps it in the nucleus (82, 83, 114).  Another such example involves proteins c-Jun 
and ATF2, involved in cellular transformation, stress response and regulating organ 
development.  Even though ATF2 possesses a nuclear export signal, dimerization 
with c-Jun in the nucleus prevents its export (115).  In another example, the nuclear 
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export signal of BCR-ABL protein has been suggested to be inactive due to its 
location in the hydrophobic core of the protein (116).  The area of intracellular 
transport involved with mutual regulation of protein localization by masking or 
unmasking the localization signal, has been least explored for therapeutic purposes.  
Designing delivery systems and drugs (small molecules as well as peptides) to mask 
and unmask the localization signals is a promising avenue for controlling 
intracellular movement of proteins.  
Besides the classical subcellular pathways of transport, there are other 
mechanisms of protein import/export that have not been completely delineated yet.  
CRT has been studied to be involved in nuclear export of steroid hormone receptors, 
independent of the classical CRM1 pathway (63-65).  However, some researchers 
have claimed that CRT acts as an export receptor only under stress conditions (67), 
and steroid hormone receptors such as glucocorticoid receptor (GR) are indeed 
exported via a CRM1 dependent transport (117).  Another group has proposed that a 
β helix structure in androgen receptor ligand binding domain acts as a NES (118) 
though the mechanism for its activity has yet to be delineated.  BCR-ABL, a 
cytoplasmic protein, still localizes to the cytoplasm on removal of its NES (89) which 
is likely due to interactions between its F-actin binding domain and the cellular 
cytoskeleton (116).  Similar to nuclear export, it appears that multiple pathways 
exist for nuclear import as well. In our recent study we have shown that the 
progesterone receptor (PR) translocates to the nucleus on ligand induction even after 
mutating its constitutive NLS, albeit at a much slower rate (119).  GR has also been 
shown to constitute two NLSs with one acting via the classical importin α pathway, 
while the other through an agonist specific pathway independent of importin α (117).  
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Some proteins are transported between two compartments by a facilitator 
protein or a “piggy-back” mechanism. Localization of various proteins involved in 
cellular functioning such as p53 (72, 73, 120, 121), β-catenin (72, 88, 101) is 
regulated by other interacting proteins.  Heat-shock protein (Hsp90), one of the most 
abundant proteins in cells, is touted to be a chaperone protein involved in 
intracellular movement of various other proteins (122-124).  However, the 
mechanism of transport of Hsp90 is still not defined.  Ligand binding domains of 
steroid receptors are known to affect change in localization of these molecules while 
in the full length receptor or when taken out of it and induced with a ligand, but no 
single mechanism explaining change in their localization has been proposed as yet.  
Thus, there are mechanisms of subcellular trafficking that still need to be elucidated.   
Exploring mechanisms of intracellular transport holds the key to devise 
means to treat a large number of diseases ranging from metabolic disorders to 
cancer.  Studying cellular pathways of macromolecule movement would also aid in a 
more comprehensive understanding of certain known diseases, resulting in 
management.  Harnessing signal sequences to change localization of proteins and 
hence their activity, is a novel way of finding cure for many diseases.  Designing new 
delivery systems and drug modalities based on the current knowledge of signal 
sequences and transport pathways, for treatment and management of diseases, is an 
exciting new area of molecular pharmaceutics that offers great potential.  
  
   
88 
References 
1. A Nobel Prize for cell biology. Nat Cell Biol. 1999;1(7):E169. 
2. Hagmen M. Protein ZIP codes make Nobel journey. Science. 
1999;286(5440):666. 
3. Heemels MT. Medicine Nobel goes to pioneer of protein guidance mechanisms. 
Nature. 1999;401(6754):625. 
4. Shields D. Gunter Blobel--still passionate after all these years. Trends Cell 
Biol. 2001;11(8):349-50. 
5. Gorlich D, Kutay U. Transport between the cell nucleus and the cytoplasm. 
Annu Rev Cell Dev Biol. 1999;15:607-60. 
6. Hodel MR, Corbett AH, Hodel AE. Dissection of a nuclear localization signal. 
J Biol Chem. 2001;276(2):1317-25. 
7. Kanwal C, Li H, Lim CS. Model system to study classical nuclear export 
signals. AAPS PharmSci. 2002;4(3). 
8. Bogerd HP, Fridell RA, Benson RE, Hua J, Cullen BR. Protein sequence 
requirements for function of the human T-cell leukemia virus type 1 Rex 
nuclear export signal delineated by a novel in vivo randomization-selection 
assay. Mol Cell Biol. 1996;16(8):4207-14. 
9. Henderson BR, Eleftheriou A. A comparison of the activity, sequence 
specificity, and CRM1-dependence of different nuclear export signals. Exp 
Cell Res. 2000;256(1):213-24. 
10. Ikuta T, Eguchi H, Tachibana T, Yoneda Y, Kawajiri K. Nuclear localization 
and export signals of the human aryl hydrocarbon receptor. J Biol Chem. 
1998;273(5):2895-904. 
11. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular 
Biology of the Cell. 4th ed: Garland Science (Taylor and Francis Group); 2002. 
1463 p. 
12. Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. 
Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's 
amyloid precursor protein impairs mitochondrial function in neuronal cells. J 
Cell Biol. 2003;161(1):41-54. 
13. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER 
proteins. Cell. 1987;48(5):899-907. 
14. Andres DA, Dickerson IM, Dixon JE. Variants of the carboxyl-terminal 
KDEL sequence direct intracellular retention. J Biol Chem. 
1990;265(11):5952-5. 
   
89 
15. Bonifacino JS, Traub LM. Signals for Sorting of Transmembrane Proteins to 
Endosomes and Lysosomes. Annu Rev Biochem. 2003;6:6. 
16. Gould SJ, Keller GA, Hosken N, Wilkinson J, Subramani S. A conserved 
tripeptide sorts proteins to peroxisomes. J Cell Biol. 1989;108(5):1657-64. 
17. Zeng Q, Tran HT, Tan HX, Hong W. The cytoplasmic domain of Vamp4 and 
Vamp5 is responsible for their correct subcellular targeting: The N-terminal 
extension of Vamp4 contains a dominant autonomous targeting signal for the 
trans-Golgi network. J Biol Chem. 2003;6:6. 
18. Guo YX, Dallmann K, Kwang J. Identification of nucleolus localization signal 
of betanodavirus GGNNV protein alpha. Virology. 2003;306(2):225-35. 
19. Liu J, Du X, Ke Y. Mapping nucleolar localization sequences of 1A6/DRIM. 
FEBS Lett. 2006;580(5):1405-10. 
20. Nakamura T, Imai H, Tsunashima N, Nakagawa Y. Molecular cloning and 
functional expression of nucleolar phospholipid hydroperoxide glutathione 
peroxidase in mammalian cells. Biochem Biophys Res Commun. 
2003;311(1):139-48. 
21. Turpin P, Ossareh-Nazari B, Dargemont C. Nuclear transport and 
transcriptional regulation. FEBS Lett. 1999;452(1-2):82-6. 
22. Hood JK, Silver PA. In or out? Regulating nuclear transport. Curr Opin Cell 
Biol. 1999;11(2):241-7. 
23. Reichelt R, Holzenburg A, Buhle EL, Jr., Jarnik M, Engel A, Aebi U. 
Correlation between structure and mass distribution of the nuclear pore 
complex and of distinct pore complex components. The Journal of Cell Biology. 
1990;110(4):883-94. 
24. Akey CW, Radermacher M. Architecture of the Xenopus nuclear pore complex 
revealed by three- dimensional cryo-electron microscopy. Journal of Cell 
Biology. 1993;122(1):1-19. 
25. Suntharalingam M, Wente SR. Peering through the Pore: Nuclear Pore 
Complex Structure, Assembly, and Function. Developmental Cell. 
2003;4(6):775-89. 
26. Allen TD, Cronshaw JM, Bagley S, Kiseleva E, Goldberg MW. The nuclear 
pore complex: mediator of translocation between nucleus and cytoplasm. J 
Cell Sci. 2000;113(10):1651-9. 
27. Stoffler D, Fahrenkrog B, Aebi U. The nuclear pore complex: from molecular 
architecture to functional dynamics. Curr Opin Cell Biol. 1999;11(3):391-401. 
   
90 
28. Seedorf M, Damelin M, Kahana J, Taura T, Silver PA. Interactions between a 
Nuclear Transporter and a Subset of Nuclear Pore Complex Proteins Depend 
on Ran GTPase. Mol Cell Biol. 1999;19(2):1547-57. 
29. Shah S, Tugendreich S, Forbes D. Major Binding Sites for the Nuclear Import 
Receptor Are the Internal Nucleoporin Nup153 and the Adjacent Nuclear 
Filament Protein Tpr. J Cell Biol. 1998;141(1):31-49. 
30. Iovine MK, Wente SR. A Nuclear Export Signal in Kap95p Is Required for 
Both Recycling the Import Factor and Interaction with the Nucleoporin 
GLFG Repeat Regions of Nup116p and Nup100p. J Cell Biol. 
1997;137(4):797-811. 
31. Iovine MK, Watkins JL, Wente SR. The GLFG repetitive region of the 
nucleoporin Nup116p interacts with Kap95p, an essential yeast nuclear 
import factor. J Cell Biol. 1995;131(6):1699-713. 
32. Paine PL, Moore LC, Horowitz SB. Nuclear envelope permeability. Nature. 
1975;254(5496):109-14. 
33. Feldherr CM, Akin D. The location of the transport gate in the nuclear pore 
complex. Journal of Cell Science. 1997;110(24):3065-70. 
34. Weis K. Regulating Access to the Genome: Nucleocytoplasmic Transport 
throughout the Cell Cycle. Cell. 2003;112(4):441-51. 
35. Lindsay ME, Plafker K, Smith AE, Clurman BE, Macara IG. Npap60/Nup50 
Is a Tri-Stable Switch that Stimulates Importin-[alpha]:[beta]-Mediated 
Nuclear Protein Import. Cell. 2002;110(3):349-60. 
36. Griffis ER, Altan N, Lippincott-Schwartz J, Powers MA. Nup98 is a mobile 
nucleoporin with transcription-dependent dynamics. Molecular Biology of the 
Cell. 2002;13(4):1282-97. 
37. Pritchard CEJ, Fornerod M, Kasper LH, Van Deursen JMA. RAE1 is a 
shuttling mRNA export factor that binds to a GLEBS-like NUP98 motif at 
the nuclear pore complex through multiple domains. Journal of Cell Biology. 
1999;145(2):237-53. 
38. Nakielny S, Shaikh S, Burke B, Dreyfuss G. Nup153 is an M9-containing 
mobile nucleoporin with a novel Ran-binding domain. The EMBO Journal. 
1999;18(7):1982-95. 
39. Blower MD, Nachury M, Heald R, Weis K. A Rae1-Containing 
Ribonucleoprotein Complex Is Required for Mitotic Spindle Assembly. Cell. 
2005;121(2):223-34. 
40. Belgareh N, Rabut G, Bai SW, Van Overbeek M, Beaudouin J, Daigle N, et al. 
An evolutionarily conserved NPC subcomplex, which redistributes in part to 
   
91 
kinetochores in mammalian cells. Journal of Cell Biology. 2001;154(6):1147-
60. 
41. Winey M, Hoyt MA, Chan C, Goetsch L, Botstein D, Byers B. NDC1: a 
nuclear periphery component required for yeast spindle pole body duplication. 
The Journal of Cell Biology. 1993;122(4):743-51. 
42. Karniely S, Pines O. Single translation--dual destination: mechanisms of dual 
protein targeting in eukaryotes. EMBO Rep. 2005;6(5):420-5. 
43. Weis K. Regulating access to the genome: nucleocytoplasmic transport 
throughout the cell cycle. Cell. 2003;112(4):441-51. 
44. Pemberton LF, Paschal BM. Mechanisms of receptor-mediated nuclear 
import and nuclear export. Traffic. 2005;6(3):187-98. 
45. Macara IG. Transport into and out of the nucleus. Microbiol Mol Biol Rev. 
2001;65(4):570-94. 
46. Kalderon D, Roberts BL, Richardson WD, Smith AE. A short amino acid 
sequence able to specify nuclear location. Cell. 1984;39(3 Pt 2):499-509. 
47. Goldfarb DS, Corbett AH, Mason DA, Harreman MT, Adam SA. Importin 
alpha: a multipurpose nuclear-transport receptor. Trends Cell Biol. 
2004;14(9):505-14. 
48. Mattaj IW, Englmeier L. Nucleocytoplasmic transport: the soluble phase. 
Annu Rev Biochem. 1998;67:265-306. 
49. Izaurralde E, Jarmolowski A, Beisel C, Mattaj IW, Dreyfuss G, Fischer U. A 
role for the M9 transport signal of hnRNP A1 in mRNA nuclear export. J Cell 
Biol. 1997;137(1):27-35. 
50. Kalab P, Weis K, Heald R. Visualization of a Ran-GTP gradient in interphase 
and mitotic Xenopus egg extracts. Science. 2002;295(5564):2452-6. 
51. Efthymiadis A, Shao H, Hubner S, Jans DA. Kinetic characterization of the 
human retinoblastoma protein bipartite nuclear localization sequence (NLS) 
in vivo and in vitro. A comparison with the SV40 large T-antigen NLS. J Biol 
Chem. 1997;272(35):22134-9. 
52. Ylikomi T, Bocquel MT, Berry M, Gronemeyer H, Chambon P. Cooperation of 
proto-signals for nuclear accumulation of estrogen and progesterone receptors. 
Embo J. 1992;11(10):3681-94. 
53. Guiochon-Mantel A, Loosfelt H, Lescop P, Sar S, Atger M, Perrot-Applanat M, 
et al. Mechanisms of nuclear localization of the progesterone receptor: 
evidence for interaction between monomers. Cell. 1989;57(7):1147-54. 
   
92 
54. Guiochon-Mantel A, Lescop P, Christin-Maitre S, Loosfelt H, Perrot-Applanat 
M, Milgrom E. Nucleocytoplasmic shuttling of the progesterone receptor. 
Embo J. 1991;10(12):3851-9. 
55. Tyagi RK, Amazit L, Lescop P, Milgrom E, Guiochon-Mantel A. Mechanisms 
of progesterone receptor export from nuclei: role of nuclear localization signal, 
nuclear export signal, and ran guanosine triphosphate. Mol Endocrinol. 
1998;12(11):1684-95. 
56. Kohler M, Speck C, Christiansen M, Bischoff FR, Prehn S, Haller H, et al. 
Evidence for distinct substrate specificities of importin alpha family members 
in nuclear protein import. Mol Cell Biol. 1999;19(11):7782-91. 
57. Pemberton LF, Paschal BM. Mechanisms of Receptor-Mediated Nuclear 
Import and Nuclear Export. Traffic. 2005;6(3):187-98. 
58. Macara IG. Transport into and out of the Nucleus. Microbiol Mol Biol Rev. 
2001;65(4):570-94. 
59. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for 
leucine-rich nuclear export signals. Cell. 1997;90(6):1051-60. 
60. Lindsay ME, Holaska JM, Welch K, Paschal BM, Macara IG. Ran-binding 
protein 3 is a cofactor for Crm1-mediated nuclear protein export. J Cell Biol. 
2001;153(7):1391-402. 
61. Black BE, Holaska JM, Levesque L, Ossareh-Nazari B, Gwizdek C, 
Dargemont C, et al. NXT1 is necessary for the terminal step of Crm1-
mediated nuclear export. J Cell Biol. 2001;152(1):141-55. 
62. Krause KH, Michalak M. Calreticulin. Cell. 1997;88(4):439-43. 
63. Holaska JM, Black BE, Love DC, Hanover JA, Leszyk J, Paschal BM. 
Calreticulin Is a receptor for nuclear export. J Cell Biol. 2001;152(1):127-40. 
64. Holaska JM, Black BE, Rastinejad F, Paschal BM. Ca2+-dependent nuclear 
export mediated by calreticulin. Mol Cell Biol. 2002;22(17):6286-97. 
65. Black BE, Holaska JM, Rastinejad F, Paschal BM. DNA binding domains in 
diverse nuclear receptors function as nuclear export signals. Curr Biol. 
2001;11(22):1749-58. 
66. DeFranco DB. Nuclear export: DNA-binding domains find a surprising 
partner. Curr Biol. 2001;11(24):R1036-7. 
67. Walther RF, Lamprecht C, Ridsdale A, Groulx I, Lee S, Lefebvre YA, et al. 
Nuclear export of the glucocorticoid receptor is accelerated by cell fusion-
dependent release of calreticulin. J Biol Chem. 2003;278(39):37858-64. 
   
93 
68. Meunier L, Mayer R, Monsigny M, Roche AC. The nuclear export signal-
dependent localization of oligonucleopeptides enhances the inhibition of the 
protein expression from a gene transcribed in cytosol. Nucleic Acids Res. 
1999;27(13):2730-6. 
69. Chan CK, Jans DA. Using nuclear targeting signals to enhance non-viral 
gene transfer. Immunol Cell Biol. 2002;80(2):119-30. 
70. Subramanian A, Ranganathan P, Diamond SL. Nuclear targeting peptide 
scaffolds for lipofection of nondividing mammalian cells. Nat Biotechnol. 
1999;17(9):873-7. 
71. Jans DA, Chan CK, Huebner S. Signals mediating nuclear targeting and 
their regulation: application in drug delivery. Med Res Rev. 1998;18(4):189-
223. 
72. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism 
to intervention. Nat Rev Cancer. 2004;4(2):106-17. 
73. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast 
cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A. 
1992;89(15):7262-6. 
74. Fabbro M, Henderson BR. Regulation of tumor suppressors by nuclear-
cytoplasmic shuttling. Exp Cell Res. 2003;282(2):59-69. 
75. Craig E, Zhang ZK, Davies KP, Kalpana GV. A masked NES in INI1/hSNF5 
mediates hCRM1-dependent nuclear export: implications for tumorigenesis. 
Embo J. 2002;21(1-2):31-42. 
76. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor 
gene. N Engl J Med. 1993;329(18):1318-27. 
77. Wurzer G, Mosgoeller W, Chabicovsky M, Cerni C, Wesierska-Gadek J. 
Nuclear Ras: Unexpected subcellular distribution of oncogenic forms. J Cell 
Biochem. 2001;81(S36):1-11. 
78. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR, et al. 
Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic 
activity in response to chemotherapeutic drugs. Mol Cell Biol. 
2004;24(10):4395-406. 
79. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. 
Forkhead transcription factors are critical effectors of cell death and cell cycle 
arrest downstream of PTEN. Mol Cell Biol. 2000;20(23):8969-82. 
80. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent 
bystander to major culprit. Nat Rev Cancer. 2002;2(4):301-10. 
   
94 
81. Henkel T, Zabel U, van Zee K, Muller JM, Fanning E, Baeuerle PA. 
Intramolecular masking of the nuclear location signal and dimerization 
domain in the precursor for the p50 NF-kappa B subunit. Cell. 
1992;68(6):1121-33. 
82. Fabbro M, Rodriguez JA, Baer R, Henderson BR. BARD1 induces BRCA1 
intranuclear foci formation by increasing RING-dependent BRCA1 nuclear 
import and inhibiting BRCA1 nuclear export. J Biol Chem. 
2002;277(24):21315-24. 
83. Rodriguez JA, Schuchner S, Au WW, Fabbro M, Henderson BR. Nuclear-
cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is 
regulated by dimerization with BRCA1. Oncogene. 2004;23(10):1809-20. 
84. Rodriguez JA, Henderson BR. Identification of a functional nuclear export 
sequence in BRCA1. J Biol Chem. 2000;275(49):38589-96. 
85. Liang XJ, Shen DW, Garfield S, Gottesman MM. Mislocalization of 
membrane proteins associated with multidrug resistance in cisplatin-
resistant cancer cell lines. Cancer Res. 2003;63(18):5909-16. 
86. Min YH, Cheong JW, Kim JY, Eom JI, Lee ST, Hahn JS, et al. Cytoplasmic 
mislocalization of p27Kip1 protein is associated with constitutive 
phosphorylation of Akt or protein kinase B and poor prognosis in acute 
myelogenous leukemia. Cancer Res. 2004;64(15):5225-31. 
87. Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, et al. 
Delocalization and destabilization of the Arf tumor suppressor by the 
leukemia-associated NPM mutant. Cancer Res. 2006;66(6):3044-50. 
88. Rosin-Arbesfeld R, Cliffe A, Brabletz T, Bienz M. Nuclear export of the APC 
tumour suppressor controls beta-catenin function in transcription. Embo J. 
2003;22(5):1101-13. 
89. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia 
cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 
2001;7(2):228-34. 
90. Keeshan K, Cotter TG, McKenna SL. Bcr-Abl upregulates cytosolic p21WAF-
1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. Br J 
Haematol. 2003;123(1):34-44. 
91. Dryja TP, Li T. Molecular genetics of retinitis pigmentosa. Hum Mol Genet. 
1995;4 Spec No:1739-43. 
92. Edwards SW, Tan CM, Limbird LE. Localization of G-protein-coupled 
receptors in health and disease. Trends Pharmacol Sci. 2000;21(8):304-8. 
93. Tsukaguchi H, Matsubara H, Taketani S, Mori Y, Seido T, Inada M. Binding-, 
intracellular transport-, and biosynthesis-defective mutants of vasopressin 
   
95 
type 2 receptor in patients with X-linked nephrogenic diabetes insipidus. J 
Clin Invest. 1995;96(4):2043-50. 
94. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in 
familial hypercholesterolemia: mutational analysis of a membrane protein. 
Annu Rev Genet. 1990;24:133-70. 
95. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel 
dysfunction in cystic fibrosis. Cell. 1993;73(7):1251-4. 
96. Karpa KD, Lin R, Kabbani N, Levenson R. The dopamine D3 receptor 
interacts with itself and the truncated D3 splice variant d3nf: D3-D3nf 
interaction causes mislocalization of D3 receptors. Mol Pharmacol. 
2000;58(4):677-83. 
97. Goodchild RE, Dauer WT. Mislocalization to the nuclear envelope: an effect of 
the dystonia-causing torsinA mutation. Proc Natl Acad Sci U S A. 
2004;101(3):847-52. 
98. Motley A, Lumb MJ, Oatey PB, Jennings PR, De Zoysa PA, Wanders RJ, et al. 
Mammalian alanine/glyoxylate aminotransferase 1 is imported into 
peroxisomes via the PTS1 translocation pathway. Increased degeneracy and 
context specificity of the mammalian PTS1 motif and implications for the 
peroxisome-to-mitochondrion mistargeting of AGT in primary hyperoxaluria 
type 1. J Cell Biol. 1995;131(1):95-109. 
99. Karan G, Yang Z, Zhang K. Expression of wild type and mutant ELOVL4 in 
cell culture: subcellular localization and cell viability. Mol Vis. 2004;10:248-
53. 
100. Kirschner KM, Baltensperger K. Erythropoietin promotes resistance against 
the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia 
cells. Mol Cancer Res. 2003;1(13):970-80. 
101. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a 
nuclear export function. Nature. 2000;406(6799):1009-12. 
102. Dean DA. Nuclear transport: an emerging opportunity for drug targeting. 
Adv Drug Deliv Rev. 2003;55(6):699-702. 
103. Gasiorowski JZ, Dean DA. Mechanisms of nuclear transport and 
interventions. Adv Drug Deliv Rev. 2003;55(6):703-16. 
104. Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y, Yanagida M, et al. 
Leptomycin B inhibition of signal-mediated nuclear export by direct binding 
to CRM1. Exp Cell Res. 1998;242(2):540-7. 
105. Meissner T, Krause E, Vinkemeier U. Ratjadone and leptomycin B block 
CRM1-dependent nuclear export by identical mechanisms. FEBS Lett. 
2004;576(1-2):27-30. 
   
96 
106. Koster M, Lykke-Andersen S, Elnakady YA, Gerth K, Washausen P, Hofle G, 
et al. Ratjadones inhibit nuclear export by blocking CRM1/exportin 1. Exp 
Cell Res. 2003;286(2):321-31. 
107. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, et al. A 
synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear 
export. Proc Natl Acad Sci U S A. 2002;99(22):14440-5. 
108. Yan Liu X, Robinson D, Veach RA, Liu D, Timmons S, Collins RD, et al. 
Peptide-directed suppression of a pro-inflammatory cytokine response. J Biol 
Chem. 2000;275(22):16774-8. 
109. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J 
Cancer. 1996;74(4):648-9. 
110. Allen NP, Patel SS, Huang L, Chalkley RJ, Burlingame A, Lutzmann M, et al. 
Deciphering networks of protein interactions at the nuclear pore complex. 
Mol Cell Proteomics. 2002;1(12):930-46. 
111. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa 
molecular chaperone family: structure, function, and clinical applications. A 
comprehensive review. Pharmacol Ther. 1998;79(2):129-68. 
112. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA. Mitogen Activated Protein 
Kinase Regulates Nuclear Association of Human Progesterone Receptors. Mol 
Endocrinol. 2003;9:9. 
113. Kanwal C, Mu S, Kern SE, Lim CS. Bidirectional on/off switch for controlled 
targeting of proteins to subcellular compartments. J Control Release. 
2004;98(3):379-93. 
114. Fabbro M, Schuechner S, Au WW, Henderson BR. BARD1 regulates BRCA1 
apoptotic function by a mechanism involving nuclear retention. Exp Cell Res. 
2004;298(2):661-73. 
115. Liu H, Deng X, Shyu YJ, Li JJ, Taparowsky EJ, Hu CD. Mutual regulation of 
c-Jun and ATF2 by transcriptional activation and subcellular localization. 
Embo J. 2006;25(5):1058-69. 
116. Hantschel O, Wiesner S, Guttler T, Mackereth CD, Rix LL, Mikes Z, et al. 
Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Mol Cell. 
2005;19(4):461-73. 
117. Savory JG, Hsu B, Laquian IR, Giffin W, Reich T, Hache RJ, et al. 
Discrimination between NL1- and NL2-mediated nuclear localization of the 
glucocorticoid receptor. Mol Cell Biol. 1999;19(2):1025-37. 
118. Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, et al. Identification 
and characterization of a ligand-regulated nuclear export signal in androgen 
receptor. J Biol Chem. 2003;278(43):41998-2005. 
   
97 
119. Li H, Fidler ML, Lim CS. Effect of initial subcellular localization of 
progesterone receptor on import kinetics and transcriptional activity. Mol 
Pharm. 2005;2(6):509-18. 
120. Freedman DA, Epstein CB, Roth JC, Levine AJ. A genetic approach to 
mapping the p53 binding site in the MDM2 protein. Mol Med. 1997;3(4):248-
59. 
121. Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of 
p53 protein is mediated by several nuclear localization signals and plays a 
role in tumorigenesis. Mol Cell Biol. 1990;10(12):6565-77. 
122. Pratt WB, Gehring U, Toft DO. Molecular chaperoning of steroid hormone 
receptors. Exs. 1996;77:79-95. 
123. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and 
immunophilin chaperones. Endocr Rev. 1997;18(3):306-60. 
124. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking 





OPTIMIZING THE PROTEIN SWITCH: ALTERING NUCLEAR 
IMPORT AND EXPORT SIGNALS, AND 
LIGAND BINDING DOMAIN1 
Abstract 
Ligand regulated localization controllable protein constructs were optimized 
in this study. Several constructs were made from a classical nuclear export signal 
(HIV-rev, MAPKK, or progesterone receptor) in combination with a SV40 T-antigen 
type nuclear import signal. Different ligand binding domains (LBDs from 
glucocorticoid receptor or progesterone receptor) were also tested for their ability to 
impart control over localization of proteins. This study was designed to create 
constructs that are cytoplasmic in the absence of ligand and nuclear in the presence 
of ligand, and also to regulate the amount of protein translocating to the nucleus on 
ligand induction. The balance between the strengths of import and export signals 
was critical for overall localization of proteins. The amount of protein entering the 
                                                
Reprinted from J Controlled Release. 120: 220-32 (2007) 
Kakar, M., Davis, J.R., Kern, S.E., Lim, C.S. 
MK was the main contributor to this paper, but JRD contributed intellectually with 
most aspects of the work, and provided technical assistance for microscopy, and 
image and data analysis. The original publication has been modified here to reflect 
the experiments that JRD contributed to, and includes additional work done by JRD 
that cannot be separated from the original paper. SEK contributed intellectually to 
the import modeling section (not reprinted here), and CSL contributed intellectually 
to all aspects of the work. 
 99 
nucleus was also affected by the dose of ligand (10-100nM). However, the overall 
import characteristics were determined by the strengths of localization signals and  
the inherent localization properties of the LBD used. This study established that the 
amount of protein present in a particular compartment could be regulated by the use 
of localization signals of various strengths. These optimized localization controllable 
protein constructs can be used to correct for diseases due to aberrant localization of 
proteins. 
Introduction 
Intracellular localization of genes and gene products plays an important role 
in maintaining normal cellular functions. Molecules involved in regulation of the cell 
cycle–splicing factors, proteasomes, transcription factors, protein kinases, cell cycle 
inhibitors, chromatin assembly proteins, and numerous other regulatory proteins–
undergo changes in intracellular localization during various phases of the cell cycle 
(1-6). Studies have shown that mislocalization of these proteins and other tumor 
suppressors can lead to cancer. Over 10 known tumor suppressors are regulated via 
nucleo-cytoplasmic shuttling, including p53, p73, Beclin, BRCA1, APC, VHL, PML, 
Smad4, p130, and INI1/HSNF5 (7). Malfunctioning of shuttling can cause disease; 
conversely, manipulation of shuttling could be utilized to treat disease. In our 
previous study (Kanwal et al.) (8) a bi-directional protein construct called the 
“protein switch” was devised, responsive to an external ligand to control 
intracellular localization of protein. Our current study describes an improved and 
optimized ligand inducible protein construct that could be used to correct for 
mislocalization of endogenous proteins involved in certain diseases. The engineered 
construct containing the mislocalized protein has controlled localization, and can 
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overcome the aberrant localization of the endogenous malfunctioning protein. Aside 
from the compartmentalization application presented in this research, ligand 
induced localization controllable protein constructs can also be used for independent 
regulation of genes, artificial control of transcription (via transcription factors), 
engineering of enzymes, gene therapy applications, and biosensor arrays. This 
ability to regulate and control localization of genes and gene products has the 
potential to make gene therapy safer and more efficient. It would also expand the 
range of gene therapy by allowing customized disease management and a greater 
control over the therapy.  
 In eukaryotes, DNA replication and RNA synthesis occur in the nucleus, 
while protein synthesis occurs in the cytoplasm (9). All nuclear proteins, such as 
histones and transcription factors are synthesized in the cytoplasm and are 
transported back to the nucleus, whereas, transfer RNA, messenger RNA, and 
ribosomal RNA are transcribed in the nucleus and are transported to the cytoplasm 
for translation. Compartmentalization of these macromolecules allows for regulation 
of these cellular events (10). The double-membrane nuclear envelope separates the 
contents of the nucleus and cytoplasm (9, 10). Nucleo-cytoplasmic transport of 
proteins and other macromolecules occurs through nuclear pore complexes present 
in the nuclear envelope. These pores (diameter ~9nm) allow for passive diffusion of 
small molecules less than 45-60 kDa in size (9, 11-13). Large macromolecules are 
transported by an active process utilizing specific transport signals (10) which 
consist of specific amino acid sequences recognized by different receptors to shuttle 
proteins to their active compartments.  
 Signal sequences that are recognized by import receptors and facilitate 
movement of molecules from the cytoplasm to the nucleus are called nuclear 
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localization signals (NLS). There are three different classes of NLSs. Classical NLSs 
are either monopartite, single stretches of basic amino acids (PKKKRK), or bipartite 
(two short sequences with a spacer) basic amino acid stretches 
(KRPAATKKAGQAKKKKLDK) (8, 10, 13-16). The mono- and bipartite import 
signal sequences, from SV40 T-antigen and nucleoplasmin respectively, are 
considered to be prototypes of classical nuclear localization signals (10, 14, 17). The 
third class of NLSs, for example, the yeast homeodomain-containing protein Matα-2, 
has polar residues interspersed with nonpolar residues (MNKIPIKDLLNPQ) (13). 
The sequences flanking the NLSs are often important for localization (15, 16). In 
addition to these three classes, tripartite signals (three short sequences with a 
spacer) have been identified in some steroid hormone receptors, encompassing a 
SV40 T-antigen like monopartite signal within the signal sequence (18). All NLS 
sequences are recognized by the importin α/β heterodimer (8, 10, 13). Importin α 
recognizes the NLS sequence and binds to it via its NLS binding site, while importin 
β mediates translocation of this importin α-NLS cargo complex through the nuclear 
pore complex to the nucleus (8-10, 19). SV40 T-antigen type classical NLSs have 
already been studied for their relative strengths based on their interaction with 
importin α (16). These classical NLSs with varying import strengths are used in our 
research. There have been many studies using nuclear import signals to facilitate 
the movement of macromolecules into the nucleus of cells (20-22). Others have used 
NLSs have been used to facilitate import of plasmid DNA into the nucleus of cells 
(23, 24).   
Opposing nuclear import, the cell uses leucine-rich nuclear export signals 
(NES) that actively transport proteins from the nucleus to the cytoplasm. These 
sequences are recognized by the classical export receptor CRM1 (chromosome region 
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maintenance), also called exportin 1 (10, 25, 26). Classical NESs are ~ 10 amino 
acids in length with hydrophobic residues, especially leucines. As a common 
consensus a NES sequence is LX (1-3) LX (2-3) LXJ where L is leucine, X is a spacer 
and J is either leucine, valine or isoleucine (8, 27-30). We have shown in our 
previous study that classical NESs from HIV-rev protein and MAPKK (mitogen 
activated protein kinase kinase) protein can individually confer export to an 
enhanced green fluorescent protein (EGFP)-containing construct (8).  
 Previously we devised localization controllable protein constructs containing 
a nuclear export signal, a nuclear import/localization signal, and a ligand binding 
domain to confer responsiveness to an external ligand (8). EGFP was used as a gene 
of interest to track the localization of a protein construct using fluorescence 
microscopy (8, 30-34). In the absence of external ligand, the protein construct was 
mostly present in the cytoplasm due to the dominant effect of the NES. Upon ligand 
addition, the protein construct translocated to the nucleus via the LBD and the NLS. 
It was shown that the rate and amount of protein translocating to the nucleus 
correlated with the dose of ligand (8). The purpose of our current work was to 
optimize the protein switch to make it more cytoplasmic in the “off” state 
(unliganded) and more nuclear in the “on” state (with ligand). The utility of the 
protein switch constructs lies in the ability to keep the attached therapeutic protein 
in one cellular compartment where it is inactive. Upon addition of ligand, the 
therapeutic protein can move to another compartment where it has activity. The 
optimization process leads to improved control of protein location, and better control 
of protein function. The effect of the critical balance between NES and NLS 
strengths on the localization of constructs was tested. Based on our previously 
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published observation indicating that NLSi is a weak import signal (35), the NLSi 
used in our prototype constructs (8) was replaced with stronger classical NLSs.  
The first protein switch used a truncated form of the LBD from the 
progesterone receptor that is responsive to mifepristone (RU486) (36), and non-
responsive to natural agonist progesterone or synthetic agonist R5020. The benefit 
of an LBD with this ligand response is that naturally occurring hormone in the body 
would not trigger the translocation of the switch, meaning that it can only be 
externally controlled. A drawback of this ligand choice is that mifepristone can 
antagonize wild-type endogenous progesterone and glucocorticoid receptors, and is 
also used as an abortifacient (8). A protein switch reliant upon a ligand with many 
natural targets is sub-optimal if this system is to ever reach the clinic, so an LBD 
that responds to a ligand with fewer side effects or controversies was sought. This 
chapter focuses on the alternative NES, NLS, and LBD combinations that were 
examined in the optimization of the protein switch. Table 3.1 shows the various 
combinations of protein switch constructs discussed in this chapter. 
Materials and Methods   
Cell Line and Culture Conditions 
The murine adenocarcinoma cell line 1471.1 (which does not express 
endogenous progesterone receptor) was used in this research. Cells were grown as 
monolayers in 175cm2 flasks containing DMEM (GIBCO BRL, Grand Island, NY) 
supplemented with 10% FBS (Hyclone Laboratories, Logan, UT), 1% penicillin-
streptomycin (GIBCO BRL), 0.1% gentamicin (0.5mg/ml, Hyclone), and 1% L-
glutamine (2nM, Hyclone), and maintained in a 5% CO2 incubator at 37 oC.  
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Table 3.1 
Nuclear Export Signals, Nuclear Import Signals, and Ligand  






Amino acid sequence 
(or numbering) 
Strength of 
signal (Kd nM 




   MAPKK LQKKLEELEL (28) strong 
   HIV LQLPPLERLTL (28) medium 
   PRB NES2 LHDLVKQLHL (30) n/a 




   SV40 SPKKKRKVE (16) 9+4 strong 
   SV40A1 SAKKKRKVE (16) 36+2 medium 
   SV40A7 SPKKKRKAE (16) 53+4 medium 
   MycA8 PAAKRVKADE (16) 85±7 medium 
   SV40A4 SPKKARKVE (16) 335+7 weak 
   CDC2 GVVYKGRHKTTG (37) n/a weak 
   PKC FVVHKRCHE (37) n/a weak 
   NLSi RAMEGQHNYLCAGRNDCIVDKIR- 
RKNCPACRLRKCCQAGMVLGG (38) 
n/a weak 




   PR LBD 645-891aa (30) Mifepristone 
(MFP) 
   GR LBD 
    
   Ecr LBD 
    














Transient transfections of 1471.1 cells were carried out by electroporation as 
previously defined (8, 30). Transfected cells were plated on a clear cover glass 
(Corning no.1, 22mm2 ) in six well plates or plated into live cell chambers (Lab-tek 
chamber slide system, 2 ml, Nalge NUNC International, Naperville, IL) containing 
complete phenol-free DMEM with 10% FBS (charcoal/dextran treated, Hyclone), 1% 
penicillin streptomycin (100U/ml, GIBCO BRL), 0.1% gentamycin (0.5mg/ml, 
Hyclone), and 1% L-glutamine (2nM, Hyclone), and maintained in a 5% CO2 
incubator at 37 oC for 18-24 hours. 
Microscopy   
Approximately 18-24 hours after electroporation, localization of protein 
constructs was viewed by fluorescence microscopy (8). An Olympus IX701F inverted 
fluorescence microscope (Scientific Instrument Company, Aurora, CO) with high-
quantity narrow band GFP filter (excitation HQ480/20nm, emission HQ510/20nm, 
with beam splitter Q4951p) from Chroma Technology (Brattleboro, VT) was used. 
Cells were photographed at a magnification of 40x using an F-View Monochrome 
CCD camera. To minimize photobleaching of EGFP chromophore, cells were imaged 
using neutral density filters at short exposure times of 500ms. An air stream 
incubator (Nevtek ASI 400, Burnsville, VA) with temperature control was used to 
maintain the microscope stage at 37oC.  
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Construction of Plasmids   
Different plasmid constructs were created by changing the sequence of NES, 
NLS and LBD, which hereafter follow the pattern NES-NLS-LBD. The plasmids 
HIV-NLSi-PRLBD and MAPKK-NLSi-PRLBD, from our previous study (8), were 
used for construction of new plasmids. 
 HIV-SV40-PRLBD and MAPKK-SV40-PRLBD were constructed by removing 
NLSi using restriction enzymes EcoRI and SalI and replacing it with oligonucleotide 
5’- AATTCTAGCCCAAAGAAGAAGAGAAAAGTAGAAG -3’ and its complementary 
strand which encodes the classical NLS from SV40 T-antigen protein (see Table 3.1 
for NLS amino acid sequence). 
MAPKK-MycA8-PRLBD was constructed by removing NLSi out of MAPKK-
NLSi-PRLBD using restriction enzymes EcoRI and SalI and replacing it with 
oligonucleotide 5’- AATTCTCCAGCAGCAAAAAGAGTAAAAGCAGACGAAG - 3’ and 
its complementary strand which encodes the classical type NLS sequence from 
MycA8 protein (see Table 3.1 for NLS amino acid sequence). 
HIV-MycA8-PRLBD was constructed by removing MycA8 NLS from MAPKK-
MycA8-PRLBD using EcoRI and SalI and inserting it in HIV-NLSi-PRLBD already 
digested with EcoRI and SalI (to remove NLSi). 
HIV-SV40A1-PRLBD and HIV-SV40A7-PRLBD were constructed by 
removing NLSi using EcoRI and SalI from HIV-NLSi-PRLBD and replacing it with 
oligonucleotide 5’- AATTCTAGCCCAAAGAAGAAGAGAAAAGTCGAAG - 3’ and its 
complementary strand which encodes SV40A1, a truncated version of classical NLS 
from SV40 T-ag protein, and oligonucleotide 5’- AATTCTAGCCCAAAGAAGAAG-
AGAAAAGCAGA AG - 3’ and its complementary strand which encodes SV40A7, a 
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truncated version of NLS from SV40 T-antigen protein, respectively (16) (see Table 
3.1 for NLS amino acid sequence). 
 MAPKK-CDC-PRLBD, MAPKK-PKC-PRLBD and MAPKK-SV40A4-PRLBD 
were constructed by removing NLSi using EcoRI and SalI from MAPKK-NLSi-
PRLBD and replacing it with oligonucleotides and their complementary strands 
encoding NLSs for the respective plasmids. Oligonucleotide 5’- 
AATTCTGGAGTAGTATACAAAGGA AGACACACAAAACA - 3’ and its 
complementary strand which encodes the NLS from CDC2HS; 5’- 
AATTCTTTCGTAGTACACAAAAGATGCCACGAAG - 3’ and its complementary 
which strand encodes the NLS from protein kinase C (PKC); and 5’-
AATTCTAGCCCAAAAAAAGCAAGAAAAGTAGAAG - 3’ and its complementary 
strand which encodes the truncated NLS (SV40A4) from SV40 T-antigen protein 
were used to make these constructs (see Table 3.1 for NLS amino acid sequence). 
 PRNES2-SV40-PRLBD and PRNES2-MycA8-PRLBD were constructed by 
replacing MAPKK NLS from MAPKK-SV40-PRLBD and MAPKK-MycA8-PRLBD 
using restriction enzymes BspEI and XhoI by the oligonucleotide 5’ - 
CCGGACTACAC GACCTAGTAAAACAACTACACCTAGC - 3’and its complementary 
strand which encodes the classical consensus NES present in progesterone receptor 
(PRNES2) (8) (see Table 3.1 for NES amino acid sequence). 
 HIV-MycA8-MycA8-PRLBD was constructed by inserting the oligonucleotide 
5’- TCGAGGACCAGCAGCAAAAAGAGTAAAAGCAGACGAAGGG - 3’ and its 
complementary strand which encodes the classical type NLS from MycA8 protein 
into the construct HIV-MycA8-PRLBD previously digested with XhoI and EcoRI. 
 HIV-HIV-MycA8-MycA8-PRLBD was constructed by replacing HIV NES 
from HIV-MycA8- MycA8-PRLBD with the oligonucleotide 5’- CCGGACTCCAACTG-
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CCTCCCTTGGAGCGCCTAACTTGGGAGCACTCCAACTGCCTCCCTTGGAGCGCC
TAACTTTGTC - 3’ and its complementary strand which encodes the two repeats of 
the classical consensus NESs from HIV-Rev protein, using enzymes BspEI and XhoI. 
 HIV-SV40-GRLBD and HIV-MycA8-GRLBD were constructed by replacing 
PR LBD with GR LBD (C656G GR LBD (39)) in the constructs HIV-SV40-PRLBD 
and HIV-MycA8-PRLBD respectively, using restriction enzymes KpnI and BamHI. 
The 248 amino acid long C656G GR LBD was taken out of full length GFP-C656G 
GR by performing PCR using the primers 5’ - AGGGTACCCTCACCCCTACCTTG - 3’ 
and 5’- CGCGCGGATCCTTTTTGATGAAACAG - 3’with KpnI and BamHI ends, 
respectively. 
The plasmid encoding the ecdysone receptor was a kind gift by Carl Thummel, 
PhD (University of Utah). To isolate EcR from the plasmid, PCR was performed with 
forward primer 5’-AATTGGTACCCAGGATGGCTATGAG-3’, and reverse primer 5’-
TAATTCCCGGGTCCCAGATCTCCTC-3’, yielding a fragment with the EcR LBD 
flanked with KpnI and XmaI restriction sites on the 5’ and 3’ termini, respectively. 
After digestion with these restriction enzymes, the fragment could be ligated to the 
EGFP plasmid containing the desired signal sequences that was also digested with 
those restriction enzymes.   
Mutated murine estrogen receptor was a kind gift by Dr. Michael Reth (Max 
Plank Institute, Germany). This receptor carries the G525R mutation that renders it 
1000-fold less responsive to estradiol compared to wild-type, but does respond to 4-
hydroxytamoxifen (41). The ligand-binding portion of the receptor was amplified by 
PCR with forward primer 5’-TAGGTACCAAGAAGAATAGCCCTGCCTTGTC-3’ and 
reverse primer 5’-TGGATCCTGGGGCATGAAGGCGGTG-3’, which introduces KpnI 
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and BamHI restriction enzyme sites. This fragment and the desired protein-switch 
vector were digested with these enzymes, and subsequently ligated together. 
Protein Translocation Studies 
All protein constructs were induced with ligand 24 hours after transfection. 
Mifepristone and dexamethasone were used as ligands for constructs with PR and 
GR LBD respectively. Based on our previous studies showing maximum import 
occurring within one hour of ligand induction (14), constructs were induced with 
10nM dose of ligand for 1 hour. Pictures of live cells were taken using a fluorescence 
microscope after 1 hour. As controls, cells were also photographed without inducing 
with ligand. The constructs were constructed and tested for localization 
simultaneously. Depending on the localization results constructs with extreme 
combinations (for instance, a very strong NES and a very weak NLS) were ruled out 
and not constructed. 
Protein Import Studies  
As previously, import kinetics of protein constructs was studied by 
conducting time lapse experiments at three different concentrations: 1nM, 10nM 
and 100nM. Cells (2.5ml) were plated in live cell chambers after transfection by 
electroporation (8). After 18-24 hours of transfection, media was removed, cells were 
washed three times with PBS without calcium, and 2.5 ml of fresh media were 
added. Cells were incubated at 37 oC for 45 minutes prior to induction. Pictures were 
taken without ligand, and also with ligand induction, at time 0, 2, 5, 10, 15, 20, 30, 
40, 50, 60, 90 and 120 minutes.  
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Quantitation of Protein Translocation   
Fluorescence microscopy was used to study and quantify the amount of 
protein present in a cellular compartment as done previously by us and others (8, 31, 
42, 43). Fluorescence intensity of a particular compartment relates to the amount of 
protein present in that compartment; therefore, quantitation of protein in the 
nucleus and cytoplasm was carried out by measuring the fluorescence intensity of 
EGFP, tagged to the protein construct, as previously described (8, 30). All the 
images were analyzed using analySIS® software (Soft Imaging System, Lakewood, 
CO).  The nuclear and cytoplasmic intensity values were divided by the area values 
of the nucleus and cytoplasm to obtain average nuclear and cytoplasmic intensities, 
respectively, to normalize for differences in cell shape and size. Relative nuclear 
intensity was calculated by dividing the average nuclear intensity with average 
cytoplasmic intensity. Percentage nuclear increase is the increase in the nuclear 
intensity (which indicates the increase in the total amount of protein present in the 
nucleus) on ligand induction. Change in relative nuclear intensity on ligand 
induction, are calculated as below to compare different versions of protein constructs.  








                                                         (Equation 2.1)                
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(Equation 2.3)  
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                                                      (Equation 2.5) 










(Equation 2.6)  
 
Where NI = nuclear intensity, NA = area of nucleus, CI = cytoplasmic intensity, CA 
= area of cytoplasm, ANI = average nuclear intensity, ACI = average cytoplasmic 
intensity, PN = percentage of total protein present in the nucleus 1hr. after ligand 
induction, PNo = percentage of total protein present in the nucleus without ligand 
induction, RNI = relative nuclear intensity 1hr. after ligand induction, RNIo = 
relative nuclear intensity without ligand induction. 
Statistical Analysis 
Ligand induction and import studies for all constructs were repeated in 
triplicate (n=3), and 10 cells representative of the whole population were analyzed in 
each experiment. Statistical differences between the relative nuclear intensity 
values were resolved using unpaired t-test with Welch’s correction. One way 
ANOVA with Tukey’s Multiple Comparison Post test was used to assess differences 
between RNI and PNI values for all constructs. 
Results and Discussion 
In our previous study (8), we established that intracellular localization of an 
exogenous protein can be controlled by using a protein construct containing NES, 
NLS and LBD. This construct is present in the cytoplasm in the absence of ligand 
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and translocates to the nucleus on addition of ligand. In this study we aimed to 
rationally design constructs which were more cytoplasmic in the absence of ligand 
and more nuclear in the ligand presence compared to the prototype devised in our 
previous study. We demonstrated that the amount of protein present in a particular 
compartment can be regulated by using NES and NLS of different strengths and in 
different combinations. It was also seen that localization controllable protein 
constructs can be made responsive to more than one ligand, and also show a certain 
degree of dose-responsiveness before saturation. 
As seen in Figure 3.1, the addition of ligand caused a change in localization of 
the protein constructs. Most of these tested protein constructs showed a significant 
change (p<0.05) in localization from the cytoplasm to the nucleus on ligand 
induction. However, as noted in Figure 3.2 this change in amount of protein in the 
nucleus varied for each protein construct. The localization of protein depends on the 
strengths of NES and NLS, while the LBD provides a means to externally control 
this localization with a ligand. In the absence of a ligand, protein constructs are 
mostly cytoplasmic due to a dominant NES, while on addition of ligand, changes in 
conformation of LBD make the constructs translocate to the nucleus via a now 
dominant NLS. The amount of protein entering the nucleus depends on the critical 
balance between the strengths of NES and NLS. This balance of NES-NLS strengths 
has not been given numeric value in  this  study  because relative strengths of some 
of the signals used in this study are not known. Further, the balance indicates that 
the protein constructs are responsive to the ligand and show a change in localization. 
A lack of balance would make the constructs refractory to ligand and result in 





Figure 3.1. Change in protein localization on ligand induction. Change in 
localization of protein is observed after induction with ligand for 1hour. 10nM doses 




























































































































































































































































































































































































Changing the Strength of NLS Regulates the Amount of 
Protein Transported to the Nucleus 
Since nuclear localization signals vary in strength, the effect of changing the 
NLS sequence in the presence and absence of ligand was studied (16). Starting from 
one of the original plasmids, HIV-NLSi-PRLBD (8), other constructs were cloned 
containing constant NES and LBD sequences and substituting NLSs of different 
strengths (one “medium” strength NLS from MycA8 (16), and a “strong” NLS from 
SV40 (16) and others (16, 37); see Table 3.2). Percentage nuclear increase and 
change in relative nuclear intensity values were calculated (as described in methods) 
to compare different protein constructs. As shown in Figure 3.2, HIV-SV40-PRLBD 
(3rd pair of columns) had the maximum relative nuclear intensity on ligand induction 
with 10nM mifepristone, and HIV-NLSi-PRLBD (1st pair of columns) the least. It 
was also observed that the difference in relative nuclear intensities in the presence 
and absence of ligand was greater for HIV-SV40-PRLBD than HIV-NLSi-PRLBD. 
The difference in relative nuclear intensity values for these constructs was 
presumably due to the variation in strengths of NLSs used. Studies have shown that 
SV40 NLS is one of strongest NLSs known, as suggested by its low Kd (dissociation) 
value for interaction with importin α (16). The lower the Kd value of a NLS, the 
stronger the binding with importin α and hence greater nuclear import (16).  
Though NLSi does not have a published value for its interaction with 
importin α, it has been reported to have very weak import activity (35). NLSi has not 
been directly tested in comparison to SV40 NLS or MycA8 NLS, though. From 
relative nuclear intensity values in Figure 2.2, it is observed that the amount of 
protein present in the nucleus even without ligand induction was more for HIV-
SV40-PRLBD (3rd pair of columns) than HIV-NLSi-PRLBD (1st pair of columns), due   
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Table 3.2 











NES NLS LBD 
HIV NLSi PRLBD 
HIV SV40 PRLBD 
HIV MycA8 PRLBD 
HIV SV40A1 PRLBD 
HIV SV40A7 PRLBD 
MAPKK NLSi PRLBD 
MAPKK SV40 PRLBD 
MAPKK MycA8 PRLBD 
MAPKK SV40A4 PRLBD 
MAPKK PKC PRLBD 
MAPKK CDC PRLBD 
PRB NES2 SV40 PRLBD 
PRB NES2 MycA8 PRLBD 
HIV SV40 GRLBD 
HIV MycA8 GRLBD 
HIV MycA8 x 2 PRLBD 













 to the strong SV40 NLS. On the other hand, HIV-MycA8-PRLBD constructs had the 
least amount of protein in the nucleus in the absence of ligand, compared to the 
other two constructs (Figure 3.2, 2nd pair of columns), because of relatively weaker 
nuclear import activity of MycA8 NLS versus SV40 NLS (16). The difference 
between HIV-MycA8-PRLBD and HIV-NLSi-PRLBD in the absence of ligand was 
not statistically significant. On ligand induction, the relative nuclear intensity for 
HIV-MycA8-PRLBD (Figure 3.2, 2nd pair of columns) protein construct was also less 
than HIV-SV40-PRLBD (Figure 3.2, 3rd pair of columns) due to the lower strength of 
MycA8 NLS.  
The nuclear intensity, and hence the amount of protein present in the 
nucleus on ligand induction is affected by the amount of protein present in the 
nucleus before ligand induction. Accordingly, the percentage nuclear increase (PNI, 
Figure 3.3A) and the change in relative nuclear intensity (RNI, Figure 3.3B), on 
ligand induction, were calculated to determine the best protein construct (the least 
amount of protein in the nucleus coupled with the highest protein translocation to 
the nucleus on ligand induction). It can be seen from Figure 3.3A that there was a 
39% increase in amount of protein present in the nucleus on ligand induction for 
HIV-SV40-PRLBD (column 3) while a 44% increase for HIV-MycA8-PRLBD (column 
2). The change in relative nuclear intensity values was 140% and 109% for these two 
constructs respectively (Figure 3.3B, column 3 and 2). The change in PNI and RNI 
values for HIV-NLSi-PRLBD were only 17% (Figure 3.3A, column 1) and 38% 
(Figure 3.3B, column 1), respectively. Both new constructs, HIV-MycA8-PRLBD 
(Figure 3.3A column 2) and HIV-SV40-PRLBD (Figure 3.3A column 3), showed 
significant improvement (p < 0.05) in the amount of protein present in the nucleus 
on ligand induction over HIV-NLSi-PRLBD (Figure 3.3A column 1); however, HIV-  
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Figure 3.3. Comparison of protein constructs based on ligand induction studies. A) 
Percentage increase in the amount of protein in the nucleus on ligand induction for 
each construct is shown in this graph. The amount of protein in the nucleus was 
calculated in the presence and absence of ligand and the percentage increase value 
was calculated. A 10nM dose of MFP and DEX was used as ligand for protein 
constructs with PR and GR LBD, respectively. B) Change in relative nuclear 
intensity on ligand induction for protein constructs is depicted in this graph for 
different protein constructs. Relative nuclear intensity was calculated in the 
presence and absence of ligand, and percentage change was calculated. A 10nM 
dose of MFP and DEX were used as ligand for protein constructs with PR and GR 
LBD, respectively. 
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MycA8-PRLBD and HIV-SV40-PRLBD were not significantly different from each 
other (compare Figure 3.3A column 2 vs column 3). HIV-SV40A1-PRLBD and HIV-
SV40A7-PRLBD constructs tested did not show a significant change in localization 
on ligand induction (data not shown). These results suggest that changing the 
strength of NLS in the protein construct considerably changes the amount of protein 
in the nucleus in the presence and absence of ligand.  
Changing the Strength of the NES Affects the  
Localization of Protein Constructs 
To investigate the affect of the NES on the localization of protein constructs, 
the NES in the prototype HIV-NLSi-PRLBD version was changed. In one set, HIV 
NES was replaced by NES from MAPKK protein to make MAPKK-NLSi-PRLBD, 
MAPKK-MycA8-PRLBD and MAPKK-SV40-PRLBD (8) (Table 3.2). In another set of 
constructs, PRNES2 was used to make PRNES2-MycA8-PRLBD and PRNES2-SV40-
PRLBD (Table 3.2). As seen in Figure 3.1 (d and f) and Figure 3.2 (columns 6 and 4) 
only the MAPKK-MycA8-PRLBD and PRNES2-MycA8-PRLBD constructs showed a 
significant change (p<0.05) in localization of protein from the cytoplasm to nucleus 
on ligand induction. The change in relative nuclear intensity for MAPKK-NLSi-
PRLBD, MAPKK-MycA8-PRLBD and MAPKK-SV40-PRLBD was 16%, 36% and 
19%, respectively (Figure 3.3B, columns 5, 6 and 7), compared to over 100% change 
with the HIV NES constructs (Figure 3.3B, columns 2 and 3). The percentage 
nuclear increase for these MAPKK constructs was also low, at 8%, 17% and 8%, 
respectively (Figure 3.3A, columns 5, 6 and 7). As mentioned above, of the three 
constructs containing MAPKK NES, only MAPKK-MycA8-PRLBD showed a 
significant difference in the amount of protein in the presence and absence of ligand; 
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however, the magnitude of the change in PNI and RNI was low. This is observed 
because MAPKK is a much stronger NES than HIV, and due to its greater export 
strength it presumably prevents movement of protein to the nucleus from the 
cytoplasm on ligand induction. Other MAPKK versions of the protein construct with 
weaker NLSs–MAPKK-CDC-PRLBD, MAPKK-PKC-PRLBD and MAPKK-SV40A4-
PRLBD–also did not show significant change in nuclear import on ligand induction 
(our unpublished data). 
 The PRNES2-MycA8-PRLBD construct showed a significant change in 
localization on ligand induction, except with a different extent of localization, 
presumably since PRNES2 is a weaker NES than MAPKK NES. There was a 40% 
increase in the amount of protein in the nucleus (Figure 3.3A, column 4) and a 
relative nuclear intensity change of 120% (Figure 3.3B, column 4) on ligand 
induction. There was no significant difference observed between this construct 
(PRNES2-MycA8-PRLBD) and the construct containing the HIV NES (HIVNES-
MycA8-PRLBD) (Figure 3.3A and B, columns 4 and 2), presumably due to 
comparative strengths of PRNES2 and HIV NES (8). The PRNES2-SV40-PRLBD 
construct did not induce well and show any change in localization (our unpublished 
observation). Since PRNES2-SV40-PRLBD is already quite nuclear to begin with, 
the import machinery may already be saturated, even without ligand.  Adding 
ligand does not cause more to go into the nucleus.  In this particular construct, the 
balance between the NES and the NLS is tipped to the NLS in the unliganded state, 
so import does not occur with ligand. 
Overall, these findings indicate that the strength of NES impacts the 
effectiveness of protein constructs by influencing the initial localization of the 
construct in the absence of ligand, and the overall balance of NES-NLS strengths (8).  
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Protein Constructs Can Be Made  
Responsive to Other Ligands 
The ligand-binding domain provides control over the localization. Protein 
constructs described above contain a truncated version of PR LBD not responsive to 
endogenous PR, but responsive to antagonist mifepristone (8, 44). To confer 
responsiveness to a different ligand, protein constructs were created using the 
glucocorticoid receptor LBD (C656G GRLBD). These constructs were designed to be 
responsive to dexamethasone (dex) (45). GR LBD with a point mutation C656G was 
used in these constructs because this mutated GR LBD is 9-fold more sensitive to 
dex (39, 45). The benefit of this particular system is that low doses of dex can be 
used to cause nuclear induction, and these sub-nanomolar levels of dex will not 
activate endogenous GRs (39). Constructs containing C656G GR LBD, HIV-MycA8-
GRLBD and HIV-SV40-GRLBD, showed change in localization on ligand induction 
similar to constructs containing PR LBD (Figure 3.1). Upon inducing the constructs 
with 10nM dexamethasone, as observed in Figure 3.2, pairs of columns 8 and 9, 
there was a significant difference (p<0.05) in relative nuclear intensity values 
compared to uninduced. The increase in amount of protein present in the nucleus 
was 33% for HIV-MycA8-GRLBD constructs (Figure 3.3A, column 8) and 35% for 
HIV-SV40-GRLBD constructs (Figure 3.3A, column 9). The change in relative 
nuclear intensity values was 90% and 91%, respectively, for these two constructs 
(Figure 3.3B, columns 8 and 9).  
A mutated version of the murine ERLBD was also examined for efficient 
nuclear translocation in the context of the protein switch. The G525R mutation 
renders the receptor unresponsive to endogenous estradiol agonism, but allows 
hydroxytamoxifen to agonize the receptor (41). Like the GRLBD that is hyper-
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responsive to external ligand dexamethasone, a protein switch that only responds to 
external ligand hydroxytamoxifen (OHT) is more ideal as a potential treatment 
modality than one that can be activated unnecessarily by circulating hormones. The 
translocation results of MAPKK-MycA8-ERLBD construct can be seen in Figure 
3.4A. At 2 hours, there was no visible change in nuclear localization upon induction 
by 100 nM OHT. To rule out the possibility that a higher dose, or a greater time 
exposure time was needed for this particular LBD, MAPKK-MycA8-ERLBD was 
then exposed to 1000 nM OHT for 24 hours. Again, no change in localization was be 
seen under these conditions, suggesting that either the LBD does not produce a 
conformational change needed to expose the NLS, or the particular MAPKK-MycA8 
combination is not effective. The MAPKK-NLSi-ERLBD combination also resulted in 
no visible nuclear localization under the two treatment conditions.  
The opportunity to use a completely non-native ligand-binding domain that 
would not respond to any endogenous hormones can be found in the insect EcR. This 
receptor is also part of the nuclear receptor superfamily, but is only found in insects. 
Its main purpose is to control insect molting transitions, and its ligands are thought 
to be non-toxic to humans (40, 46). The EcR LBD was fused to MAPKK-MycA8 and 
tested for ligand responsiveness of insect ecdysteroid muristerone A (Figure 3.4B). A 
dose of 100 nM was tested at 1 hour, 2 hours, and 4 hours with apparently similar 
results at these times. These results also suggest that either the combinations of 
NES and NLS were not optimal, or that the conformational change of EcR LBD in 
response to ligand is not sufficient to produce a translocation response of the protein 
switch. A quantitative measurement of nuclear protein after drug addition is 
represented in Figure 3.4C, which shows MAPKK-MycA8-EcRLBD having 4.4±1.9 %  
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Figure 3.4. Additional ligand-binding domains for inducible nuclear localization. A) 
The mouse ER LBD was fused to MAPKK-MycA8 (top row) and MAPKK-NLSi 
(bottom row). Images were captured at 2 hours and 24 hours, with little visible 
change in localization. B) The EcR LBD does not demonstrate a visible nuclear 
localization change after addition of 100 nM muristerone A (MUR) after 1, 2, or 4 
hours.C) Percent nuclear increase of constructs after 2 hours of respective ligand 
addition. Plotted on the same scale as Figure 3.3 A.  
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(mean±SEM), MAPKK-MycA8-ERLBD having 1.3±2.2 %, and MAPKK-NLSi- 
ERLBD having 8.7±4.9 % nuclear increase in response to their respective ligands. 
These results were plotted on the same scale as other other protein switch 
combinations (Figure 3.3A). These results were comparable to those seen with other 
MAPKK-MycA8 and MAPKK-NLSi constructs with PRLBD. Taken together, it is 
most likely that the combination of signal sequences was suboptimal, and the 
contribution of these LBDs is inconclusive.  
To conclude, protein constructs for controlled intracellular localization of 
proteins can be customized with different ligand binding domains to confer 
responsiveness to a range of ligands.  Responsiveness of protein switch to different 
ligands will provide greater flexibility and ease of therapy by utilizing already 
available and tested noncontroversial and nontoxic ligands.  
Multiple NLS and NES Render the Protein Construct  
Unresponsive to External Ligand 
In order to study the effect of multiple localization signals on nuclear import 
of protein constructs a second MycA8 NLS was added to HIV-MycA8-PRLBD, 
resulting in HIV-MycA8-MycA8-PRLBD. It was observed that this construct with 
two NLSs was mostly nuclear even in the absence of ligand, and localization was not 
altered by addition of ligand (Figure 3.5). Addition of another export signal (HIV-
HIV-MycA8-MycA8-PRLBD) also did not alter the nuclear localization of the 
constructs. No significant difference was observed in the amount of protein present 
in the nucleus in the presence and absence of ligand for these constructs with 




Figure 3.5. Effect of multiple signal sequences on construct localization. 
Addition of two NLSs made the constructs completely nuclear even in the 
absence of ligand. No change in localization was observed on adding a second 
NES to these constructs. Significant difference was not observed in localization 
of these constructs in the presence and absence of ligand. 
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To summarize, various protein constructs were made by using classical 
NESs—HIV, MAPKK and PRNES2—in combination with SV40 T-antigen type 
NLSs of various strengths (Table 3.2). Most of the constructs tested showed a 
significant change in localization on ligand induction. All of the new constructs 
reported in this study showed a significant improvement in control of localization 
over our previous prototype constructs. New constructs containing stronger NLSs 
than the one used in our previous study (NLSi) showed a much greater increase in 
the amount of protein in the nucleus on ligand induction, signifying that the 
strength of NLS used influences the overall translocation of the construct, shifting 
the localization of constructs to the nucleus. It was seen that stronger NLSs, due to 
their greater interaction with import receptors (16), tend to shift the protein to the 
nucleus even in the absence of ligand. Similarly, the strength of NES also influences 
the localization of protein constructs, however, in the opposite direction. In all the 
constructs used in this study containing MAPKK NES, addition of ligand did not 
cause a significant change in localization from the cytoplasm to the nucleus. This 
indicated that a strong NES, such as MAPKK, tends to keep the constructs mostly in 
the cytoplasm in the absence of ligand. We also observed that addition of multiple 
repeats of localization signals tends to shift the balance of localization towards one 
compartment to a greater degree, making it unresponsive to the ligand. The 
construct containing “medium” strength HIV NES, “medium” strength MycA8 NLS 
and PR LBD showed most favorable results with the least amount of protein present 
in the nucleus in the absence of ligand, and the greatest translocation to the nucleus 
with ligand. Hence, ultimately it is the balance of NES and NLS strengths that 
determines the overall localization of protein constructs in the presence and absence 
of ligand. This balance can be manipulated to control the amount of protein 
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translocation to a compartment. It was also observed that the rate of nuclear import 
of the protein constructs depends on the dose of the ligand used, as well as the 
inherent import characteristics of the LBD used. These protein constructs can 
however be made responsive to more than one ligand. In our study, we successfully 
tested two sets of constructs containing truncated PR LBD and mutated C656G GR 
LBD, responsive to mifipristone and dexamethasone, respectively. The ability to 
substitute LBDs to make localization controllable protein constructs provides the 
advantage of using various nontoxic, previously tested ligands, thus allowing 
creation of customized protein constructs.  
Intracellular transport and localization of proteins is significant for normal 
functioning of cells, and any deviation from this highly regulated transport system 
results in diseases which may range from metabolic disorder to cancer (3, 7, 47-50). 
The constructs described here exploit nuclear localization and nuclear export signals 
to optimize a system for controlling intracellular localization of proteins. Control 
over intracellular protein localization may render a protein inactive in one 
compartment and active in another; thus manipulating the localization of a protein 
using an external ligand would provide more control over the therapy. An 
endogenous gene, with native localization signals intact, may still not localize to its 
correct compartment in the cell on transfection, due to malfunctioning of transport, 
mutations or other cellular events that are difficult to control (8). However, 
attaching the gene with localization controlled protein constructs would render the 
ability to target the gene (and hence protein) to its desired compartment with 
greater control and assurance. Changing the localization of a protein by utilizing 
signal sequences to treat diseases is advancement over current gene therapy.  Many 
diseases are caused due to mislocalization of proteins. Various types of cancers, 
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ranging from breast cancer to certain leukemia’s involve mislocalization of proteins 
(51). Most of these cancers involve mislocalization between the nucleus and the 
cytoplasm. In our recent review we stressed the need of exploring modes for 
controlling intracellular localization of proteins (51). Localization controllable 
protein constructs with a range of NES-NLS combinations studied in this paper is 
one such approach, exploiting intracellular localization for treatment of diseases. A 
protein which is mislocalized in a disease state can be directed to its “normal” 
compartment by using localization controllable protein constructs. These constructs 
can also be used in states where there is inadequate production of a certain protein 
by using a construct with appropriate NES-NLS balance to regulate the amount of 
protein translocating to a compartment.  
 
Conclusions 
The optimization of localization controllable protein constructs was carried 
out in this study. Classical NESs from HIV-rev, PR and MAPKK proteins were used 
in combination with SV40 T-antigen NLSs of various strengths, along with a LBD to 
make the constructs. The overall localization of the constructs was influenced by the 
individual strengths of the localization signals used, as well as the critical balance 
between the NES-NLS strengths. A strong NES, such as MAPKK, tends to keep the 
constructs cytoplasmic and did not show any significant change in localization with 
ligand. On the other hand, a strong localization signal such as SV40 NLS, caused 
translocation of the protein constructs to the nucleus even in the absence of ligand. 
Using multiple repeats of localization signals also tend to shift localization of the 
constructs towards one compartment. Thus, the NES-NLS used in a protein 
construct can be manipulated to regulate the amount of protein translocating to a 
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compartment. In this study, protein constructs were made by using two different 
LBDs responsive to their respective ligand providing a means of making customized 
constructs. The optimized versions of localization controllable constructs also 
showed a significant change in import rate at various ligand doses. It was observed 
that the change in rate of nuclear import was affected by the type of LBD used. The 
optimized localization controllable protein constructs discussed in this study provide 
a mean for regulating the amount of protein present in a compartment, and protein 
translocation across various intracellular compartments, and pave the way for 
treating diseases which are caused due to mislocalization of proteins.  
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UTILIZING THE ESTROGEN RECEPTOR LIGAND- 
BINDING DOMAIN FOR CONTROLLED  




The estrogen receptor forms insoluble aggregates in the cytoskeletal 
subcellular fraction when bound to the antagonist fulvestrant. The ligand-
binding domain was isolated and fused to signal sequences to target subcellular 
compartments. Sequestering a pro-apoptotic peptide tested the utility of a 
protein targeted to the insoluble fraction. The ligand-binding domain of the 
estrogen receptor was isolated and fused with signal sequences, either a nuclear 
localization signal or nuclear export signal. The subcellular localization when 
bound to drug fulvestrant was examined, specifically its interaction with 
cytokeratins 8 and 18. The ability to target a therapeutic peptide to the 
insoluble fraction was tested by fusing a therapeutic coiled-coil from Bcr-Abl in 
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K562 cells. The estrogen receptor ligand-binding domain responds to fulvestrant 
by translocating to the insoluble fraction. Adding a signal sequence significantly 
limited the translocation to either the nucleus or cytoplasm. The cytokeratin 
8/18 status of the cell did not alter this response. The therapeutic coiled-coil 
fused to ERLBD was inactivated upon ligand induction. Isolating the ligand-
binding domain of the estrogen receptor creates a ligand-controllable protein 
capable of translocation to the insoluble fraction. This can be used to sequester 
an active peptide to alter its function. 
Introduction 
In nature, many proteins function exclusively in one subcellular 
compartment or another. Therefore, tight regulation of protein subcellular location 
provides a way for cells to control protein function in the complex cellular milieu. 
Much work in the past decade has focused on discovering, defining, and utilizing 
signal sequences for regulating protein location in cells (1, 2). Subcloning allows the 
addition or removal of signal sequences to known proteins for altered location and 
function (1, 3, 4). For example, we have shown that it is now possible to send the 
normally oncogenic protein Bcr-Abl, the causative agent in chronic myelogenous 
leukemia, to the nucleus, where it instead acts as an apoptotic factor (5). We also 
have shown that targeting p53 (a tumor suppressor) or c-Abl (a proto-oncogene) to 
the mitochondria can cause apoptosis (6, 7). Our laboratory has also pioneered the 
concept of the “protein switch” where the location of a cytoplasmic protein can be 
made nuclear in a ligand-dependent fashion (3, 4). We were also interested in 
creating different kinds of protein switches that would be capable of capturing active 
proteins and sequestering them into other subcellular compartments, rendering 
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them inactive. This paper, to our knowledge, is the first to describe a protein switch 
capable of translocating from the nucleus or cytoplasm (or both) to an insoluble 
cytoskeletal fraction. This protein switch utilizes a version of the estrogen receptor 
ligand-binding domain (ERLBD) that is exclusively responsive to fulvestrant, a non-
natural ligand that can be used for exquisite regulation of the protein location in the 
cell. We provide proof of concept of dysregulation of an active peptide (8) whose 
function is altered when triggered to the cytoskeletal fraction upon addition of 
ligand.   
The ERLBD is derived from the estrogen receptor (ER), a member of the 
steroid hormone nuclear receptor  (SHR) family (9).  SHRs have an N-terminal 
activation domain, a central DNA binding domain, and a C-terminal ligand binding 
domain (LBD) (10). As with other steroid receptors, ER functions as a transcription 
factor when bound to its cognate agonist by dissociating from chaperone proteins 
and binding target DNA or other proteins involved in gene transcription (11, 12). 
The stability of the ER has been shown to be dependent upon the ligand to which it 
is bound (13). In addition to activating gene transcription through the activation 
function domains, the endogenous ligand estradiol (E2) destabilizes ER levels by 
increasing proteasomal degradation and receptor turnover. The drug tamoxifen (one 
of the members of the selective estrogen receptor modulators, or SERMs) is a partial 
agonist at the ER, but also acts to stabilize the receptor. Fulvestrant (ICI 182,780, 
Faslodex®) is a member of the selective estrogen receptor down-regulators (SERDs) 
which act to disrupt the typical nucleocytoplasmic shuttling of ERα and result in 
cytoplasmic accumulation in a protein-synthesis dependent process (14, 15). 
Fulvestrant is a clinically useful antiestrogen that prevents transcriptional 
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activation and rapidly degrades ERα (13, 14, 16-22). The bulky side chain of 
fulvestrant induces a conformational change of helix 12 within ERα’s LBD that 
increases hydrophobicity (23, 24). Lupien et al. suggest receptor insolubility follows 
antagonist binding, mediated by hydrophobic residues L356, L540, and M543 
residing in the helix 12 of the LBD (25). In HepG2 cells, the disappearance of the 
estrogen receptor after fulvestrant treatment appears to be caused by failure to 
extract the insoluble ER aggregates, though in MCF-7 cells receptor insolubility and 
degradation was observed. Long et al. speculate that the degradation of ER in the 
presence of fulvestrant is due to cytokeratins 8 and 18, which facilitate proteasomal 
degradation of ERα (19).  Proteasomal degradation of ERα requires a functional 
helix 12 (19), and an active transcriptional activation complex (26-28). Removal of 
activation domains also prevents transactivation in the presence of receptor agonists, 
such as 17ß-estradiol. Cytokeratins 8 and 18 are the primary intermediate filaments 
of single-layer epithelial cells, and play a variety of roles including cell-cycle 
regulation, protection from cell stress and apoptosis (see Moll et al. and references 
within) (29). Unsurprisingly, these filaments may be useful in diagnostic 
immunohistochemistry, and may also be involved in the oncogensis of cutaneous 
squamous cell carcinoma (30), and may confer a favorable prognosis in breast 
carcinomas, likely due to the facilitation of ERα degradation in ER+ tumors (19, 31, 
32).  
A GFP fusion protein with the ligand-binding domain of ER (ERLBD) was 
utilized to target the insoluble cytoskeletal fraction when bound to fulvestrant. The 
role of cytokeratins 8 and 18 in ERLBD cytoskeletal targeting is also examined. We 
show that fusing either a nuclear localization signal (NLS) or nuclear export signal 
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(NES) to ERLBD can confer subcellular compartment specificity, thus allowing the 
ERLBD cytoskeleton interaction to occur either in the cytoplasm or nucleus.  We 
also present an example of a protein capable of being sequestered in the insoluble 
fraction via the ERLBD, rendering it inactive. 
Materials and Methods 
Cell Culture 
The murine breast adenocarcinoma cell line 1471.1 (a kind gift from G. Hager, 
NCI, NIH) and human ovarian carcinoma cell line A2780 (Sigma Aldrich, St. Louis, 
MO) were grown as monolayers in DMEM (Invitrogen, Grand Island, NY) 
supplemented with 10% FBS (Invitrogen), 1% penicillin-streptomycin-L-glutamine 
(Invitrogen), 0.1% gentamicin (Invitrogen). Human breast adenocarcinoma MCF-7 
cells (ATCC, Manassas, VA) were grown in monolayer in RPMI media (Invitrogen) 
supplemented as above, with the addition of insulin 4 mg/L (Sigma Aldrich). Monkey 
kidney fibroblast COS-7 cells were cultured as monolayer in RPMI media with 
antibiotic supplements. All cells were maintained in 5% CO2 incubator at 37ºC. 
Plasmid Construction 
A plasmid containing the ligand-binding domain of the human estrogen 
receptor α (amino acids 302 to 553, ERLBD) was a kind gift from Carolyn Smith 
(Baylor College of Medicine). To subclone ERLBD into the multiple cloning site 
(MCS) of EGFP-C1, a KpnI restriction site was introduced before the ERLBD by 
site-directed mutagenesis with top primer 5’-GGACAAGGCCAGGCTGTT-
CTTCTTAGAGGTACCAC-CGGATCTAGATAACTGATC-3’ and bottom primer 5’-
GATCAGTTATCTAGATCCGGTGGTACCTCTAAGAAGAACAGCCTGGCCTTGTCC
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-3’. The KpnI digested ERLBD fragment was subcloned into the KpnI site of EGFP-
C1 resulting in EGFP-ERLBD. Sequence analysis (at the University of Utah Core 
DNA Sequencing Facility) verified successful cloning. 
To create EGFP-NLS-ERLBD, the NLS sequence from SV40 large T-antigen 
was placed between BspEI and XhoI sites. The oligonucleotides containing the NLS 
sequence were synthesized by the core facility, and were annealed together, creating 
a double stranded insert flanked by BspEI and XhoI overhangs.  The sequences for 
the oligonucleotides are as follows: top strand: 5’-CCGGAAGCCCG-
AAAAAAAAACGCAAAGTGGAATC-3’ and bottom strand: 5’ TCGAGATTCCAC-
TTTGCGTTTTTTTTTCGGGCTT-3’. The annealed oligonucleotides were ligated into 
a digested EGFP-ERLBD vector. Similarly, the NES from mitogen activated protein 
kinase kinase (MAPKK) was cloned between BspE1 and XhoI to form EGFP-NES-
ERLBD. The oligos were synthesized as follows: top strand: 5’-
CCGGACTGCAGAAAAAACTGGAAGAACTGGAACTGTC-3’ and bottom strand: 5’-
TCGAGACAGTTCCAGTTCTTCCAGTTTTTTCTGCAGT-3’. In addition, the EGFP-
ERLBD-CCmut3 was constructed by amplifying the DNA encoding ERLBD by 
polymerase chain reaction, using the primers 5"-GGATCACTCTCGGCATGG-3" and 
5"-GCGCGCGCGCTCCGGAGCTAGTGGGCGCATGTAGG-3" followed with BspEI 
digestion. This was subcloned into the BspEI restriction enzyme site in our 
published EGFP-CCmut3 plasmid (8). 
Transient Transfections 
For microscopy studies, cells were plated on a clear cover glass in six well 
plates (Greiner Bio-One Cellstar, Monroe, NC) or live cell chambers (Nalg Nunc, 
Rochester, NY) with corresponding media the day before transfection. For western 
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blot, cells were plated in 60 mm dishes (Corning Inc., Corning, NY). Transfections 
were performed with Lipofectamine 2000 (Invitrogen) per manufacturer’s 
recommendations. K562 cells were transfected according to the Cell Line 
Nucleofector Kit V Protocol (program T-013) using the Amaxa Nucleofector II (Lonza 
Group, Basel, Switzerland). 
Microscopy and Image Analysis 
Approximately 16 to 24 hours after transfection, cells were viewed on an 
Olympus IX701F inverted fluorescence microscope (Scientific Instrument Company, 
Aurora, CO) as previously described (33). To quantitate protein location, the 
fluorescent images obtained were analyzed using analySIS® software (Soft Imaging 
System, Lakewood, CO) as previously described (4). To obtain average cytoplasmic 
intensity data for all constructs, 10 representative cells from each experiment were 
analyzed and averaged from 3 separate experiments (n=3), and are expressed as 
percent cytoplasmic intensity. Statistical differences between the constructs were 
determined using one-way ANOVA with Tukey’s post-hoc test.  
Western Blot 
Approximately 24 hours after transfection, cells were treated as indicated, 
briefly rinsed with PBS, removed from the dish by trypsinization, then centrifuged 
at 500 x g for 5 minutes. Cell lysis and subcellular fractionation were carried out 
with the Subcellular Protein Fractionation Kit (Thermo Scientific). Cytoplasmic and 
cytoskeletal fractions were separated on a Novex Bis-Tris 10% gel (Invitrogen), 
transferred to PVDF membrane by iBlot (Invitrogen). Blocking was accomplished 
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with Blocker BLOTTO (Thermo Scientific, Rockford, IL). Primary antibodies were 
diluted in Blocker BSA 2% (Thermo Scientific) in TBST. For detection of cytokeratin 
18, a rabbit polyclonal to cytokeratin 18 (Abcam ab52948, Cambridge, MA) was used, 
diluted to 1:10,000. For detection of GFP, rabbit polyclonal Anti-GFP (Sigma Aldrich 
G1544) was diluted to 1 µl/mL. Loading control anti-GAPDH (Cell Signaling #5174, 
Danvers, MA) was diluted to 1:1000. Secondary anti-rabbit IgG conjugated to 
horseradish peroxidase (Cell Signaling #7074) was diluted 1:2500 in BSA 2% in 
TBST. To produce chemiluminescence, the SuperSignal West Pico 
Chemiluminescent substrate (Thermo Scientific) was incubated on the membrane. 
Western images were acquired with FluorChem FC2 imaging station with 
AlphaView Software (AlphaInnotech, San Leandro, CA). 
Indirect Immunofluorescence 
Approximately 24 hours after transfection, MCF-7 cells were treated with 
drug or vehicle for 1 hour, and then rinsed briefly with ice-cold PBS. Cells were fixed 
with 4% paraformaldehyde solution for 15 minutes at room temperature, and then 
washed twice with ice-cold PBS. Cell membranes were permeabilized with 0.5% 
Triton X-100 in PBS for 10 minutes, and then washed with PBS three times for 5 
minutes each. Blocking was done with BLOTTO for 1 hour. Primary antibody 
against CK18 was diluted 1:500 in 5% BSA in PBS, and then incubated with cells for 
1 hour at room temperature. Cells were washed x 3 with PBS for 5 minutes. Goat 
anti-rabbit secondary antibody conjugated to Texas Red (Abcam ab6719) was diluted 
1:500 in BLOTTO and incubated with cells for 1 hour at room temperature. Excess 
antibody was removed by washing x 3 for five minutes. Cover slips were mounted to 
glass slides with Fluoromount G (Electron Microscopy Sciences, Hatfield, PA). Fixed 
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slides were viewed with an Olympus IX81 FV1000-XY confocal microscope (Imaging 
Core Facility, University of Utah) with a 60X objective and 3.0x digital zoom as 
previously described (8). Excitation and emission filters for EGFP and Texas Red 
were 488 nm excitation, 500-530 nm emission filter, and 543 excitation, 555-655 nm 
emission filter, respectively. To account for variations in expression of EGFP, the 
exposure settings and laser gain of each channel were kept below detected pixel 
saturation for each cell. Olympus FluoView software was used to capture images; 
ImageJ (http://rsb.info.nih.gov/ij) was used for image analysis. Prior to statistical 
analysis, cell images were corrected for background noise. Identical regions of 
interest (ROIs) were created around whole cells for each fluorophore, and these ROIs 
were compared using JACoP colocalization plugin to estimate Costes’ colocalization 
coefficient (34, 35). To better visualize colocalization, the Colocalization ColorMap 
plugin was used (36).  
7AAD Assay 
K562 cells were stained with 7-aminoactinomycin D (7-AAD, Invitrogen) 
according to manufacturer’s instructions 48 and 72 hours after transfection. The 
samples were analyzed using the FACSCanto-II (BD-BioSciences, University of 
Utah Core Facility) with FACSDiva software. Only transfected cells were analyzed 
by gating for EGFP positive cells. EGFP and 7-AAD were excited with the 488 nm 
laser, and were detected at 507 nm and 660 nm, respectively. Each construct was 
assayed three times (n=3). The means of each group were compared by ANOVA with 




Three protein constructs were constructed and transiently transfected into 
various cell lines. Figure 4.1 shows the results from microscopy of these cells. The 
first construct tested was EGFP-ERLBD, a truncation of the human ERα consisting 
of amino-acids 302-595. This region of the receptor is responsible for ligand binding 
and transactivation, but lacks the domains capable of interacting with DNA. The 
result is a construct that takes on whole-cell localization when viewed by 
fluorescence microscopy in the presence of ethanol (vehicle), but in the presence of 
fulvestrant takes on a punctate staining pattern. The basal localization is in 
contrast to full-length receptor that localizes exclusively in the nucleus, and only 
appears in the cytoplasm after fulvestrant addition (14). This distribution was 
visualized in murine breast adenocarcinoma cell line 1471.1, human breast 
adenocarcinoma MCF-7 cells, human cervical carcinoma HeLa cells, and monkey 
kidney fibroblast COS-7 cells.  
To test the ability to control the subcellular localization of the construct in 
these cell lines, we then fused a nuclear export signal from the mitogen activating 
protein kinase kinase (MAPKK) “NES-ERLBD”, or a classical monopartite nuclear 
localization signal from the SV40 large-T antigen “NLS-ERLBD” (Figure 4.2).  The 
results demonstrate an ability to predetermine the subcellular compartment of an 
introduced protein. The NES excludes the introduced protein from the nucleus 
(Figure 3.2, left half), with or without the presence of fulvestrant, and the NLS 




Figure 4.1. Fluorescence microscopy of cells transfected with EGFP-ERLBD. 
Presented here are representative fluorescence microscopy images of cells from 
multiple cell types (1471.1, MCF-7, HeLa, or COS-7 cells). Cells were treated with 
EtOH (ethanol, left) or fulvestrant (ICI, right) 100 nM for 1 hour. With EtOH 
treatment, the protein can be seen as having a whole-cell distribution. When 
treated with fulvestrant, the protein was seen in dense punctate clusters, in both 





Figure 4.2. Effect of signal sequences on localization. The inclusion of signals 
sequences changes the distribution of ERLBD across multiple cell types (1471.1, 
MCF-7, HeLa, or COS-7 cells). A nuclear export signal fused to EGFP-ERLBD 
(left) shows a more prominent cytoplasmic distribution with or without treatment 
with fulvestrant 100 nM for 1 hour.  A nuclear localization signal (right) clearly 
demonstrates a pronounced nuclear accumulation with or without fulvestrant. In 
both cases, a change to punctate clusters occurs in the presence of fulvestrant in 
their respective subcellular compartment (nucleus or cytoplasm).  
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Quantification of the amount of fluorescence of each construct in the 
cytoplasm in 1471.1 cells was done (Figure 4.3A). ERLBD was found to have 36.7% ± 
2.2 (mean ± SD) cytoplasmic fluorescence, NES-ERLBD had 54.5% ± 1.5, and NLS-
ERLBD had 20.9% ± 2.7. Compared to ERLBD, NES and NLS constructs were 
significantly different, with p-values < 0.001 by ANOVA with Tukey’s post-hoc test. 
Figure 3B shows the fluorescence from a region within the cell before and after drug 
addition, demonstrating the displacement of proteins to aggregates.  Figure 4.3C 
shows the change, in percent, of this movement. The negative value signifies the loss 
of fluorescence in a defined region of interest as the protein translocates away from 
the region to insoluble punctate dots. Only ERLBD and NLS-ERLBD showed high 
protein displacement after fulvestrant addition (> 80%). Nevertheless, NES-ERLBD 
does show a change in the cytoplasmic pattern, going from a dispersed to a punctate 
pattern, but no overall displacement of fluorescence intensity in that region. 
ERLBD Localization by Fractionation 
It has been proposed that the distribution change of ER when bound to 
fulvestrant is due to an interaction with cytoskeletal cytokeratins (19). To examine 
this possible interaction, microscopy and subcellular fractionation of a cytokeratin-
negative cell line A2780 was compared to cytokeratin positive MCF-7 cells. 
Microscopy of A2780 (Figure 4.4A) reveals the same pattern of cytoplasm-to-
punctate pattern seen in other cell lines transfected with EGFP-ERLBD in the 
presence of fulvestrant. Subcellular fractionation of untransfected (naked DNA only) 
versus transfected was performed to rule-out possible upregulation of cytokeratins 
by Lipofectamine reagent alone (Figure 4.4B). Lipofectamine transfection did not 
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fractions (Figure 4.4B, Lipo +/-). MCF-7 cells are known to be cytokeratin positive, 
and these cells did demonstrate cytokeratins in both untransfected and transfected 
cells. Knowing the cytokeratin status of these cells, the subcellular fraction of EGFP-
ERLBD was evaluated 1 hour after ethanol (ICI -) or fulvestrant 100 nM (ICI +) 
treatment conditions (Figure 4.4C). In both A2780 and MCF-7 cells, EGFP-ERLBD 
resided in the cytoplasm (Figure 4.4C, CP, -) when induced with vehicle. However, 
fulvestrant induced a change in subcellular location to the cytoskeleton (Figure 4.4C, 
CS, +). Hence we conclude that the cytokeratin status does not affect the subcellular 
location of EGFP-ERLBD bound to fulvestrant. 
 
Cytokeratin 18/ERLBD Colocalization 
To further assess the interaction of the ERLBD truncation with cytokeratins, 
indirect immunofluorescence of CK18 (red channel) on fixed MCF-7 cells transiently 
transfected with ERLBD (green channel) was performed. A single plane of each cell 
was captured in both red and green channels (Figure 4.5). The distribution of 
ERLBD was similar to that seen in Figure 4.1, with whole-cell distribution after 
ethanol treatment, and punctate distribution after fulvestrant treatment Figure 
4.5A, top and bottom panels). CK18 as visualized by indirect immunofluorescence 
revealed a typical cytoskeletal interconnected filament pattern (Figure 4.5B, top and 
bottom panels). The images were pseudocolored with red or green, and merged to 
visualize colocalization. The merged images revealed little yellow color—which 
denotes overlapping fluorescence in the red and green channels, so a Colocalization 
Colormap plugin was utilized in ImageJ to better visualize truly overlapping pixels, 
and JACoP plugin was used to quantify the colocalization by the Costes’ coefficient, 
which quantifies the colocalization of two fluorophores by statistically correlating  
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Figure 4.4. Comparison of cytokeratin positive and negative cells. A: Fluorescence 
microscopy images of A2780 cells transfected with EGFP-ERLBD, and treated 
with EtOH or fulvestrant 100 nM for 1 hour. B: Western blot after subcellular 
fractionation of A2780 and MCF-7 cells, with (+) or without (-) transfection by 
lipofection. Cytokeratins (CK) 8 and 18 were only detected in MCF-7 cells, 
regardless of transfection status, and appeared only in the cytoskeletal fraction 
(CS), not the cytoplasmic fraction (CP) while no CK8 or CK18 were detected in 
A2780. GAPDH was used as a marker of cytoplasmic proteins. C: ERLBD was 
detected in the cytoplasmic fraction (CP) when treated with ethanol (-), but was 
seen exclusively in the cytoskeletal fraction (CS) after fulvestrant treatment (+). 






































































































































































































































































































































































































































































the overlap and pixel intensity of each color (35). The Costes’ coefficient predicts 
colocalized fluorophores for values over 0.5. High degrees of pixel intensity overlap 
are depicted in the colormap by red and brown colors, where low degrees of overlap 
are depicted as blue and green (Figure 4.5D, top and bottom panels). ERLBD treated 
with ethanol had a Costes’ coefficient of 0.38 ± 0.05; whereas with fulvestrant 
treatment yielded a coefficient of 0.089±0.03. Neither treatment condition suggests a 
significant colocalization of the ERLBD with cytokeratin 18.  
Induced Sequestration of ERLBD-bearing Protein 
To test the ability of ERLBD to control a protein’s localization, and therefore 
function, we subcloned a mutated coiled-coil (CCmut3) motif from Bcr-Abl previously 
developed in our lab (8). When introduced into Bcr-Abl positive CML cells, this 
coiled-coil disrupts signaling by Bcr-Abl and induces apoptosis. We hypothesized 
that ERLBD-CCmut3, when bound to fulvestrant, would cause sequestration of 
CCmut3 thereby preventing the disruption of Bcr-Abl signaling and nullifying its 
apoptotic response. Microscopy studies reveal that fulvestrant does indeed sequester 
ERLBD-CCmut3 similarly to ERLBD alone in K562 cells, whereas ER agonist 
estradiol and partial agonist tamoxifen did not induce protein translocation (Figure 
4.6A). To test the decrease in apoptotic potential of ERLBD-CCmut3 sequestered by 
fulvestrant, flow cytometry with 7AAD staining was performed. Bcr-Abl positive 
K562 CML cells were transfected with EGFP, EGFP-ERLBD, or EGFP-ERLBD-
CCmut3. These cells were treated with ethanol or fulvestrant at escalating doses for 
48 and 72 hours; untransfected cells were treated with Gleevec® as a positive 
control (Figure 4.6B). EGFP with or without fulvestrant demonstrated low 7AAD 
staining, with 2.2% ± 0.4 and 1.8% ± 0.4 respectively. EGFP-ERLBD trended toward 
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Figure 4.6. ERLBD-CCmut3 in K562 cells. A: Fluorescence microscopy of K562 cells 
transfected with EGFP-ERLBD-CCmut3 and treated with either ethanol (EtOH), 
estradiol (E2) 100 nM, tamoxifen (OHT) 100nM, or fulvestrant (ICI) 100nM for 1 
hour. Fulvestrant was the only ligand causing appreciable protein translocation. The 
same subcellular distribution pattern was demonstrated when treated with 
fulvestrant, despite the inclusion of a functional peptide capable of binding an 
endogenous protein. B: 7AAD staining as detected by flow cytometry, as a percent of 
cell population. Only cells transfected with ERLBD-CCmut3 showed significantly 
higher 7AAD staining than the negative control (EGFP).  ERLBD-CCmut3 treated 
with ethanol demonstrated the highest staining of transfected cells, significantly 
higher than EGFP, p < 0.001. When bound to fulvestrant, however, 7AAD staining 
significantly decreased, p < 0.01. Untransfected cells were treated with Gleevec® as 
a positive control for 7AAD staining.  *** = p < 0.001, ** = p < 0.01, * p < 0.05. 
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 higher 7AAD staining, though not statistically significant with either ethanol or 
fulvestrant treatment: 5.7% ± 1.9, and 5.7% ± 0.8, respectively. The construct with 
CCmut3 significantly increased 7AAD staining compared to EGFP as expected due 
to disruption of Bcr-Abl signaling, but only when treated with ethanol (vehicle), 
12.2% ± 1.7, p <0 .001. When treated with fulvestrant, the sequestration of CCmut3 
allowed Bcr-Abl to continue its proliferative effects, with decreased apoptosis as 
measured by 7AAD to 5.8% ± 0.8 (significantly different from ethanol treatment, p < 
0.01). The results were consistent at 48 (data not shown) and 72 hours of treatment. 
Fulvestrant was also tested at higher doses (400 nM and 800 nM), though these 
were not significantly different from 100 nM (data not shown).  
 
Discussion 
Our lab has previously had success in creating novel “protein switches” 
capable of ligand-dependent subcellular translocation of exogenous proteins. To our 
knowledge, this is the first paper to describe harnessing the ligand-inducible 
translocation of the estrogen receptor ligand-binding domain (ERLBD) to generate a 
protein switch capable of controlled movement from the cytoplasm, and/or nucleus to 
the insoluble cytoskeletal fraction. This controlled translocation is accomplished 
when the LBD binds the synthetic antagonist fulvestrant. The estrogen receptor 
(ER) is a protein that typically resides in the nucleus, but when bound to the SERD 
fulvestrant, is found in insoluble clusters in both the nucleus and cytoplasm (14, 15). 
Here, we showed that removing the ligand-binding domain (LBD) from the full-
length receptor still responds to fulvestrant, but that its localization can be 
controlled by the lack-of or inclusion-of signal sequences. Microscopy studies 
revealed that the inclusion of a nuclear localization signal (NLS) directed the protein  
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to the nucleus before ligand, and maintained the nuclear location while forming 
insoluble aggregates upon ligand addition. Similarly, fusing a nuclear export signal 
(NES) to the LBD directed the protein to the cytoplasm. This control of protein 
localization was demonstrated in a wide array of cell types, including those with or 
without cytokeratins 8 and 18, and cancer or non-cancer types. Previously, the 
response of the ER to fulvestrant was attributed to its interaction with cytokeratins 
8 and 18 in both the cytoplasm and the nucleus (19), and this was also claimed to be 
an intermediate step toward proteasomal degradation when bound to ligand (13, 19). 
Our subcellular fractionation in MCF-7 cells (cytokeratin 8 and 18 positive) and 
A2780 (cytokeratin 8 and 18 negative) showed that the ERLBD fusion protein is 
capable of translocation from the cytoplasm to the insoluble cytoskeletal fraction 
regardless of cytokeratin status. Confocal microscopy confirmed that colocalization 
of ERLBD with cytokeratins was minimal, and played no role. Perhaps in other 
studies, localization to CK 8 and 18 may be mediated by other domains of the ER not 
present in our ERLBD constructs. 
     The utility of this controlled localization was demonstrated by fusing the 
ERLBD protein to a functional peptide (CCmut3) that had previously been shown to 
bind to and disrupt Bcr-Abl signaling in K562 cells and induce apoptosis (8). We 
hypothesized that after fulvestrant addition, ERLBD-CCmut3 protein would 
translocate away from Bcr-Abl to insoluble clusters, and would relieve the Bcr-Abl 
signaling inhibition. Indeed, despite the fact that CCmut3 interacts with Bcr-Abl, 
microscopy studies corroborated that ERLBD-CCmut3 formed insoluble clusters 
with the addition of fulvestrant, indicating ligand-inducible controlled localization of 
CCmut3. Lastly, ERLBD-CCmut3 showed apoptosis without fulvestrant, but a 
significant drop in apoptosis when bound to drug, confirming our hypothesis of 
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location altering function. This technology has the potential to be used as a 
controlled tool to test and verify synthetic exogenous protein or peptide function, as 
demonstrated here, but may also be useful to induce an in trans sequestration of an 
endogenous protein target. Any protein binding domain can easily be cloned into an 
ERLBD vector, thus allowing a large variety of potential cellular targets, in multiple 
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 CHAPTER 5 
CONTROLLED ACCESS OF P53 TO THE NUCLEUS  
REGULATES ITS PROTEASOMAL  
DEGRADATION BY MDM21 
Abstract 
The tumor suppressor p53 can be sent to the proteasome for degradation by 
placing its nucleo-cytoplasmic shuttling under ligand control. Endogenous p53 is 
ubiquitinated by MDM2 in the nucleus, and controlling the access of p53 to the 
nuclear compartment regulates its ubiquitination and proteasomal degradation. 
This was accomplished by the use of a “protein switch” that places nuclear 
translocation under the control of externally applied dexamethasone. Fluorescence 
microscopy revealed that sending protein switch p53 (PS-p53) to the nucleus 
produces a distinct punctate distribution in both the cytoplasm and nucleus. The 
role nuclear access was investigated by inhibiting classical nuclear export with 
leptomycin B. Trapping PS-p53 in the nucleus only allows this punctate staining in 
that compartment, suggesting that PS-p53 must translocate first to the nuclear 
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compartment for cytoplasmic punctate staining to occur. The role of MDM2 binding 
was explored by inhibiting MDM2/p53 binding with nutlin-3. Inhibition of this 
interaction blocked both nuclear export and cytoplasmic and nuclear punctate 
staining, providing evidence that any change in localization after nuclear 
translocation is due to MDM2 binding. Further, blocking the proteolytic activity of 
the proteasome maintained the nuclear localization of the construct. Truncations of 
p53 were made to determine smaller constructs still capable of interacting with 
MDM2, and their subcellular localization and degradation potential was quantified. 
PS-p53 and a smaller construct, construct containing the two MDM2 binding regions, 
Box I+V, were indeed degraded by the proteasome as measured by loss of enhanced 
green fluorescent protein that was also fused to the construct. The influence of these 
constructs on p53 gene transactivation function was assessed, and revealed that PS-
p53 decreased gene transactivation, while PS-p53(BoxI+Vmut) did not significantly 
change baseline gene transactivation.  
Introduction 
Protein subcellular localization is tightly regulated in order for cells to control 
their function. Protein mislocalization has been implicated in a number of diseases, 
(1) and it has been proposed that correcting this mislocalization may be a potential 
treatment option (1, 2). It has also been found that inducing a change in a protein’s 
localization can be used to prevent that protein from functioning (3), or can exploit 
that protein’s activity in a different compartment (4). In an effort to control protein 
localization, our lab has developed technologies aimed at altering location and 
function (3-8). Recently, we have shown that a protein’s function can be altered if it 
is sequestered in cytoskeletal aggregates (3), or that apoptosis can be induced by 
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sending p53 to the mitochondria (9). One of the technologies we have developed is 
the cytoplasm-to-nucleus protein switch (PS). This PS contains a nuclear export 
signal, a nuclear localization signal, and a ligand-inducible domain from the 
glucocorticoid receptor (GR). Ligand binding controls localization by a 
dexamethasone-specific ligand-binding domain (LBD) from GR, such that when 
expressed the protein is localized to the cytoplasm but is targeted to the nucleus 
upon induction by the ligand dexamethasone (dex) (7, 8, 10).  
p53 is a tumor suppressor that is maintained at low levels in normal cells, 
but rapidly accumulates in the nucleus in response to stress, such as DNA damage, 
hyperproliferation, chemotherapeutic agents, ultraviolet light, and hypoxia (11-15). 
The half-life of p53 is 6-20 minutes in healthy cells. However the concentration of 
p53 is increased 3- to 10-fold and the half-life is improved to hours in response to 
stress (11, 12). The accumulation is due to two factors: induced transcription of the 
TP53 gene and reduced ubiquitination and proteasomal degradation (16). The 
accumulated p53 proteins are able to activate genes that promote growth arrest, 
apoptosis, and DNA repair through its transactivation function (17), and by 
inhibiting p53’s degradation (18). MDM2 (HDM2 in humans) is the main protein 
responsible for the maintenance of p53, and does so with its RING finger domain E3 
ligase activity that coordinates the transfer of ubiquitin from an E2 enzyme to lysine 
residues within p53 (16, 19-24). Proteasomes recognize ubiquitinated proteins and 
degrade them (25, 26). However, overexpression of MDM2 results in downregulation 
of p53 and may lead to cell hyperproliferation, and this has been implicated in a 
variety of human cancers (27, 28). Small molecule inhibitors of the MDM2-p53 
interaction have been developed to restore p53 activity, and may provide significant 
clinical benefit (29-36). 
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Though the field of study of MDM2 and p53 is immense, the exact process of 
ubiquitination and subsequent degradation has not been fully elucidated. It is clear 
that conformation of p53, and the relative concentration of MDM2 to p53 greatly 
influence the ubiquitination fate of p53 (21, 37). It is also known that MDM2 and 
p53 shuttle back and forth between the cytoplasm and nucleus via their respective 
NES and NLS, but that ubiquitination of p53 by MDM2 is mostly localized within 
the nucleus, and that access to both compartments is necessary for degradation (38). 
MDM2 can monoubiquitinate or polyubiquitinate p53; monoubiquitination exposes 
an NES in the C-terminal region of p53 and results in nuclear export, possibly with 
MDM2 in tow (37, 39). In the cytoplasm, MDM2 can efficiently polyubiquitinate p53, 
but it requires p53 to be in tetrameric form. Polyubiquitination can occur in the 
nucleus, and may favor proteasomal degradation within the nucleus (37). 
In this work, we hypothesized that p53 fused to our cytoplasm-to-nucleus 
protein switch could provide for a controlled interaction of p53 with MDM2, and 
thereby control the proteasomal degradation by ligand induction. We found that 
indeed controlling the access of p53 to the nucleus limited the apparent interaction 
of p53 to MDM2 to ligand induction, and we found this to be dependent upon nuclear 
translocation, nuclear export, and a functioning proteasome, with the ultimate 
outcome of proteasomal degradation of our construct. We also found that smaller 
domains of p53 could be fused to the protein switch with similar outcomes. To our 
knowledge, this is the first time that the interaction of p53 with MDM2 has been 
controlled by ligand induction, and represents an interesting method of targeting a 




Materials and Methods 
Construction of EGFP-PS-p53 
The DNA encoding p53 was amplified through PCR from pCMV-p53 wt (a 
generous gift from Dr. S. J. Baker, Addgene, Cambridge, MA) using the primers 5!- 
GCGCGCGGATCCGCCATGGAGGAGCCGCAGT-3! and 5!-GCGCGCGGATCCT-
CAGTCTGAGTCAGGCCCTTCTGTC-3!. This was subcloned into the BamHI 
restriction enzyme site in the EGFP-HIV-MycA8-GRLBD (EGFP-PS) plasmid 
constructed previously (7). The EGFP-PS contains a nuclear export signal (NES) 
from HIV-rev protein (8), a nuclear localization signal (NLS) from MycA8 protein (7) 
and a ligand binding domain from glucocorticoid receptor (GRLBD) with a point 
mutation (C656G) that makes it 10 times more sensitive to the agonist 
dexamethasone (dex) (40). 
Construction of Modified EGFP-PS-p53 Plasmids 
EGFP-PS-p53ΔMBD: p53 was amplified without its MDM2 binding domain 
(MBD) through PCR using 5!-GCGCGCGCGCGGTACCGCTCCCAGAATGCCAGA-
GGC-!3 and 5!-GCGCGCG-GATCCTCAGTCTGAGTCAGGCCCTTCTGTC-3! primers. 
This was subcloned into the KpnI and BamHI restriction enzyme sites in EGFP-PS 
(40). 
EGFP-PS-p53ΔC: p53 was amplified without its C-terminal region by PCR 
using 5’- AATAATCTCGAGTTATGGAGGAGCCGCAGTCAG-3’ and 5’- TAATAAC-
TGCAGCCCAGCCTGGGCATCCTTG-3’ primers, which introduce XhoI and PstI 
restriction enzyme sites. After PCR, the fragment and EGFP-PS plasmid were 
digested with these enzymes, and ligated together. 
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EGFP-PS-p53ΔTD: To remove the tetramerization domain (TD) the pre- and 
post- TD fragments were spliced together. The pre-TD fragment of p53 was 
amplified by PCR using ‘5- AATAATCTCGAGTTATGGAGGAGCCGCAGTCAG-3’ 
and 5’- TACGAACTGCAGTGGTTTCTTCTTTGGCTGG-3’ primers, which introduce 
XhoI and PstI restriction sites. The post-TD domain was amplified with 5’- 
AATAATGGTACCTAAGGAGCCAGGGGGGAGCAG-3’ and 5’- TAATAAGGGCC-
CGTCTGAGTCAGGCCCTTCTG-3’ primers, which introduce KpnI and ApaI 
restrictions sites. The fragments and plasmids were digested and ligated with their 
respective enzymes, and ligated together in a two-step process.  
EGFP-PS-p53(Box I) and (Box I + V): DNA oligonucleotides were synthesized 
by the DNA/Peptide Core Facility at the University of Utah. For Box I the sense and 
antisense fragments were 5’-TCGAGTTGAGCCCCCTCTGAGTCAGGAAACA-
TTTTCAGACCTATGGAAACTACTTCCTGAAAACAACCTGCA-3’ and 5’-GGTTG-
TTTTCAGGAAGTAGTTTCCATAGGTCTGAAAATGTTTCCTGACTCAGAGGGGGC
TCAAC-3’. These oligos were annealed, and ligated between XhoI and PstI in the 
parent plasmid. For Box V, 5’-CTCGGAACAGCTTTGAGGTGCGTGTTTGTGCC-
TGTCCTGGGAGAGACGGGCC-3’ and 5’- CGTCTCTCCCAGGACAGGCACAAA-
CACGCACCTCAAAGCTGTTCCGAGGTAC-3’ were annealed, and ligated between 
KpnI and ApaI restriction sites in the parent plasmid. 
F270A mutations: All template plasmids had the F270A mutation introduced 
using the QuickChange II Site Directed Mutagenesis Kit (Agilent Technologies, 
Santa Clara, CA) with forward primer 5’- CTACTGGGACGGAACAGCGCT-




The University of Utah Core DNA Sequencing Facility verified the sequences 
of all subcloned constructs. 
 
Cell Lines and Transient Transfections 
C127-derived murine mammary carcinoma cells (1471.1 cells)(41) (gift of G. 
Hager, NCI, NIH) were grown as monolayers in DMEM (Invitrogen, Carlsbad, CA), 
supplemented with 10% fetal bovine serum (Invitrogen), 1% penicillin-streptomycin-
glutamine (Invitrogen), and 0.1% gentamicin (Invitrogen). The cells were 
maintained in a 5% CO2 incubator at 37ºC. 7.5 × 104 cells were seeded in 2-well live 
cell chambers (Nalgene Nunc, Rochester, NY). Transfections were carried out 24 
hours after seeding using 1 pmol DNA and Lipofectamine 2000 (Invitrogen) 
following the manufacturer’s recommendations. Constructs were induced with 100 
nM of the dex ligand, 24 hours after transfection for 1 hour, or as otherwise noted (7). 
Fluorescence Microscopy 
Approximately 24 hours after transfection, protein localization was viewed by 
fluorescence microscopy. For microscopy studies, cells were plated on a clear cover 
glass in six well plates (Greiner Bio-One Cellstar, Monroe, NC) or live cell chambers 
(Nalge Nunc, Rochester, NY). Prior to cell imaging, media was replaced with phenol 
red-free DMEM (Invitrogen) containing 10% charcoal-stripped fetal bovine serum 
(CS-FBS, Invitrogen). Images were acquired as previously,(4) using an Olympus 
IX71F fluorescence microscope (Scientific Instrument Company, Aurora, CO) with 
high-quality narrow band GFP filter (ex: HQ480/20 nm, em: HQ510/20 nm) from 
Chroma Technology (Brattleboro, VT) with a 40X or 60X PlanApo oil immersion 
objectives (NA 1.00) on an F-View Monochrome CCD camera. For live-cell imaging, 
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the microscope stage was maintained at 37°C with an air stream incubator (Nevtek 
ASI 400, Burnsville, VA). All experiments were repeated in triplicates (n=3) and 10 
cells were analyzed for each time-point in each experiment. Green fluorescent 
images in this publication have been pseudocolored with ImageJ software, and 
brightness and contrast have been adjusted for visibility. 
Treatment with LMB, Nutlin-3, and MG132 
Cells were incubated with 10 nM leptomycin B (LMB, an inhibitor of nuclear 
export) 10 hours after transfection and 14 hours before ligand induction with dex 
followed by microscopy. Another population of transfected cells was incubated with 
10 µM nutlin-3 1 hour before ligand induction (Sigma, St. Louis, MO). MG132 
(Sigma) was used at a concentration of 50 µM. 
Flow Cytometry for GFP Intensity 
MCF-7 cells were treated with 10 mg/mL cycloheximide 24 h after 
transfection to inhibit protein synthesis (42). Cells were then treated with 100nM 
dex for 0, 2, 4, and 6 h. After treatment, cells were suspended in PBS and analyzed 
using the FACSCanto-II (BD-BioSciences, University of Utah Core Facility) and 
FACSDiva software (43). Excitation was set at 488 nm and detected at 507 for EGFP 
intensity. The means from three separate experiments (n=3) were analyzed using 
two-way ANOVA with Sidak’s multiple comparisons post-hoc test. 
Reporter Gene Assay 
As previously (9), 3.5 µg of each construct was co-transfected with 0.35 µg of 
pRL-SV40 plasmid encoding for Renilla luciferase (Promega, Madison, WI) as well 
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as 3.5 µg of p53-Luc Cis-Reporter (Agilent Technologies, Santa Clara, CA) in MCF-7 
cells. Cells were then treated with 100nM dex to be compared to no dex treated cells. 
Firefly and Renilla luminescence were detected via the Dual-Glo Luciferase Assay 
System (Promega) per manufacturer's instructions using the PlateLumino 
Luminometer (Stratec Biomedical Systems, Birkenfeld, Germany). The Firefly 
luciferase activity was normalized with Renilla luciferase values. The positive 
control (E-p53) was set at 100% and untransfected cells were set at 0%. The 
experiment was performed with an n=3 and analyzed using two-way ANOVA with 
Bonferroni’s post-hoc test.  
Results 
p53 Fused to the Proteasome Switch Localizes to the  
Cytoplasm after Nuclear Import and Export 
Our previous studies have shown that the localization of exogenous proteins 
can be controlled by fusing a protein switch (PS) containing an NES, NLS, and 
ligand-binding domain (LBD) (2, 4, 7). In this study, we aimed to rationally design a 
protein switch that would target the proteasome; in the absence of ligand, it would 
localize in the cytoplasm, but after ligand addition (dexamethasone; dex), it would 
target the proteasome. We hypothesized that a PS-p53 fusion would target the 
proteasome when p53 was allowed to interact with MDM2, which is mainly localized 
within the nucleus.  
The p53 cDNA was subcloned into the protein switch (PS) to create E-PS-p53. 
The enhanced green fluorescent protein (EGFP; E) tag facilitates localization 
tracking with fluorescence microscopy. After transient transfection in 1471.1 mouse 
mammary adenocarcinoma cells, the “empty” protein switch (E-PS) protein localizes 
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in the cytoplasm (Figure 5.1 A, top left), but translocates into the nucleus after dex 
addition (Figure 5.1 A, top right). Wild-type p53 tagged to EGFP is unaffected by dex 
treatment, and appears to localize mostly in the nucleus and in cytoplasmic clusters 
(Figure 5.1 A, middle). The localization of transiently transfected p53 (E-PS-p53) 
was examined (Figure 5.1 A, bottom panel) before and after dex treatment. Before 
drug, the protein had a mostly cytoplasmic localization, similar to E-PS. However 
within an hour of dex treatment, the protein took on a distinct punctate distribution 
in both the cytoplasm and nucleus.  
E-PS-p53 was transiently transfected in human breast cancer cell lines MCF-
7, T-47D, and MDA-MB-231 (Figure 5.1 B). E-PS-p53 appeared to follow the same 
response pattern to dex in the human breast cancer cells. However, ligand 
responsiveness was not observed in HeLa cells; the localization did not change with 
dexamethasone addition (data not shown). 
PS-p53 Interacts with MDM2 in the  
Nucleus Before Export 
 To investigate the mechanism behind the cytoplasmic and nuclear punctate 
localization of E-PS-p53, the effect of drug inhibitors of nuclear export (leptomycin 
B; LMB) and MDM2 interaction (nutlin-3) were examined.  LMB is an inhibitor of 
CRM1 (chromosome region maintenance/exportin 1), which mediates classic nuclear 
export via nuclear export signals, including the nuclear export of wild-type p53 (1, 
44, 45). By inhibiting export, proteins localized within the nucleus are trapped there, 




Figure 5.1. Localization of PS-p53 in breast cancer cells. A: Fluorescence microscopy 
of transiently transfected 1471.1 cells, with no drug treatment (left) and 150 nM 
dexamethasone (dex) at 1 hour (right). The protein switch, E-PS, localized in the 
cytoplasm without drug, but translocated to the nucleus after dex addition. Wild-
type p53 tagged to EGFP (E-p53) did not respond to dex treatment, and had similar 
localization regardless of drug treatment. The protein switch fused to p53 (E-PS-
p53) localized in the cytoplasm without dex, but demonstrated a distinct punctate 
pattern in the cytoplasm and nucleus.  B: E-PS-p53 transiently transfected in 
various cancer cell lines (MCF-7, T47D, MDA-MB-231), with and without 1 hour of 





results of a 14 hour preincubation with 10 nM LMB, followed by 1 hour incubation 
with 150 nM dex, demonstrate that E-PS-p53 accumulates within the nucleus, 
showing the same punctate distribution only in the nucleus (Figure 4.2 A). The 
accumulation is due to the unavailability of the nuclear export machinery to shuttle 
the construct back to the cytoplasm. This confirms that the protein translocates to 
the nucleus upon dex treatment, before shuttling back to cytoplasm. 
MDM2 is the main E3 ubiquitin ligase for p53, and it resides mainly in the 
nucleus. We already determined that E-PS-p53 first travels to the nucleus after dex 
addition (Figure 5.1), so we speculated that the subsequent nuclear export and 
punctate distribution was due to MDM2 by facilitating ubiquitin conjugation to the 
p53 domain of our construct. Adding nutlin-3, a competitive inhibitor of the 
interaction of p53 with MDM2, elucidated the role of MDM2 in our system. Figure 
4.2 B shows the results of nutlin-3 incubation in 1471.1 cells transfected with E-PS-
p53, with or without dex addition. Without dex (left image), but with nutlin-3, the 
localization is no different from that seen without nutlin-3 incubation; the protein is 
localized mainly in the cytoplasm. However, dex induction in the presence of nutlin-
3 (right image) demonstrates nuclear translocation but lacks any evidence of nuclear 
export, and the protein does not show punctate staining. The localization with 
nutlin-3 appears similar to E-PS with dex alone—the p53 domain does not appear to 
have an impact on localization. Taken together, these results suggest that E-PS-p53 
responds to dex treatment by translocating to the nucleus where it interacts with 




Inhibiting the Proteasome Alters  
PS-p53 Localization 
 Wild-type p53 is sent to the ubiquitin-proteasome pathway by MDM2. To 
investigate whether the cytoplasmic and nuclear clusters were indeed constructs 
destined for the proteasome, we tested the effect of proteasomal inhibition on EGFP-
PS-p53 localization. 1471.1 cells were again transiently transfected with EGFP-PS-
p53 and incubated with the proteasomal inhibitor MG132 ± dex. MG132 did not 
appear to have an effect on the localization of the construct in the absence of dex 
(Figure 5.2 C, left image), but in the presence of dex, the construct demonstrated 
nuclear accumulation without visible clusters in the nucleus or cytoplasm (Figure 
5.2 C, right image). Thus, a functioning proteasome was necessary for the nuclear 
export and punctate distribution of E-PS-p53 after dex treatment.  
p53 Truncations Also Interact with  
MDM2 in the Nucleus 
 We sought to determine if smaller constructs comprised of p53 domains could 
produce the same localization change in response to ligand when fused to the protein 
switch. Figure 5.3 A shows representative images of select p53 truncations. A table 
of all tested constructs is shown in Figure 5.3 B. All constructs had varying degrees 
of cytoplasmic and nuclear localization upon dex addition, and some constructs did 
not result in proteasome pathway targeting. The constructs that did yield 




Figure 5.2. Mechanism of PS-p53 localization. The effect of inhibition of nuclear 
export or MDM2 was examined in 1471.1 cells transiently transfected with E-PS-
p53. A: Cells incubated with LMB, an inhibitor of nuclear export, showed a 
cytoplasmic localization before dexamethasone treatment (left), but constructs 
demonstrated nuclear accumulation and punctate staining almost exclusively in the 
nucleus after 1 hour of 150 nM dex (right). B: Cells were incubated with an inhibitor 
of the interaction between MDM2 and p53. Without dex, nutlin-3 did not 
significantly change the baseline localization of E-PS-p53, but after 1 hour of 150 nM 
dex, the construct accumulated in the nucleus and did not show any punctate 
distribution. C: The role of the proteasome was evaluated by incubating cells with an 
inhibitor of the proteasome, MG132. The inhibitor had no effect on the baseline 
localization of the construct, but after 1 hour of incubation with 150 nM dex, the 
construct took on a mostly nuclear localization, and showed a lack of cytoplasmic or 






Figure 5.3. Localization of p53 truncations A: Representative fluorescence 
microscopy images of 1471.1 cells transiently transfected with plasmids encoding 
truncated p53 constructs fused to the protein switch. The top row is no drug, 
whereas the bottom row is 1 hour of 150 nM dexamethasone. ΔC, ΔMBD, and Box 
I+Vmut constructs demonstrated proteasome pathway targeting; the TD construct 
was equivocal in regard to proteasome pathway targeting. B: Table of all created 
constructs, their localization after dexamethasone addition, and whether they 




PS-Box I+Vmut. E-PS-TD only included the tetramerization domain of p53, and 
showed equivocal targeting in microscopy studies. Interestingly, removal of the N-
terminal MBD domain did not abrogate targeting. The F270A mutation (mut) has 
been previously described as leading to destabilization and hyperubiquitination and 
increased proteasomal degradation of p53 beyond the C-terminal region typically 
associated with polyubiquitination (46). We included this mutation in several 
constructs to see if it imparted increased targeting to the proteasome pathway. The 
mutation did not universally increase proteasome pathway targeting, but it did for 
the Box I+V construct.  
The PS-p53 Proteasomal Degradation is  
Under Ligand Control 
 To further examine the degradation of the PS-p53 upon ligand addition, 
MCF-7 cells were transfected with selected constructs followed by dex and 
cycloheximide treatments. Cycloheximide was used to ensure no additional protein 
synthesis (42) after the addition of dex to be able to quantify only the loss of GFP 
intensity (43) before and after dex treatment. Expectedly, the negative controls 
(EGFP, E-p53, and E-PS-TD) did not show any change in GFP intensity over the 6 
hour dex treatment (Figure 5.4). On the other hand, E-PS-p53 and E-PS-Box 
I+Vmut displayed decreased GFP intensity (p<0.05). Similar to the negative controls, 
the E-PS-ΔC with dex treatment was not degraded despite its punctate formation. E-




































Figure 5.4. Protein degradation by loss of GFP fluorescence intensity. The GFP 
intensity was measured in transfected MCF-7 cells after 6 hours of dex treatment. 
The dashed line represents the intensity before drug addition. E-PS-p53 and E-PS-
Box I+Vmut were the only constructs showing reduction in relative GFP intensity 
compared to EGFP control. E-p53 had a significant increase in intensity.  Mean 
values before and after treatment were analyzed using one-way ANOVA with 
Tukey’s multiple comparisons post-hoc test (*p<0.05). Error bars represent standard 









PS-p53 Constructs do not Initiate Transactivation 
Via p53 Promoter 
In addition to its proteasomal targeting, we investigated the ability of p53 in 
the proteasomal switch to act as a transcription factor. Since the p53 cis-reporter 
system is widely utilized to evaluate the transcriptional activity of p53, MCF-7 cells 
were used to evaluate the activity of our proteasomal constructs before and after dex 
(Figure 5.5). The negative controls (EGFP and E-PS) reflected the endogenous 
transcriptional activity (all cells contain endogenous p53), which is significantly 
lower than the E-p53 treated cells (positive control). Both E-PS-p53 and E-PS-Box 
I+Vmut showed no additional activity. Similar to the negative controls, the E-PS-
Box I+Vmut did not affect the endogenous transcriptional activity. However, the E-  
PS-p53, similar to E-PS-TD, showed lower transcriptional activity than the negative 
control.  
Discussion 
This work demonstrated that p53 could be fused to a protein switch capable 
of nucleo-cytoplasmic translocation under the control of external ligand. We took 
advantage of our nuclear protein switch (PS), which contains a ligand inducible 
nuclear import (47) and an export signal to control the localization to the nucleus 
(48). The localization is controlled by a dex-specific LBD, which was cloned from the 
GR. When expressed, the protein is localized to the cytoplasm but is targeted to the 
nucleus upon ligand induction (7, 8, 10). This placed MDM2’s access to p53, and 
subsequent ubiquitination and degradation, also under control of external ligand. To 
our knowledge, this is the first time that a protein’s targeting to the ubiquitin- 
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Figure 5.5. Transcriptional activation of PS-p53 constructs. Relative luminescence 
represents the transcriptional activity of p53 in MCF-7 cells. E-p53, the positive 
control, showed high transcriptional activity regardless of drug addition. EGFP, E-
PS, and E-PS-Box I+V mut did not appear to alter transcriptional activity, either 
positively or negatively. E-PS-p53 exhibited reduction in transactivation similar to 
E-PS-TD. Comparisons were analyzed using two-way ANOVA with Tukey’s 
multiple comparisons post-hoc test (* significantly different from E-p53, p<0.05; ** 
significantly different from positive (E-p53) and negative (EGFP) controls, p<0.05). 





proteasome pathway has been controlled by regulating access to subcellular 
compartments. Knowledge of the ubiquitin-proteasome system is pivotal for 
understanding the degradation of proteins via the proteasome (49). A protein that is 
destined for degradation goes through a post-translational modification called 
ubiquitinylation, which is a process that covalently modifies proteins with ubiquitin 
via the enzymatic activity of an E1, an E2, and an E3 protein. Ubiquitin is first 
activated and transferred to the E1 active cysteine residue via a thioester linkage in 
a process requiring ATP. Ubiquitin is then transferred to the active cysteine residue 
of an ubiquitin-conjugating enzyme, E2, via a trans(thio)esterification reaction. 
Ubiquitin ligase, E3, interacts with both E2 and the targeted protein. In general, E3 
is important for mediating substrate specificity (50). Subsequently, ubiquitin is 
ligated to the ε-amino group of a lysine of the target protein through a more stable 
isopeptide linkage. Since ubiquitin itself contains seven lysine residues, it allows the 
synthesis of polyubiquitin chains through isopeptide linkages. The process is then 
repeated giving rise to a polyubiquitin chain, which is recognized by the 19S 
regulatory caps of the proteasome. In the case of p53 degradation, MDM2 acts as the 
ubiquitin ligase (E3) while Ubc5 is the ubiquitin conjugating enzyme (E2) (20). 
Degradation of p53 is dependent on the nuclear exclusion of p53 by MDM2 (51). 
However, some nuclear proteasomal degradation of p53 can be induced by MDM2 
(52). 
The mechanism by which our proteasomal protein switch occurs is illustrated 
in Figure 5.6. We propose that when p53 translocates to the nucleus, it binds to 
MDM2 and is subsequently ubiquitinated, which results in cytoplasmic and nuclear 
punctate staining, possibly as ubiquitinated aggregates committed to proteasomal 











































































































































































































































































































































being exported to the cytoplasm by inhibiting nuclear export, which 
demonstrated nuclear accumulation of our construct (Figure 5.2A). When the 
interaction of MDM2 with p53 was inhibited by nutlin-3, wholesale proteasome-
pathway targeted was blocked (Figure 5.2B), verifying that MDM2 was involved in 
the ubiquitination process. Interestingly, in addition to preventing punctate 
distribution of our construct, blocking the proteolytic activity of the proteasome 
promoted nuclear localization (Figure 5.2C), possibly due to lack of ubiquitin 
availability. Interestingly, fusing the PS to p53 increased its availability to bind to 
MDM2 compared to E-p53, which shows minimum punctate formation and no 
degradation compared to E-PS-p53.  
There are six lysine residues in p53 that get ubiquitinated by MDM2: K370, 
K372, K373, K381, K382, and K386 (53). The ubiquitination of p53 by MDM2 begins  
with the binding of MDM2 to the N-terminal Box-I region of p53. This single 
interaction is not enough for MDM2 to ubiquitinate p53; small molecule mimetics of 
this interaction do not prevent the E3 ligase activity of MDM2 (19, 54-57). A second 
region within p53, called Box-V, was determined to be capable of providing a 
ubiquitination signal and docking site for MDM2 (54, 58). This lead Wallace et al. 
proposed a model where binding of MDM2 to the N-terminal Box-I region of p53 
allosterically promotes binding of the acidic domain of MDM2 to the Box-V region 
(58, 59). In other words, the allosteric activation of MDM2 by the N-terminal Box-I 
region allows a conformation in MDM2 to bind the Box-V region within p53’s DBD to 
allow E2 transfer of ubiquitins to the C-termius of p53. 
Indeed, we found that isolating the regions of MDM2 binding (Box I+V) could 
target the proteasome pathway if a specific destabilizing F270A mutation was made 
(Figure 5.3A). This phenylalanine residue can block ubiquitination activity by 
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MDM2, and its removal is associated with hyperubiquitination of p53 (46) The 
unmutated Box I+V construct lacks the tetramerization domain, which has 
previously been recognized as necessary for efficient polyubiquitination by MDM2 
(46) The F270A mutation may overcome that inefficiency, which explains the 
degradation seen with Box I+Vmut (Figure 5.4). This construct might be 
advantageous over E-PS-p53 to future applications for several reasons. Smaller 
plasmids are easier to transfect, and will leave room for the fusion of other 
downstream domains. Also, it did not appear to block gene transactivation like full-
length p53 fused to the protein switch (Figure 5.5), which might bind to and hence 
deactivate endogenous p53 because of its intact TD. This was confirmed with similar 
results when E-PS-TD was used (Figure 5.5). Other truncations of p53 also 
demonstrated visual proteasome pathway targeting, but these failed to demonstrate 
degradation. The reason for the difference in fate could be the interplay of 
monoubiquitination and/or polyubiquitination by MDM2 based on construct 
localization and dimerization potential (21, 60).  
The protein switch was designed to regulate cellular proteins by changing 
their location, and hence, their function (61, 62). The protein switch has the 
advantage of being regulated by externally added ligand (1, 7, 8). The proteasomal 
protein switch can be engineered with a dimerization domain of a protein of interest, 
which will allow it to “capture” a cytoplasmic endogenous protein and send it for 
proteasomal degradation upon ligand induction. Since the ubiquitin ligase (E3) is 
what mediates substrate specificity (50), we envision the use of the constructed 
proteasomal protein switch as a therapeutic to target oncogenic proteins. Depleting 
cytoplasmic oncogenic proteins such as Bcr-Abl, survivin, p27, and Raf-1 (4, 63-65) 
would be a specific treatment for cancer cells. This might prove useful in cancer with 
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elevated levels of MDM2 such as breast cancer, melanoma, esophageal cancer, 
leukemia, sarcoma, non-small cell lung cancer, and non-Hodgkin’s lymphoma (27). 
In addition, the EGFP-PS-p53 construct could also be used as a p53-MDM2 binding 
assay using fluorescence microscopy to screen for inhibitors that could disrupt the 
p53-MDM2 interaction. Nutlin-3, a MDM2 inhibitor, was used to confirm the 
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THE PROTEASOME-TARGETED PROTEIN: DEGRADATION  
OF THE ONCOGENIC PROTEIN SURVIVIN AND ITS  
POTENTIAL IMPLICATIONS IN BREAST CANCER 
Abstract 
 Survivin is an inhibitor of apoptosis protein, whose over-expression has been 
broadly implicated in cancer. Survivin lacks a “druggable” site so conventional 
means of inhibition are not thought to be possible; agents against survivin currently 
in clinical trials target the promoter region of the survivin gene, as well as antisense 
molecules to prevent survivin mRNA translation. In this work, we aimed to disrupt 
survivin’s inhibition of apoptosis by sending it to the ubiquitin-proteasome pathway 
where it would be degraded by the proteasome. Our proposed proteasome-targeting 
(protarg) proteins are comprised of an ubiquitin-interacting domain, a ligand-
controllable domain, and a dimerization/binding domain that will capture the target 
protein, i.e. survivin. We tested our proposed full-length estrogen receptor protarg 
that responds to fulvestrant treatment. Survivin forms a homodimer, so we 
incorporated the survivin gene into the protarg as a means of capture. To assess the 
binding capabilities of a survivin homodimer for use in a subcellular trafficking 
application, we applied the nuclear translocation assay developed in our lab. We also 
directly assessed the colocalization of survivin with the protarg after induction with 
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ligand. We concluded that the survivin:survivin homodimer was not robust enough 
for use as a capture domain for this application.  
Introduction 
Survivin is a member of the inhibitor of apoptosis (IAP) family of proteins 
that has been found to be undetectable in differentiated tissue, but overexpressed in 
embryonic and cancerous cells (1). Survivin is among only a few nodal proteins 
involved in multiple signaling pathways implicated in tumor progression, and 
knocking out its function may halt tumor growth (2). Its primary function in healthy 
dividing cells is to aid in stabilization of the mitotic spindle to aid in chromatid 
separation and cytokinesis, and to inhibit apoptosis of cells under the stress of cell 
division. Survivin does this in conjunction with the other members of the 
chromosome passenger complex (CPC) (3-7). A separate function of survivin that is 
important for tumor cell survival is its ability to interact with cytosolic proteins, 
specifically those involved in mitochondrial-associated cell death (Figure 6.1). 
Through these interactions, caspase-9 is inhibited, which prevents the initiation of 
mitochondrial-induced apoptosis (8, 9). However, SMAC/DIABLO (second 
mitochondrial-derived activator of caspase) is released from the mitochondria in 
response to apoptotic stimuli and can block the inhibition of apoptosis by survivin 
(10-12).  
The expression of survivin increases in cancer cells, possibly as a result of 
loss of p53 function. Part of p53’s normal function is to suppress the BIRC5 promoter 
region, which is the regulatory element for survivin transcription. When p53 is lost, 













































































































































































improved cell survival. (1, 2, 13, 14). This cancer-specific increase of survivin 
presents itself as an ideal model target for a proteasome-targeted protein system. 
In the last chapter, the controlled proteasomal degradation of p53 was 
described, but here we present a different protarg: one based on full-length estrogen 
receptor (ER), whose degradation can be controlled by the addition of fulvestrant. 
We hypothesized that endogenous survivin will be degraded if it binds to the protarg 
(Figure 6.2).  
The human estrogen receptor responds to the endogenous hormone, which 
causes a conformational change of helix 12 (within the LBD) that allows for 
coactivator binding and subsequent interaction with EREs. However, the pure 
antagonist fulvestrant has been found to block all ER transactivation, and to 
potently induce the proteasomal degradation of the receptor (15-20). We propose to 
exploit this efficient degradation process to create a ligand-controllable protarg 
responsive to the ligand fulvestrant. A system that exploits this ligand-controlled 
degradation could result in an on/off proteasomal switch: on in the presence of 
fulvestrant, off in its absence. In this study, this ER proteasome-targeted protein 
was constructed with full-length ER, but mutated to a transcriptionally inactive 
form (S167A; ER S167A; ER(mut)) (20-22).  
Survivin exists as a homodimer (23, 24), and our protargs attempted to 
utilize this dimeric arrangement for protarg/survivin binding by simply fusing full-
length survivin to ERmut. To prevent any oncogenic function imparted by this 
survivin domain, we introduced a T34A mutation that results in a dominant 
negative survivin phenotype (7, 25, 26). Figure 6.3 shows the linear arrangement of 
survivin (A), and now we propose to use the dimerization interface of survivin in our 





























































































































































































































































































































































































































































Materials and Methods 
Cell Culture 
The murine breast adenocarcinoma cell line 1471.1 (a kind gift from G. Hager, 
NCI, NIH) was grown as a monolayer in DMEM (Invitrogen, Grand Island, NY) 
supplemented with 10% FBS (Invitrogen), 1% penicillin-streptomycin-L-glutamine 
(Invitrogen), 0.1% gentamicin (Invitrogen). All cells were maintained in 5% CO2 
incubator at 37ºC. 
Plasmid Construction 
Survivin (a kind gift from Dario Altieri, The Wistar Institute, Philadelphia) 
was cloned into DsRed2-N1 (Clontech) by polymerase chain reaction with the 
introduction of Kpn1 and BamH1 restriction enzyme sites, with forward primer 5’-
ATTTAAGGTACCTATGGGTGCCCCGACGTTG-3’ and reverse primer 5’-
ATTATAGGATCCTTATCCATGGCAGCCAGCTGC-3’.  
To clone the protarg plasmids containing the estrogen receptor and survivin, 
ER was first cloned into the multiple-cloning site of EGFP-N1 plasmid. PCR was 
used to introduce SacI and EcoRI restriction sites to the 5’ and 3’ termini, 
respectively. The primers used were 5’-TAATATGAGCTCATGACCATG-
ACCCTCCACAC-3’ and 5’-TATAATGAATTCTGACTGTGGCAGGGAAACCCTC-3’. 
Survivin was then cloned into the resulting ER-EGFP plasmid between the KpnI 
and BamHI restriction enzyme sites. PCR was used to add these restriction sites to 
the survivin CDNA with the same primers used in survivin-DsRed2 cloning. To get 
ER-survivin into the protein switch plasmid, XhoI and ApaI restriction enzyme sites 
were added through PCR, with forward primer 5’-AATTATCCTCGAG-
TTATGACCATGACCCTCCACAC-3’ and reverse primer 5’-TAAATTTGGGCCC-
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TTATCCATGGCAGCCAGCTGCTC-3’.  This fragment was then subcloned into 
EGFP-PS, resulting in EGFP-PS-ER-survivin. Further mutations were made as 
follows: To make ERS167A, forward primer 5’-GGCAGAGAAAGAT-
TGGCCGCTACCAATGACAAGGGAAG-3’ and reverse primer 5’-CTTCCCTTGTG-
CATTGGTAGCGGCCAATCTTTCTCTGCC-3’ were used with the QuickChange II 
Site-Directed Mutagenesis Kit (Stratagene/Agilent Technologies, Santa Clara, CA). 
To create the T34A mutant form of survivin, the QuickChange II Site-Directed 
Mutagenesis kit was used, with forward primer 5’-GCTGCGCCTGCGCCCCGGAG-
CGG-3’ and reverse primer 5’-CCGCTCCGGGGCGCAGGCGCAGC-3’. To generate 





Transient transfections were done as previously described (27). Briefly, cells 
were plated on a clear cover glass in six well plates or live cell chambers with media 
the day before transfection. Transfections were performed with Lipofectamine 2000 
(Invitrogen) per manufacturer’s recommendations.  
Microscopy and Image Analysis 
Cells were imaged as previously described (27-29). Approximately 16 to 24 
hours after transfection, cells were viewed on an Olympus IX701F inverted 
fluorescence microscope. To quantitate protein location, the fluorescent images 
obtained were analyzed using analySIS® software (Soft Imaging System, Lakewood, 
 196 
CO) as previously described (28). To obtain average cytoplasmic intensity data for all 
constructs, 10 representative cells from each experiment were analyzed and 
averaged from 3 separate experiments (n=3), and are expressed as percent 
cytoplasmic intensity. Statistical differences between the constructs were 
determined using one-way ANOVA with Tukey’s post-hoc test. 
Results  
Determination of Co-Localization and Co-Degradation  
of Survivin-Targeted Protarg 
The protarg consists of a protein capable of controlled proteasomal 
degradation, a target protein binding domain, and EGFP for easy subcellular 
tracking. The first protarg for testing is based upon the response of the estrogen 
receptor (ER) to the ligand fulvestrant. The estrogen receptor resides in the nucleus 
in the un-liganded state, but accumulates in the cytoplasm in a clustered 
distribution when bound to fulvestrant. This is accompanied by proteasomal 
degradation in breast cancer cells (17, 18). The estrogen receptor can be mutated at 
the serine in position 167 to alanine to prevent transcriptional activation, but 
preserving the degradation potential (20, 30). With mutated ER (ER(mut)) serving 
as the proteasome-targeted portion, survivin was added to act as a bait domain. 
Survivin is a homodimer in solution, in an inverted bowtie orientation (23). Survivin 
can also be mutated to prevent its anti-apoptotic effect by changing amino acid 
threonine to alanine in position 34 (SurvT34A). This residue does not lie within the 
dimerization domains, so it should not affect the ability to survivin to dimerize with 
itself. Microscopic evaluation of colocalization was done to determine if a co-
transfected survivin protein would colocalize with the protarg in the pre-degradation 
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cluster pattern. Figure 6.4 shows the results of this fluorescence microscopy 
experiment. In figure 6.4 (A), the ER(mut) protarg resides within the nucleus 
without drug, but when bound to fulvestrant (ICI), the protein does translocate to 
the expected cytoplasmic clusters within 1 hour. Figure 6.4 (B) shows the results of 
co-transfecting the ER(mut) protarg with wild-type survivin fused to DsRed, a red 
fluorescent protein. Without drug, the protarg resides in the nucleus, as expected. 
However, Survivin-DsRed resides in the cytoplasm. When drug is added, the 
localization of the protarg changes to cytoplasmic clusters, but the Survivin-DsRed 
protein does not follow in the clustered distribution. To test there is an interaction 
occurring with the protarg survivin domain and survivin fused to DsRed, further 
protein interaction studies were performed, discussed in the next section. 
 
Determination of Interaction by the  
Nuclear Translocation Assay 
 As no colocalization was demonstrated in the initial microscopic analysis, we 
wanted to see if using survivin could form a robust homodimer that could be used to 
drag a protein within the cell. To specifically test the ability of survivin to bind to 
itself and be robust enough to allow for intracellular trafficking, the Nuclear 
Translocation Assay developed in our labwas utilized (29). Briefly, this assay 
consists of dual transfection of cells with an EGFP based “protein switch (PS),” 
which translocates from the cytoplasm to the nucleus upon binding with ligand 
dexamethasone that contains the binding domain for the target protein, and a 


































































































































































































































































































































protein switch from the cytoplasm to the nucleus should be accompanied by the 
cytoplasm-to-nucleus translocation of the DsRed plasmid if binding of the target 
protein is occurring. If no binding occurs, then only the protein switch will 
translocate to the nucleus. Figure 6.5 (A) shows the results of the negative control 
constructs: EGFP-PS and Survivin-DsRed transfected independently in 1471.1 cells, 
and then treated with or without dexamethasone (Dex). When the PS is treated with 
Dex, it translocates to from the cytoplasm to the nucleus. When Survivin-DsRed is 
treated with Dex, no change in localization is seen. The results of the fluorescence 
intensity analysis of these images (Figure 6.5 (B)) reveals a 21.7 ± 3.2 % (mean ± SD) 
relative nuclear increase for EGFP-PS, and 6.1 ± 6.4 %. These data were 
significantly different (p < 0.05) by an unpaired t-test.  
When the full ER(mut) protarg was cloned into the PS (EGFP-PS-ER(mut)-
SurvT34A) and co-transfected with Survivin-DsRed in COS-7 and 1471.1 cells, the 
protarg robustly translocated from the cytoplasm to the nucleus as expected (Figure 
6.6 (A)). If an interaction was occurring with the mutated survivin in the protarg 
and wild-type Survivin-DsRed, there should have been a commensurate change in 
subcellular localization of DsRed. However, there was no appreciable increase in 
nuclear intensity in the red channel (Figure 6.6 (B)). The nuclear increase of the 
protarg in COS-7 cells was 30.7 ± 5.1 %, whereas the nuclear increase of Survivin-
DsRed was 1.6 ± 5.1 %, which was significantly different by an unpaired t-test (p 
value < 0.05). The results were similar for 1471.1 cells (data not shown). 
 We questioned the affect that the inherent nuclear export signal (NES) in 
wild-type survivin has on localization by creating a nuclear export pressure that  
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Figure 6.5. Protein switch:survivin colocalization. A. Separate transfection of 
negative control constructs EGFP-PS (protein switch) and Survivin-DsRed2 in 
COS-7 cells. The protein switch translocates to the nucleus as expected. 
Dexamethasone treatment did not significantly increase survivin’s nuclear 
translocation, as expected. B. Quantitation of nuclear translocation by image 
analysis, presented as % Relative Nuclear Increase. The protein switch increased 
by 21.7 ± 3.2 %, which was significantly different from Survivin-DsRed, which 




Figure 6.6. Protarg NTA with wild-type survivin. A. Co-transfection of full ER 
protarg fused to the protein switch construct in COS-7 cells. Survivin-DsRed2. 
The protein switch translocates to the nucleus as expected. Dexamethasone 
treatment caused nuclear translocation of the protargs due to the protein switch 
activity (no degradation because fulvestrant was not present), but survivin-DsRed 
did not co-translocate and co-localize within the nucleus. B. Quantitation of 
nuclear translocation by image analysis. The relative nuclear increase (%) for the 
PS-protarg was 30.7 ± 5.1 %, which was significantly different from Survivin-
DsRed, which only changed by 1.6 ± 5.1 % (p < 0.05). 
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cannot be overcome by the homodimer formed with the protarg survivin. To test this 
question, we removed the NES by site-directed mutagenesis in both the protarg 
survivin (SurvT34A) and Survivin-DsRed, and repeated the NTA. Figure 6.7 (A) 
shows the microscopy images. The protarg did again translocate from the cytoplasm 
to the nucleus, but Survivin-DsRed did not. Image intensity analysis was done, but 
for only one experiment (analysis of 10 cells, Figure 6.7 (B)).  
 Lastly, we sought to determine the layout of the protargs was creating a 
steric hindrance in the dimerization of survivin. The order of the protarg was 
switched to PS-ER(mut)-SurvT34A-EGFP. The microscopy results of this experiment 
can be seen in Figure 6.8. Changing the order of the PS-protarg resulted in an 
increase in nuclear localization before any dexamethasone addition. No overall 
change was seen in nuclear localization in the PS-protarg or Survivin (Figure 6.8B), 
and there was no statistical difference between them (p = 0.4).  
Discussion 
 Survivin is an inhibitor of apoptosis protein that is overexpressed in most 
hematopoietic and solid tumors (31). Knocking down its activity has been proposed 
as a potential treatment option for cancer, but the methods of this are currently in 
early stages of clinical and translational development, and no proven method of 
stopping survivin activity exists (32). We hypothesized that using a proteasome-
targeted protein that could seek out and bind survivin intracellularly could induce 
the degradation of survivin and perhaps block its anti-apoptotic effect. The protarg 
used in this study was based on the full-length estrogen receptor that is targeted to 
the ubiquitin-proteasome pathway when bound to antagonist fulvestrant through a 
conformational change in its ligand-binding domain region (18).  In order to bind  
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Figure 6.7. NES mutation does not improve colocalization. A. Mutations removing 
the NES from both survivin domains were made to determine if it would improve 
nuclear translocation. While the PS-protarg was still able to translocate, the 
mutations did not improve the translocation of survivin. B. One set of 10 cells 





Figure 6.8. Altered orientation does not improve colocalization. A. The linear 
arrangement of the domains of the PS-protarg was changed to determine of there 
was a steric affect preventing survivin binding. Removing the EGFP cap on the N-
terminus changed the baseline localization of PS-protarg to be more nuclear. No 
change in survivin localization was seen. B. This change of arrangement resulted in 
an ability of both constructs to significantly increase their nuclear intensity. There 
was no difference in relative nuclear increase between these two by unpaired t-test. 
(p > 0.05) 
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intracellular survivin, a survivin binding domain (SBD) was needed. Our first 
thought was to utilize the native homodimer (24) arrangement of survivin by baiting 
survivin with itself. Our rationale was that survivin has two dimerization interfaces, 
and rather than deciphering the exact domain spacing needed to reproduce binding, 
full-length survivin would suffice. Several mutations were made to ensure that any 
protein exogenously introduced into a cell would have minimal impact; estrogen 
receptor was mutated at serine 167 to alanine (20-22) (ER(mut)), and survivin was 
mutated at tyrosine 34 to alanine which has a dominant negative effect (26).   
 Before examining actual proteasomal degradation, we tested the ability of 
survivin to sustain homodimerization through intracellular trafficking. A simple co-
transfection of the ER protarg (ER(mut)-SurvT34A), with a survivin-DsRed fusion 
did not demonstrate any ability of the two constructs to colocalize, either before or 
after fulvestrant addition. To specifically assess the binding ability of the protarg 
survivin to a wild-type survivin we used the nuclear translocation assay (NTA) 
developed in our lab (33). The NTA is an extension of the protein switch that has its 
subcellular localization under the control of externally administered dexamethasone. 
A binding domain attached to the protein switch will induce the co-translocation of a 
target protein from the cytoplasm to nucleus and can be easily visualized by 
fluorescence microscopy. We found that while the ER(mut) protarg fused to the 
protein switch (PS-ER(mut)-SurvT34A) could translocate to the nucleus in response 
to dex, but again, that survivin did not follow, suggesting that there was no binding, 
or the binding was not durable.  Several changes were made to improve the 
translocation ability, like removing the NES in wild-type survivin, and rearranging 
the order of the domains in the protein-switch protarg. Neither of these improved 
nuclear translocation. The most interesting finding of these attempts was that 
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removing the EGFP fluorophore from the N-terminus of the protein switch changed 
the nuclear translocation ability completely. The NES and NLS components of the 
protein switch are in a delicate balance (28), and changing the exposure of the signal 
sequences tipped the balance in apparent favor of the NLS.  
 Without proper binding of intracellular survivin, the actual degradation 
potential could not be assessed. The future experiments in the project must start 
with seeking a new SBD, perhaps experimenting with the SMAC peptides that have 
demonstrated IAP binding (34, 35).  
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CONCLUSIONS AND FUTURE WORK 
Summary 
The body of work described in these chapters builds upon the foundation that 
protein localization control can overcome diseases due to mislocalization or 
dysfunction. The initial discovery of the “protein switch” concept in the Lim Lab has 
resulted in a broad array of potential application and localization methods (1-10). 
Three technologies have been developed with the intent of manipulating protein 
subcellular localization. There are some elements that are consistent among all 
three: a ligand-binding domain for inducibility, signal sequences to direct cell 
compartment specificity, and a domain that interacts with an intracellular target. 
While none of these technologies are ready yet for any clinical applications, they 
remain unique among the field of protein targeting, and potentially add to that 
arsenal of modalities that will aid in researching protein targets for disease therapy, 
diagnosis, and maybe one day arrive in the clinic with a yet unknown application.  
Protein Localization Can Be Controlled  
with a Protein Switch 
The protein switch was initially developed by Charu Kanwal, PhD, in the 
Lim lab as a “bi-directional on/off switch” to control protein localization between the 
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cytoplasm and the nucleus (8). With the goal of efficient cytoplasm-to-nucleus 
translocation in mind, extensive optimization of the nuclear export signal (NES), 
nuclear localization signal (NLS), and ligand-binding domain (LBD) was undertaken. 
These NESs and NLSs were tried with combinations of varying signal strengths—as 
dictated by the binding constant with the respective import/export partner. The 
result was that these signal sequences needed to be combined to delicately balance 
the initial cytoplasmic localization against the drive for nuclear localization. A 
strong NES combined with a weak NLS (MAPKK NES with NLSi, for example) 
produced a poor increase of protein in the nucleus after ligand induction. Ultimately, 
a medium-to-strong NLS combined with a medium NES produced the best 
translocation. Several LBDs were tested with varying NESs and NLSs, including the 
progesterone receptor (PR), glucocorticoid receptor (GR), estrogen receptor (ER), and 
ecdysone receptor (EcR). Overall, LBDs combined with the same NES/NLS 
combination performed similarly, with statistically insignificant differences in 
translocation measurements. In fact, the NES and NLS combination likely had the 
greatest influence on translocation ability, and potentially confounded the results of 
the LBDs tested. Both EcR and ER were tested with the MAPKK export signal. This 
strong NES may have prevented nuclear import even if the LBD provided the 
conformational change needed to tip the balance of the dominant signal sequence. 
The ideal protein switch is one that can be completely controlled by external ligand, 
so the ideal LBD would not respond to endogenous ligand. The EcR, a steroid 
hormone receptor found in insects (11-14), is the perfect candidate. Indeed, it is 
already used in gene-switch systems for this very reason (15). It responds to 
ecdysteroids that are not present in humans, and humans are constantly exposed to 
these ecdysteroids without apparent toxicity (15). The finding that MAPKK was a 
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poor NES choice was determined after the data was analyzed, so a future path for 
the protein switch is to combined the EcR LBD with the better HIV-SV40/MycA8 
signal sequence combination.  
  
Targeting the Nucleus: Future Work 
The future work of the protein switch is already underway—meaning that it 
has already been adapted for use as a protein interaction assay (16), a method for 
sending oncogenic Bcr-Abl to stop its oncogenic activity (3), and, discussed at length 
in this thesis, it can be used to control p53’s proteasomal degradation (manuscript 
submitted for publication). The nuclear translocation assay (NTA) was developed by 
Andrew Dixon, PhD, as a means to detect protein interactions by testing 
colocalization of the proteins of interest in the cytoplasm and nucleus after ligand 
addition. The “bait” could be fused to the proteins switch, and the protein of interest 
separately fused to another fluorophore, like DsRed. When co-transfected into a 
model cell line, like COS-7, the subcellular localization can be monitored by 
fluorescence microscopy before and after drug addition. If the two proteins interact, 
a co-translocation to the nucleus after ligand would be expected. If there is not a 
significant interaction, no co-translocation would be expected. This technology has 
the potential to be broadly applicable because it could be used as a molecular biology 
technique without the intent to use it as a therapy. This technology was utilized in 
the survivin:survivin homodimer study in Chapter 6, with the conclusion that 
survivin did not form a robust dimer that could withstand cellular trafficking. This 
may be a limitation of the NTA; interaction sensitivity is traded for easy 
visualization of the interaction.  
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Our experience in shuttling proteins from the cytoplasm to the nucleus has 
yielded valuable lessons that must be learned for future application of this 
technology. To send a protein from one compartment to another, not only must a 
robust binding domain be obtained, but also one must undertake a thorough 
examination of the protein-protein interactions the target protein has that may 
effect its localization. For example, Bcr-Abl strongly associated with cytoskeletal 
actin filaments, which increases the complexity of inducing the shuttling of Bcr-Abl. 
This strong interaction allows Bcr-Abl to “stick” to actin, thereby preventing any 
induced movement (3). Dixon et al. discovered that using an intracellular antibody 
against the actin-binding domain of Bcr-Abl blocked the actin interaction, resulting 
in free Bcr-Abl that can then shuttle between compartments (17-19). A similar 
approach may be necessary for proteins that do not readily respond to a controlled-
localization system. 
 The research into protein switch applications inspired the other localization 
technologies presented in this thesis. While optimizing the LBD portion of the 
protein switch, the response of ER to fulvestrant piqued our interest in investigating 
proteasomal degradation control, which may be possible in the context of full-length 
ER bound to fulvestrant. We also discovered that the LBD from ER had a slightly 
different response to fulvestrant out of context, and this produced the work 






The Estrogen Receptor Ligand-Binding Domain  
Can Be Utilized to Aggregate Proteins  
in the Cytoskeletal Fraction 
The conformational change of the ligand-binding domain of the ER when 
bound to fulvestrant increases hydrophobic interactions that contribute to receptor 
insolubility and aggregation at the cytoskeleton (20, 21). Full-length ER interacts 
with cytokeratins 8 and 18 (CK8/18) (22, 23), but we found that taking the LBD out 
of context removed the CK interaction without disrupting insolubility and general 
cytoskeletal localization. Continuing with the theme of subcellular control, we tested 
the ability of signal sequences to dictate in which compartment the LBD aggregates. 
The NES did not significantly change the localization of ER LBD, but adding an 
NLS did significantly change the baseline localization of the construct. This effect 
was seen in multiple cell lines, both cancerous (1471.1, MCF-7, HeLa, A2780) and 
non-cancerous (COS-7), and in CK8/18 positive (MCF-7) and negative (A2780) 
suggesting that the cytoskeletal target of the LBD alone was different from full-
length ER.  Confocal microscopy of ER LBD and immunofluorescently labeled CK 18 
also corroborated this hypothesis.  
 Purposefully sending an exogenous protein to the cytoskeleton is a novel 
concept, and may have a use in investigating protein function. We tested that 
hypothesis with a mutated coiled-coil (CCmut3) peptide that has activity against 
Bcr-Abl (24, 25). Bcr-Abl is a well-known protein that is the causative oncogene of 
chronic myeloid leukemia (CML) (26). This coiled-coil, originally from Bcr-Abl itself, 
was strategically mutated to bind to Bcr-Abl with higher affinity than a non-
mutated form—all while having a lower affinity for itself. In an apoptosis assay in 
K562 CML cells, a fusion of CCmut3 to ER LBD was able to disrupt Bcr-Abl 
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signaling and induce apoptosis (2) in the absence of fulvestrant, but the apoptotic 
effect was lost when fulvestrant was added to the system. Fluorescence microscopy 
of this construct reveals that indeed the LBD-peptide fusion had aggregated as a 
result of ligand binding, and this stopped the activity of CCmut3. This both provides 
evidence of the ability of ER LBD to aggregate a protein and the ability of the 
CCmut3 designed in our lab to disrupt Bcr-Abl signaling in CML cells. This on/off 
effect that fulvestrant imparted on CCmut3 could be extended to other rationally 
designed protein or peptide therapeutics as a means to prove their activity in in 
vitro studies.  
Targeting the Cytoskeleton: Future Work 
 This initial goal of this project was actually to induce cytoskeletal 
aggregation of an intracellular protein, namely Bcr-Abl. We again learned that the 
protein capture and “dragging” is a challenge that is difficult to overcome. The LBD-
CCmut3 protein could interact with Bcr-Abl at the site of Bcr-Abl localization, but 
ligand addition did not induce a localization change of this endogenous protein. The 
utility of this localization technology may depend on finding robust and specific 
binding domains for intracellular protein targets like Bcr-Abl, but also other 
oncogenic proteins like anaplastic lymphoma kinase (ALK) (27), MEK, Raf, and Ras 
(28, 29). Once a suitable binding domain has been determined, western blot analysis 
of co-subcellular fractionation, or fluorescence colocalization microscopy, are key to 
determining if sequestration of the target protein has been achieved. If the target 
protein can be detected in the insoluble fraction after drug addition, then the effect 
of sequestering that protein can be tested in downstream assays. However, if no co-
fractionation is seen, then that target protein likely has a stronger intracellular 
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interaction that will need to be disrupted before this system will work. Alternatively, 
as noted with ERLBD-CCmut3, this system could be used as a molecular biology tool 
to test the action of therapeutic peptides, or basic protein-protein interactions. 
Without fulvestrant, the binding domain is able to bind the target protein and the 
interaction can be assayed for a particular effect (apoptosis, for example). When 
drug is added, any change in that assay may indicate that the binding domain bound 
to the target protein was significant.  
p53 Can Be Targeted to the Ubiquitin- 
Proteasome Pathway 
Sending proteins to the ubiquitin-proteasome pathway is a concept borne out 
of the LBD studies in the protein switch optimization. Ligand-induced degradation 
of ER occurs with fulvestrant, and we expanded upon this mechanism to define a 
proteasome-targeted protein (protarg) as having a ligand-controllable region, and a 
region that interacts with ubiquitin and an E3 ligase (ubiquitin-interacting domain; 
UID). Two such protargs were created and examined in this work: the p53 protarg, 
and the ER-Survivin protarg.  
The interplay of p53 levels and downregulation by MDM2 provided an 
interesting model system for a protarg. p53 is ubiquitinated by MDM2 via its RING 
finger E3 ligase activity. Ubiquitination of proteins is a signal for proteasomal 
degradation, thus p53 is sent to the proteasome via ubiquitination by MDM2 (30). 
The MDM2/p53 interaction is spatially controlled—both proteins need to be in the 
same compartment for downregulation to occur (31). This is precisely the type of 
scenario in which the protein switch becomes especially useful. We hypothesized 
that p53 fused to the protein switch would localize in the cytoplasm before drug 
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addition and translocate to the nucleus where it would interact with MDM2, get 
ubiquitinated, then get sent to the proteasome for degradation. We were correct; p53 
did translocate to the nucleus with drug addition, and was subsequently degraded. 
We found that it must first translocate to the nucleus for any effect to occur, which 
validates the subcellular compartment control theory. Further, a construct that 
contains the minimally necessary MDM2 binding regions also performed like full-
length p53, but had the added benefit of not modulating p53 gene translocation. The 
protein-switch p53 construct reduced p53 gene transcription when compared to the 
negative control, but the truncated version did not. The implication is that this 
exogenously introduced protein will have fewer negative affects on the cell in which 
it is introduced.  
  
Targeting the Ubiquitin-Proteasome  
Pathway: Future Work 
The basic mechanistic characterization of the p53 protarg is largely complete, 
but proving that true proteasomal degradation is occurring is the next major step. 
The work presented in this dissertation has shown that loss of GFP fluorescence 
correlated with a change in localization of PS-p53 constructs. While it is tempting to 
seek to prove that colocalization of the protarg with the proteasome precedes loss of 
fluorescence, our unpublished data have repeatedly shown that colocalization is not 
possible to visualize. We speculate that the colocalization of the protarg with the 
proteasome is too transient; once the protein reaches the proteasome it is 
immediately degraded. The clusters of fluorescence seen in the images do not depict 
actual proteasomal localization, but rather that clusters of protein preceding 
degradation. More experiments are needed showing that the proteasome alone is 
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responsible for loss of fluorescence. A similar flow cytometry based assay as used in 
Chapter 5 may be used with a proteasomal inhibitor, along with a protein synthesis 
inhibitor, to show that without a functioning proteasome there is no loss of 
fluorescence. The key to this experiment is optimizing the time of drug addition. 
Concomitant administration of an inhibitor of the proteasome at the same time as 
dexamethasone may not yield true results without suitable drug addition timing. 
Western blots may also be a useful as supportive evidence that protein levels are 
decreasing as a result of dexamethasone administration. A blot of subcellular 
fractionation will assure that the disappearance of a protein is not simply due to 
solubility in a specific buffer.  
Next, a suitable application of this technology remains to be determined. The 
same challenges faced by the ER LBD-cytoskeleton protein are faced here: a suitable 
intracellular protein needs to be identified, and a binding domain located or 
rationally designed. Further, another drawback of this technology is that it relies 
upon the cell to produce MDM2 in order for p53 to be ubiquitinated. In cells with low 
MDM2 levels, this protarg may not function at all. Further investigation into cell 
specificity of the p53 protarg needs to be done, and a possible result is that this 
protarg is cancer-specific. Cells with high MDM2 activity, such as those in certain 
cancers (sarcoma, for example) (32) may quickly and efficiently send the p53 protarg 
to the proteasome, and hopefully with the target protein to which it has bound.    
Survivin Does Not Form a Durable Dimer  
Interface for Protarg Use 
 We tested the ability of survivin to dimerize with itself in order act as a 
capture domain in our protarg construct. Rather than using the p53 protarg, we 
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attempted to characterize the degradation potential of ER as a UID. When ER binds 
fulvestrant, it is quickly sequestered with cytokeratins in the nucleus and cytoplasm, 
and proteasomal degradation shortly follows (21, 23). This, in combination with 
survivin as bait, served as our anti-survivin protarg. We took into consideration the 
potential of our construct to actually do harm, i.e. survivin acting as an inhibitor of 
apoptosis and ER transactivating genes unnecessarily, so we made strategic 
mutations in each to prevent this occurrence (33-35). Colocalization of our protarg 
construct with a co-transfected wild-type survivin/fluorophore fusion was not 
demonstrated in two separate methods. Direct visualization of pre-proteasomal 
clusters of the ER bound to fulvestrant shows that survivin remained broadly 
localized within the cell. Using an assay that visibly demonstrates binding of two 
proteins (16) also showed that wild-type survivin did not bind to nor translocate with 
the protarg. Even though we did not see any survivin binding activity, it was an 
opportunity to deploy other technologies developed in our lab that stemmed from 
controlling protein localization: the nuclear translocation assay. Also, a valuable 
lesson learned in these experiments was that removing the enhanced green 
fluorescent protein (EGFP) cap from the N-terminus of the protein switch blocked 
localization control with dexamethasone. The obvious conclusion is that EGFP was 
assisting in masking the NLS prior to drug addition, and its removal exposed the 
NLS to the import machinery causing nuclear accumulation regardless of drug 
addition.  
 The future work on survivin must delve into a better binding domain against 
survivin. One place to start is using SMAC peptides to lure survivin. SMAC (second 
derived mitochondrial-derived activator of mitosis) is released from the mitochondria 
in response to apoptotic stimuli. A cleavage of SMAC occurs that exposes an N-
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terminal amino acid sequence that binds the Inhibitors of Apoptosis (IAPs), of which 
survivin is a member (36-42). Short peptides comprised of this N-terminal amino 
acid sequence have been made, and their binding potency characterized. We could 
incorporate a coding sequence into our protarg that when expressed by the cell 
produces an IAP biding region. This region, in association with ER, could produce a 
viable protarg that could degrade intracellular survivin. 
Localization-Controllable Proteins: Future Perspectives 
 
 The three modalities of protein localization control presented in this 
dissertation have a shared feature of ligand inducibility. The appeal of this approach 
is that the action of induced protein translocation can be specifically timed, with the 
potential of cell specificity based on ligand choice. However, it may not be necessary 
to use a complicated ligand-controllable system. The Lim lab is already underway on 
direct targeting of p53 to the mitochondria (10). The control element has been 
removed, and all that remains is a mitochondrial targeting signal fused to p53. 
When this fusion protein is expressed, intracellular processes immediately recognize 
the targeting signal and the whole protein is sent to the mitochondria. When p53 is 
sent to this organelle, the intrinsic apoptotic pathway is initiated and results in 
increased cell death. This is an example of a system that may have greater 
therapeutic potential due to its more simplistic mechanism. A similar approach may 
be explored with nuclear-targeted proteins: inclusion of nuclear localization signals; 
cytoskeletal-targeted proteins: fusing a binding domain to a highly hydrophobic 
domain; and proteasomal-targeted proteins: inclusion of a degradation signal, such 
as N-degrons or ubiquitin-fusion proteins (43-45). 
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 The delivery of these therapeutics is another major hurdle that lies ahead. 
The delivery of the mitochondrially-targeted p53 protein is also underway in the Lim 
lab with adenoviral vectors. All of the gene delivery work done in this dissertation 
was done with commercially available lipopolymers that are efficient in vitro, but 
not feasible in vivo. Adenoviral delivery has become a popular method of gene 
delivery, and is currently being tested in clinical trials, most notably with Advexin®, 
the US cognate to the Chinese Gendicine® adenoviral p53 vector (46). The 
adenovirus is capable of efficient infection of nondividing or differentiated cells (47), 
and can be engineered with tropism toward a specific tissue type (48). However, the 
utility of adenoviral vectors is limited by preexisting immunity toward adenovirus, 
infection of off-target cells, and vector immunogenicity (49). Nevertheless, it remains 
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